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The  Transcriptional  Profile  of  Microglia:  from  Brain  to  Dish  
Fiona  Elizabeth  Calvert  
Microglia  are  the  tissue  resident  macrophages  of  the  central  nervous  system  (CNS)  
and  multiple  lines  of  evidence  indicate  that  microglia  are  a  pathogenic  cell  type  in  
Alzheimer’s  disease  (AD).  It  is  important  to  understand  the  transcriptional  profiles  of  
microglia,  both  from  primary  human  cells  and  the  in-vitro  model  systems  used  to  
study  the  cells  at  scale.  In  this  thesis,  I  aim  to  build  on  previous  small-scale  studies  of  
primary  microglia  and  in-vitro  model  systems  to  answer  three  major  questions:  1.  
Can  transcriptional  data  from  fresh,  primary  human  microglia  be  used  to  identify  
novel  subpopulations  of  cells  and  understand  how  clinical  phenotypes  influence  gene  
expression?  2.  How  accurately  do  current  simple  in-vitro  model  systems  of  human  
microglia  capture  the  profile  of  primary  human  cells?  3.  Do  more  complex  model  
systems  move  cultured  cells  further  along  a  trajectory  towards  the  primary  cell  type?   
  
I  have  utilised  RNA-sequencing  technology  to  build  the  most  comprehensive  
transcriptional  profile  of  primary  human  microglia  to  date,  from  over  100  
neurosurgical  patients.  Using  single-cell  sequencing  I  have  demonstrated  that  clinical  
pathology,  particularly  major  trauma,  causes  specific  gene  expression  changes  within  
microglial  transcriptomes.  I  have  then  shown  that  in-vitro  models  of  primary  microglia  
have  significantly  reduced  expression  of  key  marker  genes  and  transcription  factors,  
such  as  P2RY12  and  SALL1 ,  when  compared  to  primary  cells.  Using  gene-set  
enrichment  analysis  tools,  I  have  shown  that  many  of  the  genes  with  higher  
expression  in  primary  cells  can  be  linked  to  neuronal  processes  such  as  CNS  
myelination.  Data  from  the  third  chapter  of  this  thesis  identified  the  CNS  environment  
as  a  major  stimulating  factor  in  the  gene  expression  profile  of  primary  microglia. 
Therefore,  I  used  single  cell  analysis  to  understand  how  culturing  stem  cell  derived  
microglia  in  the  presence  of  neurons  could  move  in-vitro  systems  closer  towards  the  
primary  cell  type.  In  summary,  the  work  in  this  thesis  has  demonstrated  that  
microglial  transcriptomes  are  constantly  reacting  to  stimuli  within  the  local  CNS  
environment,  both  to  maintain  their  unique  gene  expression  profiles  and  to  respond  
to  clinical  conditions.  I  have  also  shown  that  current  in-vitro  model  systems  do  not  
fully  capture  this  transcriptional  profile  which  largely  appears  to  be  driven  by  
environmental  stimuli  within  the  CNS.   
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Chapter  1:  Introduction  
  
  
1.1  Identification  and  characterisation  of  microglial  cells  in  the  brain   
  
Microglia  are  the  tissue  resident  macrophages  of  the  central  nervous  system  (CNS)  
and  play  an  important  role  in  it’s  immune  defense 1 .  Microglia  were  first  described  in  
the  early  1900s,  as  scientists  began  to  use  developing  microscopy  techniques  to  
study  the  brain.  Santiago  Ramón  y  Cajal,  a  Spanish  neuroscientist  famed  for  his  
descriptions  and  images  of  the  CNS,  dedicated  much  of  his  research  to  the  
non-neuronal  cells  within  the  brain,  known  as  glial  cells 2,3 .  Within  this  glial  cell 
population,  Cajal  identified  the  “third  element”  of  the  CNS  describing  the  
non-neuronal,  non-astrocytic  population  of  cells  he  observed.  Río-Hortega  divided  
this  “third  element”  into  two  subdivisions:  microglia  and  interfascicular  glia,  now  
known  as  oligodendrocytes 2 .  Río-Hortega  observed  that  microglia  were  relatively  
uniformly  distributed  in  the  brain,  although  noted  a  higher  density  in  the  grey  matter,  
and  described  the  cells  as  highly  dynamic,  often  adapting  their  morphology  to  the  
features  of  the  brain 3 .  His  later  work  focussed  on  microglial  physiology  following  
trauma  to  the  brain  where  he  described  the  cells  taking  on  an  ameboid  shape  and  
becoming  highly  phagocytic.   
  
Since  the  early  description  of  microglia,  experimental  tools  have  significantly  
improved  and  it  is  now  easier  to  identify  and  observe  microglial  cells  in  a  variety  of  
systems,  from  primary  cells  across  species  to  in-vitro  models.  Improved  microscopy  
techniques  have  confirmed  Rio-Hortega’s  initial  observation  that  microglia  have  a  
highly  ramified  morphology  (Figure  1.1),  with  dynamic  processes  that  constantly  
survey  the  environment  and  maintain  contact  with  neurons 4 .  In-vivo  time  lapse  
imaging  using  zebrafish  has  suggested  that  this  motility  is  not  a  random  process 5  and   





Figure  1.1  Microscopy  images  of  mouse  (left),  fetal  human  (middle)  and  
iPSC-derived  microglia  
Image  taken  from  Muffat  et  al . 6 ,  Figure  3  panel  b.  
  
In  addition  to  describing  the  characteristics  of  microglial  cells,  Rio-Hortega  was  the  
first  to  theorise  that  microglia  were  of  mesoderm  origin 7 .  For  many  years  this  theory  
was  overlooked  and  instead  it  was  argued  that  the  cells  were  derived  from  
neuro-ectoderm,  along  with  other  glial  cell  populations  such  as  astrocytes 8–10 .  
However,  evidence  began  to  build  that  supported  Rio-Hortega’s  original  proposal:  
microglia  were  shown  to  have  similar  morphological  features  to  macrophages 11  and  
were  shown  to  express  myeloid  markers  such  as  CD11b 12 .  In  mice,  knockout  (KO)  of  
the  PU.1  gene,  a  key  transcription  factor  (TF)  in  myeloid  cell  development,  resulted  in  
an  absence  of  microglial  populations  in  the  brain 13 .   
  
  
1.2  Lineage  of  microglial  populations  in  the  brain  
  
It  is  now  well  recognised  that  the  microglial  cells  first  described  by  Río-Hortega  are  
tissue  resident  macrophages  of  the  CNS.  While  the  myeloid  origin  of  these  cells  is  no  
longer  disputed,  unique  features  of  microglial  development  appear  to  distinguish  
them  from  other  macrophage  cells  both  in  their  initial  origin  and  maintenance  
throughout  adult  life.   
  
1.2.1  Microglial  cell  origin  in  embryonic  development   
Microglia-like  cells  have  been  identified  in  both  rodent  and  human  samples  in  the  
very  early  stages  of  embryonic  development 14,15 ,  suggesting  they  derive  from  a  
lineage  independent  of  bone  marrow  hematopoiesis.  In  human  fetal  development,  
18  
  
Iba1+  (a  myeloid  cell  marker)  precursor  cells  have  been  observed  in  the  developing  
nervous  system  as  early  as  4.5  gestational  weeks 15 ,  while  hematopoietic  stem  cells  
don’t  seed  the  fetal  liver  until  around  gestational  week  5 16 .  
  
Dissociation  of  fetal  tissue  samples  from  mice  provided  the  first  evidence  that  
microglial  progenitors  are  located  in  the  yolk  sac  (YS)  before  moving  into  the  
developing  brain  as  embryogenesis  progresses 14 .  More  recently,  a  fate-mapping  
study  has  provided  further  evidence  of  the  unique  YS  origin  of  microglial  cells 17 .  
Fate-mapping  relies  on  the  ability  to  label  cells  from  specific  developmental  origins  
and  trace  them  through  the  developmental  process.  In  the  case  of  microglia,  yellow  
fluorescent  labelled  protein  (YFP)  was  linked  to  the  RUNX1  TF,  which  is  specific  to  
YS  myeloid  development.  An  estimated  32%  of  adult  microglia  cells  were  derived  
from  YS  precursors  compared  to  only  3%  of  circulating  monocytes.  Specific  
erythro-myeloid  progenitors  within  the  mouse  YS  have  since  been  identified 18  and  it   
is  these  colony  stimulating  factor  1  receptor  (CSF-1R)  expressing-cells  that  appear  to  
give  rise  to  tissue  resident  macrophages  such  as  microglia.   
  
Mouse  models  have  also  been  used  to  identify  the  pathways  and  molecules  that  
regulate  microglial  differentiation  from  early  progenitors.  Myb  is  a  TF  which  has  
previously  been  shown  to  be  dispensable  for  yolk  sac  myelopoiesis  but  necessary  for  
the  creation  of  hematopoietic  stem  cells  in  the  bone  marrow.  The  initial  production  of  
microglia  cells  has  been  shown  to  be  a  Myb  independent  process 19,20 ,  which  further  
adds  to  the  evidence  behind  the  YS  origin  of  microglia.  Other  TFs,  like  PU.1  and  
IRF8 ,  as  well  as  protein  coding  genes,  such  as  MMP8  and  MMP9 ,  are  required  for  
the  development  of  mature  microglial  cells 19,21 .  The  expression  of  CSF-1R  by  
progenitor  cells  and  a  functional  circulatory  system  is  also  necessary  for  microglial  
differentiation 17 .  
  
1.2.2  Maintenance  of  microglial  populations  throughout  adulthood  
The  CNS  has  long  been  considered  an  “immune  privileged”  site,  which  limits  immune  
reactions  in  the  brain 22 .  This,  in  part,  is  due  to  the  presence  of  the  blood  brain  barrier  
(BBB)  that  is  thought  to  prevent  circulating  immune  cells  entering  the  brain.  In  most  
other  tissues,  circulating  monocytes  provide  a  progenitor  cell  for  expanding  
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macrophage  populations.  It  is  known  that  even  after  the  formation  of  the  BBB,  when  
monocytes  theoretically  cannot  enter  the  brain,  the  population  of  microglia  in  the  
brain  continues  to  grow  with  a  large  population  surge  two  weeks  after  birth 14 .  This  
evidence  suggests  that  microglial  cells  have  expansion  potential  and  can  
self-maintain  populations  throughout  adulthood.  There  are  three  proposed 
mechanisms  for  this  continued  growth  of  microglial  populations:  i)  microglia  are  in  
fact  replenished  by  circulating  monocytes  that  cross  the  BBB,  ii)  there  are  
populations  of  microglial  progenitor  cells  that  are  present  in  the  brain  throughout  life  
or  iii)  mature  microglia  themselves  have  the  potential  to  proliferate.   
  
Evidence  for  a  significant  contribution  of  circulating  cells  to  the  adult  microglial  
population  is  controversial.  Consistent  with  this  hypothesis,  PU.1  KO  mice  lack  any  
embryonically-derived  microglia,  but  develop  microglia-like  cells  within  their  CNS  
after  receiving  bone  marrow  transplants  after  birth 23 .  However,  fate-mapping  studies  
have  been  used  to  demonstrate  that  up  to  60%  of  microglia  in  adult  mice  are  YS  
derived 20  and  sublethal  irradiation  of  mice  followed  by  healthy  hematopoietic  cell   
transfer  only  gave  rise  to  around  5%  of  donor  derived  microglia 17 .  Parabiotic  mouse  
models  can  be  used  to  surgically  join  two  mice  and  allow  sharing  of  blood  circulation,  
providing  a  useful  tool  for  researchers  to  study  how  circulating  cells  contribute  to  
certain  populations 24 .  If  circulating  monocytes  contribute  to  the  maintenance  of  
homeostatic  levels  of  microglia,  one  would  expect  to  see  similar  levels  of  non-host  
cells  in  both  the  circulating  system  and  the  brain.  However,  multiple  studies  have  
demonstrated  that  parabiotic  mice  maintain  higher  levels  of  host-linked  microglia 25–27   
suggesting  that  monocyte  cells  do  not  contribute  to  the  adult  microglial  population  
under  normal  conditions.  It  may  be  that  under  extreme  conditions,  such  as  a  
complete  absence  of  microglia,  brain  injury  or  following  significant  
neuroinflammation,  circulating  cells  infiltrate  the  CNS.  These  cells  may  then  
contribute  to  the  population  of  microglia-like  cells  in  the  brain,  but  this  does  not  
appear  to  be  the  case  under  homeostatic  conditions 17,23,28 .   
  
The  second  theory  of  microglial  repopulation  is  that  there  are  progenitor  cells  within  
the  brain  that  can  differentiate  into  mature  microglia.  Following  depletion  of  the  
microglial  population  in  the  adult  mouse  brain,  using  CSF-1R  inhibitors,  it  has  been  
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demonstrated  that  microglia  rapidly  repopulate  the  brain 29 .  The  rate  of  repopulation  of  
microglia  described  in  this  study  (from  600  cells/slice  to  >14,000  cells/slice  in  72  
hours)  was  determined  to  be  too  quick  for  repopulation  to  be  explained  by  surviving  
cells.  However,  the  presence  of  a  progenitor  population  could  explain  these  
observations.  Within  the  same  study  a  population  of  Nestin  and  Ki67  positive  cells  
were  identified  that  appeared  to  be  the  source  of  repopulation.  Initially,  the  nestin  
positive  population  had  a  distinct  morphology  to  resident  microglia,  but  then  adopted  
the  ramified  morphology  normally  expected  of  native  cells.  However,  since  their  initial  
description,  the  presence  of  microglia  progenitor  cells  in  the  brain  has  remained  
controversial.  Future  studies  have  failed  to  identify  a  progenitor  population 27  and   
noted  that,  while  repopulating  microglia  may  transiently  express  nestin,  these  cells  
derived  solely  from  surviving  cells.  This  suggests  that  adult  microglia  have  
proliferative  potential  and  native  cells  are  the  driver  behind  population  expansion.  
  
  
1.3  Microglial  function  in  development  and  the  adult  brain   
  
There  has  been  extensive  research  into  the  various  roles  microglia  may  play  
throughout  the  lifespan  (Figure  1.2  1,30–33 ).  As  macrophage  cells,  microglia  can  clearly  
play  an  active  role  in  the  immune  defense  of  the  CNS.  However,  a  growing  body  of  
evidence  has  shown  that  microglia  are  required  for  both  neuronal  development  and  
normal  brain  function.  
  
  
Figure  1.2  Overview  of  microglial  development  and  function  




1.3.1  The  role  of  microglia  in  the  developing  brain  
Research  in  both  humans  and  mice  has  demonstrated  that  microglia  play  an  
important  role  throughout  brain  development.  Individuals  with  mutations  in  important  
regulators  of  microglial  function,  such  as  the  CSF-1R  gene,  have  profound  
neurological  abnormalities 34  including  abnormal  arrangement  of  neurons  and  a  lack   
of  corpus  callosum  development.  Studies  like  this  provide  direct  evidence  from  
human  patients  that  microglial  cells  are  required  for  normal  brain  development.  
However,  these  small  scale  patient  studies  cannot  provide  mechanistic  details  and  so  
mouse  models  are  often  used  as  tools  for  studying  microglia  in  development.   
  
At  the  cellular  level,  microglia  are  able  to  phagocytose  the  early  pool  of  neural  
precursor  cells  in  order  to  control  neurogenesis 35,36 .  Studies  have  demonstrated  that  
microglia  play  other  important  roles  in  brain  development  beyond  their  phagocytic  
function.  Experimental  evidence  supports  the  idea  that  microglia  provide  trophic  
support  to  developing  neurons  in  layer  V  cortical  neurons  in  mice 37 .  The  cells  
accumulated  close  to  the  projection  axons  and,  via  a  CX3CR1  dependent  
mechanism,  produced  IGF1  that  maintained  neuronal  survival.  Alongside  trophic  
support  for  developing  neurons  microglial  signalling  has  been  shown  to  function  in  
the  programmed  cell  death  of  neurons.  In  the  development  of  murine  retina,  
prevention  of  microglial  colonization  of  the  tissue  alleviated  the  production  of  nerve  
growth  factor  (NGF)  and  significantly  reduced  the  level  of  normal  programmed  cell  
death 38 .  More  recent  studies  in  both  mouse  Purkinje  cells 39  and  neurons  in  the  mouse   
hippocampus 40  have  implicated  superoxide  ions  produced  by  microglia,  through  a   
CD11b/DAP12  dependent  signalling  pathway,  in  programmed  cell  death.  Outside  of  
their  direct  interactions  with  neurons,  microglia  also  appear  to  be  important  for  
functional  vasculature  development  in-vivo  and,  in  the  in-vitro  based  aortic  ring  
model,  addition  of  microglia  cells  to  the  culture  stimulated  vessel  sprouting 41 .   
  
While  the  studies  described  above  provide  some  evidence  of  the  potential  impact  of  
microglia  on  neuronal  development,  one  of  the  most  well  established  and  recognised  
functions  of  the  cells  in  the  developing  brain  is  within  the  process  of  synaptic  pruning.  
Synaptic  pruning  systematically  removes  weaker  neurons  and  synaptic  connections  
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to  strengthen  and  improve  the  efficiency  of  the  remaining  connections  within  the  
brain.  Experiments  have  shown  that  microglia  closely  co-localise  to  synaptic  
connections  during  active  periods  of  pruning 42  and  lysosomal  markers  have  been   
used  to  highlight  active  engulfment  of  synaptic  material 42,43 .  Schafer  et  al. 42  studied   
microglia  engulfment  of  synapses  within  mouse  retinal  ganglions  and  demonstrated  
that  the  cells  preferentially  digested  “weaker”  synaptic  regions  further  supporting  
microglial  involvement  in  the  synaptic  pruning  process.  Other  studies  have  since  
established  that  the  active  engulfment  of  synapses  by  microglia  is  dependent  on  the  
activation  of  the  classical  complement  cascade 42,44,45 .  Disruptions  of  the  CR3/C3  
signaling  cascade  have  been  shown  to  cause  deficits  in  synaptic  connectivity 42  and   
C1q  KO  mice  also  have  large  disruptions  in  synapse  elimination 44 .  It  is  thought  that  
complement  protein  tagged  neurons  provide  the  signal  for  phagocytosis  by  
microglia 44 .   
  
1.3.2  Microglia  in  adulthood   
Under  normal  conditions  the  brain  is  considered  an  “immune  privileged”  site,  with  the  
blood  brain  barrier  (BBB)  acting  as  a  source  of  protection  from  infiltrating  pathogens.  
While  microglia  may  not  have  major  immune  functions  under  homeostatic  conditions  
in  the  adult  brain,  it  does  not  mean  they  remain  inactive  until  disease  or  disruption  
occurs.  Microglia  are  known  to  have  a  variety  of  homeostatic  functions  including  
phagocytosis  of  debris  within  the  brain  and  monitoring  of  neuronal  activity 1 .  Many  of  
the  identified  functions  of  microglial  cells  have  been  linked  to  CX3CR1  signalling.  
CX3CR1  is  a  receptor  that  is  selectively  expressed  by  microglia  within  the  brain,  
which  interacts  with  CX3CL1  ligand  produced  by  neurons 46 .   
  
Recent  evidence  has  also  shown  that  microglia  are  important  in  the  process  of  
learning  and  memory  in  adults 47–49 .  Learning  and  memory  occur  through  the  
strengthening  of  synaptic  and  neuronal  connections  via  processes  of  synaptic  
plasticity  and  long-term  potentiation  (LTP).  CX3CR1  KO  mice  have  an  impairment  in  
measurable  LTP  alongside  significant  deficits  in  behavioural  learning  tests  like  fear  
conditioning  and  the  Morris  Water  Maze 47 .  ATP  released  by  microglia  in  mice  
appears  to  modulate  synaptic  transmission  by  acting  on  P2X 4  and  adenosine  A1   
receptors 48 .  Using  a  selective  eye  closure  mouse  model,  Sipe  et  al. 49  demonstrated   
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that  microglia  actively  contribute  to  experience  dependent  plasticity  through  P2RY12  
signalling.   
  
There  is  also  some  evidence  that  external  environmental  factors  can  modulate  
microglial  function.  For  instance,  a  high  fat  diet  appeared  to  increase  the  number  of  
microglia  present  within  the  hypothalamic  region  and  was  accompanied  by  an  
increased  anti-inflammatory  phenotype 50 .  Obese  humans  studied  within  the  same  
paper  also  showed  cell  type  specific  differences,  including  microglial  dystrophy.  
Germ-free  mice  have  also  been  used  to  study  the  impact  of  microbiome  variation  on  
microglial  function 51 ;  without  manipulation  the  mice  showed  global  microglial  defects  
including  an  immature  phenotype  and  an  impaired  innate  immune  response.  
Recolonisation  of  germ-free  mice  partially  restores  microglia  function,  suggesting  the  
influence  of  the  gut  microbiome  on  the  brain  is  a  dynamic  process.  However,  these  
studies  often  do  not  provide  evidence  of  specific  molecular  mechanisms  that  may  
drive  these  effects.  Therefore,  further  research  would  need  to  be  carried  out  to  fully  
develop  the  scientific  theories.  
  
  
1.4  Microglia  and  disease  
  
As  the  only  major  population  of  immune  cells  within  the  brain,  microglia  act  as  a  first  
line  of  defence  against  infiltrating  pathogens  and  are  responsible  for  the  clearance  of  
cellular  debris.  However,  microglia  can  also  play  a  role  in  the  development  and  
progression  of  many  disorders  not  immediately  thought  of  as  immune  related  1,31,52 .  
When  discussing  microglia  and  disease  it  is  important  to  distinguish  between  
examples  where  microglia  appear  to  play  a  causal  role  and  those  where  the  cells  
react  to  disease  onset.  The  most  well  established  causal  link  between  microglial  
function  and  disease  is  Alzheimer’s  disease  (AD)  and  as  such  this  is  discussed  in  
more  detail  in  section  1.5.  The  remainder  of  this  section  describes  the  evidence  
linking  microglial  function  to  a  variety  of  other  disorders  and  how  the  cells  are  




1.4.1  Microglia  in  traumatic  brain  injury  
Traumatic  brain  injury  (TBI)  is  defined  as  “an  alteration  in  brain  function,  or  other  
evidence  of  brain  pathology,  caused  by  an  external  force” 53  and  can  often  be  further   
subdivided  depending  on  the  severity  or  outcome  of  the  injury.  As  reactive  immune 
cells  within  the  brain,  in  the  immediate  aftermath  of  TBI  microglial  processes  move  
rapidly  to  the  site  of  injury,  within  minutes  of  damage 54 .  Here,  their  primary  function  is  
to  prevent  disruption  to  the  blood  brain  barrier 54–56 .  Release  of  ATP  from  damaged  
tissue  is  thought  to  signal  to  microglia  and  stimulate  the  rapid  movement  of  
processes  to  the  injury  site,  often  without  the  movement  of  the  cell  body 54 .  In  mice  it  
appears  that  microglial  processes  form  specific  honeycomb  structures  with  
single-process  microglia  dispersed  throughout  to  assist  with  the  sealing  of  the  BBB 55 .  
A  rapid  increase  in  myeloid  cell  numbers  occurs  immediately  in  mice  and  can  
continue  for  up  to  four  days 57 .  Studies  in  human  post-mortem  brain  samples  have  
shown  that  the  neuroinflammatory  response  that  follows  TBI  can  persist  for  months  
following  injury 58 .   
  
TBI  often  has  long  term  consequences  including  a  potential  increased  risk  of  
neurodegenerative  disorders 1,59–63 .  Meta  analysis  from  32  independent  
epidemiological  studies,  totalling  “2,013,197  individuals,  13,866  dementia  events  and  
8,166  AD  events”,  showed  TBI  increased  the  risk  of  any  form  of  dementia  by  1.6  
times,  with  individuals  showing  a  1.5  times  higher  risk  for  AD  specifically 64 .  Many  of  
the  proteins  associated  with  neurodegeneration  have  been  shown  to  accumulate  in  
the  brain  following  TBI,  including  amyloid  beta 65,66 ,  tau 66  and  ɑ-synuclein 67 .  Chronic   
traumatic  encephalopathy  (CTE),  a  neurodegenerative  disorder  characterised  by  the  
accumulation  of  hyperphosphorylated  tau,  has  specifically  been  linked  to  consistent  
and  repeated  brain  trauma 68 .   
  
Research  into  the  molecular  pathways  that  may  drive  this  connection  has  suggested  
that  chronic  neuroinflammation  driven  by  microglial  responses  may  be  responsible  
for  the  long  term  neurodegeneration  risk  associated  with  TBI 63,69 .  Human  brain  
autopsy  samples  from  patients  who  have  previously  experienced  a  TBI  have  densely  
packed,  reactive  microglia  that  are  not  observed  within  aged  matched  control  
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samples 70 .  The  presence  of  these  reactive  microglia  also  appears  to  correlate  with  
white  matter  degeneration,  although  only  observational  correlations  were  provided  
within  this  study.  While  some  studies  suggest  that  prolonged  activation  of  microglia  
has  a  harmful  impact  on  cognitive  function  there  is  also  conflicting  evidence  that  
microglia  may  have  a  neuroprotective  effect  following  TBI 63 .  For  instance,  in  a  small  
randomised  control  study,  TBI  patients  treated  with  the  antibiotic  minocycline  showed  
a  reduction  in  microglial  activation  but  an  increase  in  neurodegeneration  compared  to 
those  patients  not  given  the  drug 71 .  As  well  as  the  conflicting  nature  of  some  of  the  
evidence  around  long-term  microglial  involvement  in  TBI,  it  should  also  be  noted  that  
neither  side  of  the  argument  provides  conclusive  proof  that  microglia  functions  are  
driving  the  potential  link  between  TBI  and  neurodegeneration.   
  
The  epidemiological  studies  linking  TBI  to  dementia  risk  can  also  be  difficult  to  
interpret  for  a  variety  of  reasons  including  misclassification  of  neurodegeneration  and  
a  lack  of  official  clinical  information 63 .  It  may  also  be  that  the  link  observed  between  
TBI  and  AD  could  be  driven  by  hidden  factors  that  increase  the  risk  of  both  AD  and  
TBI  without  a  causal  link  between  the  two.  This  means  further  work  needs  to  be  
carried  out  on  more  controlled  patient  groups  in  order  to  fully  understand  the  impact  
of  TBI  on  dementia  risk.  It  would  also  be  worth  building  our  understanding  of  how  
genetic  risk  factors  can  impact  both  TBI  outcome  and  dementia  risk.  For  instance,  
variants  in  the  APOE  gene  linked  to  AD  risk  have  been  shown  to  impact  TBI  
outcomes 72   but  the  interplay  between  the  two  is  poorly  understood.  
  
1.4.2  Microglia  in  Multiple  Sclerosis   
Multiple  sclerosis  (MS)  is  a  chronic  neurological  condition  that  is  classified  as  both  a  
neurodegenerative  and  autoimmune  disorder.  The  immune  system  begins  to  attack  
the  myelin  sheath  that  surrounds  neurons  in  the  brain  which  leads  to  a  multitude  of  
symptoms  including  muscle  weakness  and  coordination  deficits.  T-cells,  primed  to  
recognise  myelin  as  forgien,  are  the  driving  immune  cell  type  behind  the  
development  of  MS.  
  
While  microglia  are  not  associated  with  the  onset  of  MS,  the  cells  are  present  in  the  
characteristic  brain  lesions  of  MS  patients 73,74  and  have  been  shown  to  be  found  near   
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to  degenerating  neurons  in  the  brain 74 .  The  presence  of  the  cells  within  diseased  
regions  and  their  clear  involvement  in  the  immune  response  in  the  brain  provides  
some  evidence  that  microglia  are  involved  in  disease  progression.  However,  as  seen  
in  TBI,  different  studies  report  opposing  impacts  of  microglia  function:  either  
suggesting  they  further  the  progression  of  MS  or  that  microglia  play  a  neuroprotective  
role.   
  
Production  of  reactive  oxygen  species  (ROS)  has  been  implicated  in  a  variety  of  
processes  in  MS  75  and  microglia  are  often  thought  of  as  the  major  source  of  ROS   
within  the  brain.  Microglia  within  the  brain  have  been  shown  to  express  
myeloperoxidase  (MPO)  and  generate  ROS  as  part  of  the  myelin  phagocytosis  
process 76 .  Expression  of  MPO  also  significantly  increased  in  MS  patients  compared  
to  controls,  with  the  highest  level  of  expression  seen  in  myeloid  cells  closest  to  lesion  
sites.  The  concept  that  microglia  are  the  major  source  of  ROS  within  MS  has  been  
further  backed-up  by  more  recent  experimental  data 77  and  is  thought  to  be  due  to   
Nox2  dependent  oxidative  burst.  Microglia  have  also  been  shown  to  modulate  
neuronal  activity  in  MS,  further  adding  to  described  symptoms  of  the  condition.  In  the  
Experimental  Autoimmune  Encephalomyelitis  (EAE)  mouse  model  of  MS,  activated  
microglia  have  been  shown  to  release  TNFα 78  which  can  in  turn  lead  to  enhanced   
glutamate  function  and  synaptic  degeneration.   
  
On  the  other  hand,  a  growing  body  of  evidence  has  linked  microglial  function  to  
protective  disease  processes,  particularly  remyelination 79,80 .  CX3CR1  KO  mice,  which  
have  altered  microglial  functions,  had  a  significantly  reduced  clearance  of  myelin  
debris  in  the  EAE  model  which  prevented  remyelination 79 .  It  is  also  thought  that  
anti-inflammatory  microglia  can  aid  the  oligodendrocyte  differentiation  that  is  required  
for  the  remyelination  process 80 .   
  
1.4.3  Microglial  response  in  other  neurological  disorders  
As  the  reactive  immune  cells  within  the  brain,  microglia  have  also  been  shown  to  
respond  to  a  variety  of  other  neurological  disorders,  even  though  they  may  not  play  a  
causal  role  in  the  development  of  the  disease.  For  instance,  autism  patients  have  
increased  microglia  cell  numbers  when  compared  with  healthy  controls 81  and  have   
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increased  inflammatory  profiles  within  the  cerebrospinal  fluid,  including  increased  
expression  of  macrophage  chemoattractant  protein  (MCP)-1 82 .  Microglia  in  autistic  
individuals  may  also  be  morphologically  distinct.  Morgan  et  al. 83  described  a   
reduction  in  the  number  and  length  of  distinctive  microglial  processes  within  the  
postmortem  tissue  from  13  male  individuals  with  autism.  Positron  emission  
tomography  (PET)  scanning  has  revealed  increased  levels  of  microglial  activation  in  
autistic  brains  when  compared  to  healthy  controls 84 .  Transcriptional  profiling  of  brain  
tissue  from  autism  patients  has  highlighted  an  increased  expression  of  type  1  
interferon  genes  compared  to  controls 85  and  an  enrichment  of  immune  module  genes   
within  patient  samples 86 .  However,  the  genes  linked  to  this  immune  module  showed  
no  enrichment  for  autism  genome-wide  association  study  (GWAS)  genes.  The  lack  of  
enrichment  of  immune  genes  within  autism  GWAS  studies  implies  that  the  microglial  
response  seen  in  patients  is  reactive  rather  than  causal.   
  
Microglia  have  also  been  linked  to  the  symptoms  associated  with  neuropathic  
pain 31,87,88 ,  a  chronic  and  debilitating  pain  caused  by  trauma,  infection  or  pathology  
explicitly  linked  to  peripheral  nerve  damage.  As  well  as  chronic  pain  symptoms,  
neuropathic  pain  also  causes  tactile  allodynia:  a  disorder  when  pain  hypersensitivity  
can  be  caused  by  what  would  normally  be  considered  innocuous  stimuli.  While  
microglia  are  not  involved  in  the  initial  pain  stimuli  or  signalling,  they  have  been  
shown  to  react  to  nerve  damage  associated  with  the  disorder.  Following  initial  
peripheral  injury  there  is  marked  neuroinflammation,  microglial  proliferation  89,90  and   
increased  surveillance  91  by  microglia.  Crosstalk  between  neurons  and  microglia,  
through  the  CSF-1R  signalling  pathway,  has  also  been  linked  to  the  onset  of  pain  
hypersensitivity 92 .  Deletion  of  the  CSF1  gene  from  sensory  neurons,  which  inhibits  
production  of  the  signalling  molecule,  reduced  pain  hypersensitivity  and  microglial  
activation  in  mice.  
  
  
1.5  Alzheimer’s  disease  and  microglia  
  
Alzheimer’s  disease  (AD)  is  the  most  common  cause  of  dementia,  a  disease  that  
affects  around  850,000  people  in  the  UK.  Symptoms  include  progressive  memory  
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loss  and  a  reduction  in  general  cognitive  function.  AD  is  also  characterised  by  a  
general  loss  of  neuronal  mass.  AD  was  first  described  by  Dr.  Alois  Alzheimer  in  the  
early  1900s  93,94 ,  where  he  noted  plaques  and  tangles  in  patient  autopsy  samples  that  
are  now  classically  associated  with  AD  pathology.  AD  is  now  clinically  often  split  into  
two  distinct  categories:  familial  (early  onset)  and  late  onset  AD  (LOAD).  It  is  thought  
that  early  onset  AD  makes  up  approximately  5%  of  all  diagnosis’  with  this  branch  of  
the  neurodegenerative  disorder  thought  to  be  highly  heritable 95 .  Appearance  of  early  
onset  AD  symptoms  often  occur  in  patients  in  their  30s  or  40s  but  are  grouped  up  
until  the  age  of  65.  Those  that  appear  to  sporadically  develop  symptoms  after  the  
age  of  65,  which  is  the  more  common  condition,  are  classified  as  LOAD  patients.  
  
1.5.1  Early  hypotheses  in  Alzheimer’s  disease  research  
The  first  major  AD  hypothesis  focussed  on  the  loss  of  cholinergic  neurons  within  the  
brain 96 .  Evidence  of  reduced  acetylcholine  release  and  its  links  with  learning  and  
memory  further  added  to  the  theory 97 .  The  cholinergic  hypothesis  was  the  driver  
behind  major  pharmaceutical  developments  in  AD  treatments  including  the  
cholinesterase  inhibitors  that  are  still  used  in  therapy  today.  However,  since  their  
approval  as  AD  therapies,  the  cholinergic  based  treatments  have  appeared  to  only  
provide  symptomatic  relief  with  little  to  no  effect  on  the  progression  of  AD 98 .  These  
observations  suggest  the  specific  loss  of  cholinergic  neurons  may  not  be  driving  the  
progression  of  the  disease.   
  
As  understanding  of  the  pathology  of  AD  developed,  the  amyloid  cascade  hypothesis  
became  the  prevailing  pathological  theory.  The  amyloid  cascade  hypothesis  states  
that  it  is  the  formation  of  the  plaque  like  structures,  seen  within  AD  patient  brains,  
that  are  the  molecular  drivers  of  the  disease.  It  is  now  well  accepted  that  the  plaques  
first  described  by  Alois  Alzheimer  are  made  up  of  aggregated  amyloid  protein  (Aβ),  
specifically  Aβ-42,  and  neurofibrillary  tangles  are  composed  of  hyperphosphorylated  
tau.  Hardy  and  Higgins  were  the  first  to  coin  the  “amyloid  cascade  hypothesis”  99  and   
put  forward  the  theory  that  the  accumulation  of  plaques  in  the  brain  was  the  initiating  
stimulus  that  led  to  neuronal  loss  and  the  appearance  of  tau  tangles.  Since  its  
development,  amyloid  and  its  role  in  the  disease  has  been  a  major  focus  of  AD  




The  earliest  evidence  implicating  amyloid  in  AD  came  from  studies  of  familial  AD.  
Mutations  within  the  amyloid  precursor  protein  ( APP )  gene 100,101  and  within  the   
presenilin  genes  PSEN1  and  PSEN2 101–103  cause  familial  AD.  APP,  PSEN1  and   
PSEN2  are  all  involved  in  the  production  of  the  toxic  Aβ-42  protein  that  forms  the  
major  component  of  plaques.  The  APP  protein  can  be  cleaved  in  different  ways  that  
lead  to  the  production  of  a  variety  of  forms  of  amyloid  beta.  It  is  thought  that  
mutations  associated  with  familial  AD  cause  a  bias  towards  the  cleavage  mechanism  
that  generates  the  toxic  Aβ-42.  Further  support  came  from  early  onset  of  AD  in  
patients  with  Down’s  syndrome,  who  have  three  copies  of  the  APP  gene 104 .  While  
mice  do  not  spontaneously  develop  AD-like  pathology  or  symptomatology  as  they  
age,  APP  and  PSEN  mutant  mice  have  been  shown  to  develop  cognitive  deficits,  
amyloid  accumulation  and  synaptic  loss 104 .    
  
Since  the  initial  description  of  the  amyloid  cascade  hypothesis,  large  bodies  of  
research  using  a  variety  of  molecular  tools  have  been  used  to  demonstrate  that  
various  forms  of  Aβ  can  initiate  symptoms  of  AD 104–106 .  For  instance:  in  rat  
hippocampal  cultures  the  addition  of  aggregated  Aβ  is  neurotoxic 107 ,  APP  transgenic  
mice  have  increased  levels  of  Aβ  oligomers  and  the  same  miceshow  significant  
cognitive  impairment  compared  to  controls 108 .  In  mouse  models  of  AD  disrupting  the  
amyloid  pathway  can  result  in  a  reversal  of  many  of  the  cognitive  phenotypes  seen  in  
the  mice 109,110 .  
  
The  growing  evidence  from  in-vitro  and  in-vivo  studies  led  to  a  push  for  drugs  
targeting  the  amyloid  pathway.  However,  the  amyloid  cascade  hypothesis  is  not  
without  controversy  104,111,112 .  One  of  the  most  significant  problems  with  the  theory  that  
amyloid  is  the  driver  behind  AD  pathology  is  the  repeated  failure  of  anti-amyloid  
therapies  in  clinical  trials 113 .  These  therapies  fall  into  two  broad  categories:  direct  
reduction  of  Aβ  through  antibody-style  therapies  and  targeting  of  enzymes  involved  in  
the  production  of  amyloid,  such  as  BACE  and  γ-secretase.  Many  of  the  drugs  
targeting  the  enzymatic  pathways  have  failed  in  clinical  trials,  either  due  to  lack  of  




Despite  the  initial  clinical  safety  failings  of  immunotherapies  targeting  Aβ 117 ,  multiple  
therapies  reached  phase  II  and  III  trials 104 .  However,  the  majority  of  these  compounds  
have  also  dropped  out  of  trials  due  to  the  failure  to  meet  clinical  endpoints 113 .  In  2014,  
data  was  published  from  phase  III  trials  of  the  anti-Aβ  monoclonal  antibody  
Bapineuzumab  in  which  patients  on  the  drug  showed  no  significant  improvement  in  
AD-linked  cognitive  function  compared  to  the  placebo  group 118 .  The  failure  of  
Bapineuzumab  in  phase  III  trials  came  despite  evidence  from  earlier  phase  II  studies  
that  long  term  treatment  with  the  drug  significantly  reduced  cortical  amyloid  fibrillar  
load 119 .   
  
The  fact  that  immunotherapies  targeting  the  amyloid  pathway  appear  not  to  halt  
disease  development  despite  reductions  in  amyloid  load,  has  led  to  suggestions  that  
targeting  amyloid  is  the  wrong  strategy  since  it  is  not  driving  AD  progression 113,120 .  It  
is  worth  noting,  however,  that  in  late  2019  pharmaceutical  company  Biogen  
announced  that  they  were  seeking  FDA  approval  for  their  anti-Aβ  antibody  despite  
earlier  failure  of  the  drug  in  trials 121 .  The  repeated  failure  of  AD  modifying  drugs  in  
clinical  trials  leads  to  questions  not  just  about  the  validity  of  the  targets  but  also  
practical  factors  about  how  trials  are  carried  out 120  including  whether  patients  are   
targeted  for  treatment  too  late  in  disease  progression.  There  are  also  questions  
around  the  sensitivity  of  the  major  cognitive  test  used  in  AD  clinical  trials,  the  
Alzheimer’s  Disease  Assessment  Scale–Cognitive  Subscale  (ADAS-cogs),  
particularly  in  the  early  mild  stages  of  disease 122 .  
  
1.5.2  Alzheimer’s  disease  genetics  and  the  neuroinflammation  hypothesis  
Although  the  amyloid  cascade  hypothesis  has  driven  a  large  part  of  AD  research,  it  is  
important  to  remember  that  the  theory  was  founded  on  the  genetics  of  early  onset,  
familial,  AD.  The  genetics  behind  LOAD  is  more  complex  and  heterogeneous,  not  
driven  by  single  mutations  in  disease  linked  genes  but  by  large  numbers  of  variants  
of  individually  small  effect  sizes.  
  
One  of  the  first  major  genetic  risk  factors  that  was  identified  in  LOAD  is  the  APOE  
gene,  a  protein  involved  in  cholesterol  transport 123,124 .  Specifically  it  has  been  
demonstrated  that  the  ɛ4  allele  significantly  increases  AD  risk,  while  the  ɛ2  allele  
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confers  a  protective  effect  compared  to  the  other  alleles 125 .  Early  studies  of  the  
genetic  risk  factors  for  LOAD  were  carried  out  in  relatively  small  patient  numbers.  
This  only  allowed  for  the  identification  of  single  nucleotide  polymorphisms  (SNPs)  
which  conferred  relatively  large  increases  in  risk,  such  as  APOE ,  or  those  within  
small  targeted  gene  sets  identified  before  analysis,  such  as  SORL1 126 .  However,  
genome-wide  association  studies  (GWAS)  have  generated  large  scale  datasets  from  
case/control  comparisons  that  can  detect  small  effect  size  genetic  links  to  complex  
disorders  including  AD 127 .  
  
While  activation  of  the  immune  system,  particularly  microglia,  was  known  to  occur  in 
AD  as  part  of  normal  pathology 128,129 ,  for  many  years  this  was  thought  to  be  a  
downstream  effect  of  the  disease.  The  results  of  AD  GWAS  provided  the  first  
indication  that  the  innate  immune  system  may  have  a  causal  role  in  the  development  
of  AD.  Identification  of  SNPs  near  genes  such  as  CD33 ,  CR1  and  MS4A6A ,  which  
are  classically  considered  immune  related,  suggests  some  role  for  the  immune  
system  within  the  disease.  The  identification  of  rare  missense  variants  in  genes,  such  
as  TREM2 ,  ABI3  and  PLCG2 ,  which  are  highly  expressed  in  immune  cells 130  has   
provided  further  evidence  for  the  neuroinflammation  theory.  Table  1.1  lists  the  risk  
alleles  identified  in  AD  GWAS  studies  and  the  nearest  gene  to  each  SNP.   
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Lead  SNP  Nearest  gene  Publications  
rs3851179  
PICALM  
131–134   
rs10792832 135–137   
rs11136000  
CLU  
131–133,138   
rs9331896  134–136   
rs4236673  137   
rs3818361  
CR1  
132,139   
rs6656401  135–138   
rs4844610  134   
rs744373  
BIN1  
133,139   
rs6733839  134–136   
rs4663105  137   
rs3764650  
ABCA7  
139   
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rs4147929  135,136   
rs3752246  134   
rs111278892 137   
rs610932  
MS4A6A  
139   
rs983392  135,136   
rs2081545  137   
rs10948363 
CD2AP  
135,136   
rs9473117  134   
rs9381563  137   
rs11771145  
EPHA1  
135,136   
rs10808026 134   
rs7810606  137   
rs3865444  CD33  135–137   
rs28834970 
PTK2B  
135,136   
rs73223431 134   
rs11218343  SORL1  134–137   
rs10498633 
SLC24A4  
135,136   
rs12881735 134   
rs12590654 137   
rs8093731  DSG2/SUZ12P1 135,137   
rs35349669 
INPP5D  
135,136   
rs10933431 134,137   
rs1476679  
ZCWPW1  
135,136   
rs1859788  137   
rs17125924 FERMT2  134–136   
rs7274581  
CASS4  
135,136   
rs6024870  134   
rs6014724  137   
rs593742  
ADAM10  
136   
rs442495  137   
rs889555  
BCKDK/KAT8  
136   
rs59735493 137   
rs138190086 ACE  134,136   
rs12444183 PLCG2*  136   
rs75932628 
TREM2*  
134   
  
Table  1.1  Summary  of  reported  AD  GWAS  hits   
Lead  SNPs  and  nearest  genes  identified  in  AD  GWAS  studies.  Certain  loci  have  
differing  lead  SNPs  identified  by  studies  but  are  grouped  by  nearest  gene.  Loci  with  a  
*  next  to  the  gene  name  have  previously  been  identified  in  rare  variant  studies.  
  
The  results  of  GWAS  studies  displayed  here  provide  summaries  of  each  locus,  
highlighting  only  the  most  associated  SNP  and  the  nearest  gene  to  that  SNP  for  each  
region.  Linkage-disequilibrium  (LD)  within  the  human  genome  is  a  terminology  that  
describes  certain  SNPs  within  a  region  that  are  found  to  be  more  associated  with  
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rs187370608 137   
rs7920721  
ECHDC3  
134   
rs11257238  137   
rs28394864 ABI3*  137   
rs179943  ATXN1  140   
rs3826656  NT_011109.848  140   
rs2049161  BC040718  140   
rs597668  EXOC3L2  133   
rs670139  MS4A4E  139   
rs190982  MEF2C  135   
rs2718058  NME8  135   
rs10838725 CELF1  135   
rs9381040  TREML2  136   
rs59685680 SPPL2A  136   
rs4985556  IL-34  136   
rs3740688  SPI1  134   
rs7933202  MS4A2  134   
rs4575098  ADAMTS4  137   
rs184384746 HSEX1  137   
rs6448453  CLNK  137   
rs114360492 CNTNAP2  137   
rs117618017 APH1B  137   
rs113260531 SCIMP  137   
rs2632516  BZRAP1-AS1  137   
rs76726049 ALPK2  137   
rs76320948 AC074212.3  137   
  
each  other  than  would  be  expected  if  they  were  inherited  randomly.  This  means  there  
are  often  multiple  SNPs  within  a  region  in  strong  association  with  the  “lead”  SNP  
identified  in  a  GWAS.  It  is,  therefore,  not  possible  to  tell  from  standard  GWAS  
analysis  which  of  these  SNPs  is  causal.  Additionally,  because  disease  associated  
variants  are  noncoding,  there  are  many  genes  within  a  specific  window  of  the  
associated  SNPs  that  could  be  impacted  by  the  variant.  This  means  that  it  is  also  not  
possible  to  tell  exactly  which  gene,  and  downstream  signalling  pathways,  may  be  
linked  to  disease  risk.  
  
To  address  these  problems,  methods  to  combine  GWAS  data  with  functional  data,  
including  transcriptomics  (expression  quantitative  trait  loci  (eQTL)  maps)  and  open  
chromatin  assays  (chromatin  accessibility  quantitative  trait  loci  (caQTL)  maps).  It  is  
then  possible  to  run  co-localisation  analysis  to  identify  variants  affecting  both  disease  
risk  and  a  functional  output  have  been  developed.  Computation  tools  also  provide  
methods  to  extend  traditional  GWAS  analysis.  For  instance,  GoShifter 141  prioritises   
functional  annotations  to  identify  causal  variants  by  finding  SNP  enrichments  in  
annotated  regions.   
  
In  the  case  of  AD,  these  combination  approaches  have  further  linked  the  immune  
system  to  disease  risk.  For  instance,  when  eQTL  maps  of  monocytes  and  T  cells  
were  colocalized  with  GWAS  summary  statistics  from  a  variety  of  complex  traits,  
significant  co-localisations  with  AD  GWAS  SNPs  were  only  identified  within  the  
monocyte  eQTL  map 142 .  While  this  implied  that  the  myeloid  cell  lineage  of  the  
immune  system  may  be  driving  the  neuroinflammatory  component  of  AD,  it  did  not  
fully  rule  out  a  role  for  neurons  themselves.  Integrative  analysis  of  published  GWAS  
summary  statistics  and  whole-brain  single  cell  RNA-sequencing  data  shows  a  
significant  enrichment  of  AD  GWAS  signal  within  the  specific  gene  expression  pattern  
of  microglial  cells,  while  no  enrichment  was  seen  in  neurons 143 .  AD  risk  SNPs  are  
also  significantly  enriched  in  regions  of  open  chromatin  in  myeloid  cells,  including  
microglia,  but  not  in  whole  brain  chromatin  accessibility  data 144 .  Although  AD  genetics  
studies  have  now  identified  multiple  risk  loci  these  have  not  yet  provided  direct  




1.5.3  The  role  of  microglia  in  Alzheimer’s  disease  
Genetic  studies  have  spurred  a  resurgence  of  research  into  how  microglial  function  
changes  during  AD.  When  Alois  Alzheimer  first  described  the  brain  pathology  of  AD,  
in  addition  to  identifying  amyloid  plaques  and  tau  tangles,  he  also  observed  
alterations  in  the  glia  surrounding  these  abnormal  proteins,  including  the  
development  of  “fibers”  and  “adipose  saccules” 93 .  Since  this  initial  description,  there  
has  been  a  growing  body  of  research  that  focuses  on  microglial  involvement  in  AD.  
This  has  provided  evidence  that  often  falls  into  one  of  two  categories:  that  promoting  
microglial  activity  will  be  beneficial  in  AD  or  that  a  reduction  in  activity  will  slow  AD  
progression.  However,  these  two  ideas  may  not  be  mutually  exclusive  in  that  certain  
processes  may  be  both  beneficial  or  harmful  depending  on  the  context.   
  
Microglial  phagocytosis  is  a  good  example  of  the  above  phenomenon.  Initially,  
research  focussed  on  microglial  phagocytosis  of  amyloid  plaques  within  the  
brain 129,145,146 ,  in  part  due  to  the  observed  physical  association  of  microglia  with  the  
plaques.  It  has  been  suggested  that  microglial  recruitment  to  plaque  sites  promotes  
phagocytosis  and  lowers  plaque  burden 147 .  However,  as  the  disease  progresses  the  
phagocytic  capability  of  microglia  reduces 148  and  in  fact  the  cytokines  produced  by   
the  process  are  part  of  a  negative  feedback  loop  that  reduces  phagocytosis 147 .  The  
evidence  from  these  mouse  studies  implies  that  promoting  microglial  phagocytosis  
could  be  a  viable  therapeutic  target  as  it  reduced  amyloid  load.  However,  selective  
reduction  in  microglial  populations  in  an  AD  mouse  model  may  reduce  neuronal  loss  
without  impacting  amyloid  load 149  which  suggests  microglial  phagocytosis  of  amyloid   
is  not  necessarily  required  for  the  reversal  of  AD  symptoms.  In  fact,  microglial  
phagocytosis,  via  a  complement  dependent  mechanism,  has  since  been  linked  to  
excessive  engulfment  of  healthy  synapses 150 .  This  means  that  increasing  microglial  
phagocytic  capabilities  may  in  turn  lead  to  further  neuronal  loss.   
  
Outside  of  phagocytosis,  microglia  have  been  linked  to  a  variety  of  other  molecular  
processes  in  AD.  For  instance  CSF-1R  inhibition  in  the  5XFAD  mouse  model  of  AD  
has  been  shown  to  significantly  reduce  the  seeding  of  plaques  within  the  brain 151,152 ,  
although  Aβ  accumulation  still  appears  in  cortical  blood  vessels.  Other  work  suggests  
that  microglia  may  form  a  barrier  around  developing  plaques  which  reduces  further  
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accumulation  of  Aβ 146 .  In  tauopathy  mouse  models,  microglia  aid  the  propagation  of  
tau  across  the  brain  via  the  secretion  of  previously  phagocytosed  tau  in  exosomes 153 .  
  
Further  insights  into  microglial  functions  in  AD  have  come  from  studying  mutations  
identified  by  GWAS.  For  example,  multiple  studies  have  functionally  characterised  
mutations  in  TREM2 154,155 .  Triggering  receptor  expressed  on  myeloid  cells  2  (TREM2)  
is  a  receptor  that  signals  through  a  TYROBP/DAP12  dependent  mechanism  to  
activate  a  variety  of  signalling  pathways  and  downstream  functions,  such  as  
phagocytosis  and  chemotaxis 156 .  A  variety  of  approaches  have  shown  that  
disease-associated  missense  mutations  in  TREM2  can  alter  microglial  phagocytosis,  
survival  and  proliferation 156 .  The  soluble  form  of  TREM2,  produced  following  
cleavage  of  the  receptor,  has  also  been  implicated  in  AD 157–159 .  There  is  evidence  that  
TREM2  may  function  in  conjunction  with  other  GWAS  risk  genes  during  AD  including  
APOE 160,161 ,  CD33 162   and  MS4A 163 .  
  
Alternative  experimental  approaches  have  examined  how  microglial  functions  change  
in  AD  patients  compared  to  age  matched  healthy  controls,  particularly  at  the  level  of  
gene  expression.  In  mice,  two  studies  have  identified  microglial  populations  that  only  
appear  in  diseased  states 164,165  and  identify  a  loss  of  homeostatic  gene  expression   
( P2RY12 ,  CX3CR1  and  TMEM119 )  alongside  an  increase  in  inflammatory  markers  
such  as  AXL ,  CLEC7A  and  CST7 .  Additionally,  activation  of  TREM2  signalling  
pathways  were  required  for  the  formation  of  this  disease  associated  subtype  of  
microglia  cells  in  mice.  In  human  samples,  single  cell  analysis  of  AD  post-mortem  
brain  samples  also  identified  a  disease  specific  population  of  microglial  cells 166 .  Like  
the  populations  identified  in  mice,  these  cells  had  increased  expression  of  genes  like  
SPP1  and  APOE .  The  disease  specific  microglia  also  showed  an  increased  
expression  of  HLA  and  complement  linked  genes,  compared  to  non-disease  linked  
microglia.   
  
In  summary,  it  is  clear  that  microglia  play  a  significant  role  in  how  our  brains  function  
in  health  and  disease  but  exactly  how  microglial  processes  change  in  disease  and  
precisely  how  to  target  the  same  pathways  in  treatments  remains  unclear.  Much  of  
this  complexity  often  arises  because  microglia  seem  to  play  both  detrimental  and  
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beneficial  roles  in  many  diseases  depending  on  the  stage,  activation  pattern  or  model  
system  being  studied.   
  
  
1.6  Studying  human  microglia   
  
While  significant  advances  have  been  made  in  microglial  research,  many  of  the  
studies  that  have  been  used  to  understand  microglia  function  in  health  and  disease  
have  been  carried  out  in  mice.  Mouse  models  are  an  invaluable  tool,  enabling  large  
scale  studies,  manipulation  of  the  cells  and  providing  a  way  to  study  microglia  
throughout  the  lifespan  of  an  organism.  However,  studies  in  mice  are  not  without  
limitations  and  controversies 167–169 .  There  are  significant  differences  in  the  
fundamental  functions  of  microglia  in  mice  and  humans,  including  differences  in  
marker  expression,  such  as  IFNγ  and  TLR4,  and  differences  in  response  to  
pharmacological  compounds.  In  mouse  models  of  AD,  microglia  are  often  described  
as  taking  on  an  activated  phenotype  while  in  human  autopsy  samples  the  cells  
appear  to  degenerate  with  age,  often  referred  to  as  dystrophic  or  senescent 170 .  This  
can  lead  to  opposing  theories  about  the  role  microglia  play  in  disease.   
  
However,  primary  human  microglia  are  extremely  difficult  to  source  and  come  with  
experimental  caveats.  Many  commercially  available  human  microglia  sources  are  
fetal  samples  which  may  behave  differently  to  fully  developed  microglia.  Additionally,  
commercially  available  cells  are  often  cultured  which  can  impact  microglial  
expression 171 .  Protocols  for  accessing  human  adult  microglia  cells  from  both  
post-mortem  and  surgical  tissues  have  been  refined  and  appear  to  yield  relatively  
pure  samples 172–174 .  Although  isolated  human  microglia  may  have  high  purity,  there  
are  multiple  experimental  factors  to  consider  when  using  these  cells.  Even  small  
periods  of  culturing  can  alter  the  profile  of  human  microglia 171,175  and  little  is  known   
about  how  the  isolation  protocols  (dissociation  and  cell  marker  expression  based  
sorting)  may  impact  microglial  profiles.  Small  scale  microarray  analysis  of  sorted  
murine  mammary  glands  has  suggested  that  fluorescence  activated  cell  sorting  
(FACS)  has  minimal  impact  on  gene  expression 176 .  However,  full  comparisons  have  
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not  been  carried  out  to  understand  how  FACS  sorting  may  impact  immune  cell  
expression,  particularly  microglia.  
  
While  it  is  possible  to  isolate  fresh  primary  adult  human  microglia  from  neurosurgical  
patients,  in  order  to  study  microglia  from  healthy  individuals,  samples  must  be  
acquired  from  post-mortem  tissue.  As  microglial  phenotypes  have  been  shown  to  be  
heavily  dependent  on  the  active  neuronal  environment 171 ,  it  is  therefore  difficult  to  
know  how  much  post-mortem  delay  impacts  microglia.  A  study  comparing  isolated  
microglia  from  brains  with  differing  lengths  of  post-mortem  delay  demonstrated  that  
disease  state  had  a  greater  impact  on  microglia  than  the  time  between  death  and  
collection 175 .  However,  it  is  difficult  to  directly  compare  fresh  microglia  to  post-mortem  
samples  while  controlling  for  confounding  factors.  Therefore,  it  is  impossible  to  
definitively  know  the  impact  of  post-mortem  collection  on  microglial  phenotype.  
  
1.6.1  Transcriptomic  studies  in  primary  human  microglia  
RNA-sequencing  technology  enables  the  study  of  the  whole  transcriptome  of  cells  
and  whole  tissues.  Statistical  analysis  of  the  resulting  data  can  be  used  to  compare  
the  transcriptional  profiles  of  samples  across  a  variety  of  conditions.  As  isolation  
protocols  for  human  primary  microglia  have  improved  RNA-sequencing  has  become  
widely  used  to  understand  differing  aspects  of  microglia.  This  includes  comparisons  
between  human  and  mouse  samples 171 ,  identifying  microglia-specific  marker  
genes 177,178 ,  comparison  of  transcriptomes  across  ages 179 ,  highlighting  region  and  
disease  specific  changes  in  gene  expression 180  and  understanding  the  role   
environment  plays  in  microglial  gene  expression 171 .  
  
While  RNA-sequencing  at  a  bulk  level  has  provided  tools  to  study  large  scale  gene  
expression  and  generated  vast  amounts  of  data,  the  ability  to  use  the  technology  at  
the  single-cell  resolution  has  provided  a  tool  to  study  gene  expression  at  a  much  finer  
resolution 181,182 .  Single-cell  RNA-sequencing  (scRNA-seq)  allows  identification  of  
individual  populations  of  cells  in  silico,  obviating  the  need  for  prior  knowledge  of  cell  
markers,  and  enabling  comparisons  of  tissue  composition  between  experimental  




scRNA-seq  has  allowed  researchers  to  take  whole  brain  tissue  and  identify  multiple  
cell  types,  such  as  neurons  and  microglia 166,183,184 .  Whole  brain  single  cell  analysis  
has  been  used  to  investigate  changes  that  occur  to  different  cell  types  in  the  brain  
during  development 183  and  disease 166,184 .  Being  able  to  identify  microglia  from  whole   
brain  samples  also  removes  the  cell  sorting  step  required  for  bulk  RNA-sequencing,  
which  in  turn  reduces  the  chances  of  experimental  processes  impacting  microglial  
gene  expression.  However,  within  whole  brain  single  cell  analysis  the  fraction  of  
microglia  is  relatively  low  (3%  reported  by  Mathys  et  al. 166 )  and  smaller  numbers  of  
cells  per  subgroup  makes  statistical  comparisons  more  difficult.  Therefore,  it  is  also  
possible  to  use  single-cell  sequencing  on  sorted  primary  human  microglia 185,186 ,  in  
order  to  better  capture  subtle  microglial  population  changes.  This  has  been  used  to 
further  our  understanding  of  microglial  populations  across  ages 185   and  disease 185,186 .  
  
An  extended  review  of  how  transcriptional  analysis  of  primary  microglia  has  impacted  
our  understanding  of  the  cell  type  can  be  found  in  section  2.1.  While  current  
published  datasets  have  provided  an  insight  into  microglial  transcriptomes,  many  are  
still  based  on  relatively  small  patient  numbers.  This  is  largely  because  access  to  
primary  human  microglial  samples  is  still  difficult.  Growing  brain  bank  collections  
have  allowed  access  to  larger  numbers  of  post-mortem  samples  but  these  studies  
are  still  limited  by  patient  number  (with  the  largest  reported  at  48  collections 166 )  and  
often  cover  only  specific  disease  states.  Fresh  human  microglia  are  even  more  
difficult  to  access,  coming  from  either  fetal  samples  or  neurosurgical  patients.   
  
1.6.2  Modelling  human  microglia  
While  studying  primary  human  microglia  is  important  for  understanding  the  cells  in  
health  and  disease,  there  are  clear  limitations  with  these  studies  particularly  around  
scale  and  the  ability  to  experimentally  manipulate  the  cells.  Therefore,  a  clear  
challenge  has  been  to  develop  ways  to  model  human  cells  in  the  lab.  Induced  
pluripotent  stem  cells  (iPSCs)  are  proliferating  cells  that  have  been  reverted  back  to  
a  stem  cell  like  state  from  adult  cells  and  they  have  the  potential  to  differentiate  into  
any  cell 187–190 .  This  means  iPSC  based  cell  model  systems  provide  researchers  with  a  
useful  tool  for  studying  human  disease  in  a  dish 191 :  they  are  able  to  be  used  at  scale,  
can  be  manipulated  experimentally  and  allow  for  repeated  sampling.  Large  scale  
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banks  of  iPSC  lines,  such  as  the  HipSci  consortium,  mean  that  researchers  can  also  
run  iPSC  based  experiments  using  large  numbers  of  both  healthy  and  diseased  cell  
lines.   
  
As  iPSC  cells  can  technically  be  differentiated  into  any  cell  in  the  body,  methods  have  
been  developed  to  differentiate  these  cells  along  a  myeloid  lineage.  Initially  these  
studies  focussed  on  the  development  of  macrophage  models  and  their  utilisation  for  
studying  immune  response 192–195 .  Many  of  these  iPSC-derived  macrophage  
differentiation  protocols  make  use  of  the  induction  of  embryoid  bodies  (EB)  from  stem  
cells.  These  EB  structures  are  made  up  of  cells  from  all  three  germ  layers 196  that  can   
then  further  differentiate  into  more  specialised  cells.   
  
However,  in  more  recent  years  there  has  also  been  a  focus  on  pushing  the  myeloid 
cells  closer  towards  the  specialised  microglia-like  phenotype.  These  protocols  range  
from  simple  monoculture  based  systems 197–201 ,  similar  to  those  used  to  generate  
macrophage-like  cells,  to  more  complex  co-cultured 198,202  and  organoid  
systems 200,203–206 .  These  more  complex  model  systems  build  on  the  idea  that  much  of  
the  unique  microglial  transcriptional  signature  comes  from  the  environmental  
stimulation  they  receive  from  neurons  and  other  parts  of  the  CNS 171 .  
  
A  major  factor  to  consider  when  using  in-vitro  models  for  human  cells  is  
understanding  how  accurately  the  cell  culture  systems  capture  the  primary  cell  type.  
Often  this  comparison  is  limited  to  marker  gene  expression  and  functional  
capabilities.  For  a  detailed  analysis  of  how  the  iPSC  models  described  above  have  
been  compared  to  primary  cells  see  Chapters  3  and  4.  For  microglia  particularly,  
comparison  is  complex,  as  the  primary  cells  are  difficult  to  access  and  therefore  
transcriptional  comparisons  are  often  made  across  studies.  This  can  often  lead  to  
confounding  batch  effects,  especially  when  running  small  scale  comparisons.  
Systematic  comparisons  of  model  systems  to  the  primary  microglia  can  be  used  to  
highlight  potential  signalling  pathways  that  are  not  switched  on  in-vitro  and  could  be  





1.7  Thesis  overview  
  
The  overarching  theme  of  the  following  thesis  builds  on  section  1.6  and  the  
difficulties  around  studying  human  microglia.  I  aim  to  answer  three  major  questions  
throughout  the  thesis:  1.  How  does  microglial  composition  and  gene  expression  
profile  change  across  a  population?  2.  How  accurately  do  current  simple  in-vitro  
model  systems  of  human  microglia  capture  the  profile  of  primary  human  cells?  3.  
Does  culturing  stem  cell  derived  microglia  with  neurons  move  the  model  systems  
closer  to  the  primary  phenotype?  
  
The  analysis  in  the  second  chapter  of  my  thesis  forms  part  of  a  large-scale  project  in  
collaboration  with  Dr  Adam  Young  and  Dr  Natsuhiko  Kumasaka  studying  the  genetic  
architecture  of  human  primary  microglia.  As  part  of  the  project  we  collected  and  
processed  the  largest  number  of  fresh,  primary  human  microglia  samples  to  date  
from  a  wide  variety  of  clinical  phenotypes.  In  this  chapter  I  used  single  cell  
RNA-sequencing  to  identify  different  subpopulations  of  primary  microglia  and  
identified  how  the  likelihood  of  finding  cells  within  these  populations  is  influenced  by  
clinical  phenotypes.  I  then  used  bulk  and  single  cell  RNA  sequencing  data  from  the  
same  patient  population  to  further  understand  how  clinical  phenotypes  such  as  age,  
pathology  and  sex  influcenced  microglial  transcriptomes.   
  
In  the  third  chapter  of  my  thesis,  I  focus  on  the  transcriptional  profiles  of  in-vitro  
models  of  microglia  and  how  closely  they  match  the  transcriptional  profile  of  the  
primary  human  cell  type.  I  collected  publicly  available  data  and  combined  it  with  
available  in-house  datasets  to  generate  a  large  scale  analysis  project  to  compare  
primary  human  microglia  with  monocyte-derived  macrophages,  cancer-cell  lines,  
iPSC-derived  macrophages  and  iPSC-derived  microglia.  For  all  the  data,  I  used  raw  
sequencing  files  that  were  all  processed  through  the  same  pipeline  and  I  ensured  
that  I  collected  data  from  multiple  studies  for  each  cell  type.  Both  of  these  decisions  
were  made  to  reduce  the  batch  effects  that  can  occur  when  comparing  sequencing  
data  across  different  studies 207–209 .  I  used  the  processed  data  to  understand  how  the  
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different  in-vitro  systems  capture  the  gene  expression  of  the  primary  cells  and  which  
signalling  pathways  may  not  be  switched  on  in  these  in-vitro  systems.   
  
In  the  final  results  chapter  of  my  thesis,  I  will  focus  on  more  complex  stem  cell  based  
model  systems,  including  co-culture  and  orgainoid  based  models.  This  forms  part  of  
a  collaboration  with  Dr  Phil  Brownjohn  and  Dr  Moritz  Haneklaus,  from  the  Livesey  
Lab,  working  with  their  published  microglia  differentiation  protocols 200 .  I  initially  used  
bulk  RNA-sequencing  to  add  the  complex  model  systems  to  the  large  dataset  
generated  in  Chapter  3  in  order  to  understand  how  the  more  complex  model  systems  
compared  to  the  monoculture  systems  described  in  Chapter  2.  I  then  used  single  cell  
sequencing,  and  particularly  single  cell  trajectory  analysis,  to  understand  how  
microglial  cells  from  each  of  the  model  systems  fit  on  a  developmental  pathway  that  
ultimately  ends  with  the  primary  cell  type.   
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Chapter  2:  Heterogeneity  in  primary  adult  microglial  transcriptomes  
  
Collaboration  note  
The  work  described  in  the  following  chapter  forms  part  of  a  collaborative  project.  
Patient  samples  were  collected  and  primary  microglia  were  isolated  by  Dr  Adam  
Young  and  colleagues  at  the  Division  of  Clinical  Neurosciences  based  at  Cambridge  
University  Hospital  and  the  Wellcome  Trust  Medical  Research  Council  Cambridge  
Stem  Cell  Institute.  Single  cell  sequencing  preparation  was  carried  out  by  the  single  
cell  sequencing  facility  at  the  Wellcome  Sanger  Institute.  Myself  and  Dr  Andrew  
Knights  worked  collaboratively  to  process  the  bulk  primary  microglia  samples  for  
sequencing.  Dr  Natsuhiko  Kumasaka  ran  the  initial  quality  control  analysis  across  the  
dataset.  For  the  bulk  data,  he  used  genotype  information  to  identify  any  sample  
swaps  and  mixes  and  for  the  single  cell  analysis  he  ran  the  initial  processing  to  
remove  poor  quality  samples.  
  
Initial  analysis  of  the  single  cell  dataset  was  carried  out  by  myself  including  
visualisation  and  clustering  of  single  cell  data,  links  to  clinical  metadata  and  
Alzheimer’s  disease.  It  was  then  determined  that  the  analysis  needed  to  be  updated  
to  be  corrected  for  potential  batch  effects  or  confounding  factors.  Due  to  an  injury,  
and  a  3  month  medical  intermission  of  my  PhD,  Dr  Natsuhiko  Kumasaka  ran  the  
re-analysis  of  the  data  in  order  to  prepare  a  manuscript  for  submission 210 .  The  single  
cell  work  discussed  in  this  chapter  is  from  the  analysis  run  by  Dr  Natsuhiko  
Kumasaka  and  some  extended  work  by  myself.  Any  figures  taken  directly  from  the  
analysis  are  noted  in  the  figure  legend.   
  
  
2.1  Introduction  
  
As  interest  in  microglia  has  developed  it  is  important  to  fully  characterise  the  gene  
expression  profile  of  primary  microglia,  both  to  understand  how  they  are  perturbed  in  
disease  and  how  we  can  be  modeled  in-vitro .  To  date,  most  studies  of  primary  
microglia  have  been  in  mice,  with  validation  in  small  numbers  of  human  samples.  
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Many  studies  have  used  RNA-sequencing  to  identify  transcriptional  markers  of  
microglia,  with  a  focus  on  differentiating  the  native  cell  from  classical  macrophages  
and  other  tissue  resident  macrophages.   
  
2.1.1  Marker  gene  identification  in  mice  and  human  samples  
Microarray  analysis  has  been  used  to  compare  tissue  resident  dendritic  cells  (from  
the  spleen,  liver  and  lung)  and  tissue  resident  macrophages  (spleen,  lung  and  
peritoneal  macrophages  and  microglia)  in  C57BL/6J  mice  in  order  to  identify  markers  
of  each  cell  type 177 .  Microglia  were  shown  to  have  a  lower  expression  of  hundreds  of  
transcripts  that  were  expressed  in  other  tissue  resident  macrophages.  The  paper  
also  identified  gene  expression  that  is  specific  to  microglia  in  comparison  to  the  other  
tissue  resident  cells,  notably  the  transcription  factor  SALL1  and  cell  surface  marker  
CX3CR1 .  More  recently 178  a  six-gene  microglial  transcriptional  signature  ( P2RY12 ,   
GPR34 ,  PROS1 ,  GAS6 ,  C1QA  and  MERTK )  has  been  identified  which  appears  to  
distinguish  microglia  from  other  immune  cells,  including  other  myeloid  cell  types,  and  
other  brain  cells,  such  as  astrocytes  and  neurons.  As  well  as  validating  the  unique  
signature  within  primary  human  cells,  the  group  also  cultured  adult  mouse  microglia  
in  the  presence  or  absence  of  TGF-β  and  demonstrated  that  the  signature  they  
described  is  TGF-β  dependent.   
  
Two  independent  studies 211,212  have  since  pinpointed  TMEM119 ,  a  protein  coding   
gene  originally  linked  to  bone  formation,  as  a  marker  that  distinguishes  native  
microglia  cells  from  infiltrating  myeloid  progenitors.  It  is  currently  unclear  whether  
resident  microglia  cells  and  infiltrating  cells  play  differing  roles  in  disease,  such  as  
AD,  and  the  studies  described  above  suggest  that  finding  markers  for  each  cell  type  
may  help  future  researchers  to  follow  the  role  of  each  cell  type.   
  
2.1.2  Fresh,  primary  human  microglia  bulk  RNA-sequencing  
The  most  extensive  bulk  RNA-sequencing  dataset  of  fresh  human  primary  microglia  
to-date  profiled  the  cell  type  across  19  individuals  between  the  ages  of  5  and  15  and  
also  included  chromatin  accessibility  studies  of  the  same  samples 171 .  Here  it  was  
shown  that  broad  clinical  diagnosis  (acute  ischemia,  epilepsy  and  tumour),  age  and  
sex  had  no  observable  impact  on  microglial  gene  expression  and  highlighted  that  
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pathology  did  not  significantly  affect  expression  of  the  most  highly  expressed  
microglial  genes  in  their  dataset  (e.g.  SPP1 ,  CD74  and  ACTB ).  Using  ATAC-seq  and 
ChIP-seq,  they  detected  the  most  enriched  transcription  factor  recognition  motif  
associated  with  open  chromatin  and  highlighted  a  dominant  signature  for  the  PU.1  
transcription  factor.  The  group  also  ran  RNA,  ATAC  and  ChIP-seq  on  matched  
samples  from  fresh  collections  and  cells  that  had  been  cultured  for  varying  lengths  of  
time.  They  noted  that  expression  of  microglia  marker  genes  such  as  CX3CR1  and  
P2RY12  as  well  as  transcription  factors  such  as  SALL1 ,  decreased  after  a  period  of  
only  6  hours  in  culture  and  continued  to  decline  over  7  days  in  cell  culture.  
  
The  authors  also  demonstrated  that  the  addition  of  TGF-β  to  the  in-vitro  culture  
media  of  the  primary  cells  had  a  modest  effect  on  gene  expression,  with  expression  
of  certain  genes,  such  as  SALL1 ,  increasing  back  towards  the  levels  seen  in  the  
fresh  primary  cells.  Although,  it  was  noted  that  none  of  the  genes  whose  expression  
increased  in  the  presence  of  TGF-β  returned  to  fully  match  the  levels  seen  in  the  
primary  cells.  As  had  been  suggested  in  earlier  studies 178 ,  this  provided  further  
evidence  that  TGF-β  signalling  is,  at  least  in  part,  important  for  maintaining  microglial  
transcriptional  identity.   
  
2.1.3  Single  cell  sequencing  and  primary  microglia  
Advances  in  technology  means  that  it  is  now  possible  to  study  transcriptomes  at  a  
single  cell  level,  which  allows  researchers  to  study  heterogeneity  of  cell  types  in  a  
population.  Single  cell  profiling  of  16,000  CD45  and  CD11b  sorted  microglial  cells  
from  15  individuals  (7  autopsy  and  8  biopsy  samples)  identified  14  unique  microglial  
populations  within  the  brain 185 .  Within  the  14  subpopulations  identified,  the  authors  
noted  that  the  three  largest  clusters  were  transcriptionally  similar  with  no  differentially  
expressed  transcription  factors  between  groups.  It  was,  therefore,  suggested  that  
these  subpopulations  represented  cells  of  the  same  class  but  in  different  activation  
states.  The  remaining,  more  transcriptionally  distinct,  microglial  clusters  were  
considered  more  specialised  subtypes  of  microglial  cells.   
  
Single  cell  transcriptomics  can  also  be  used  to  understand  dynamic  changes  in  cell  
expression  or  cell  proportions  in  health  and  disease  across  whole  tissues.  In  
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microglial  research  this  is  of  particular  interest  when  looking  at  changes  that  occur  
during  Alzheimer’s  disease  (AD).  Single  cell  analysis  of  whole  brain  tissue  has  
identified  AD  specific  microglia  gene  expression  changes  in  both  mice 164  and   
human 166,184  samples.  Although  it  is  worth  noting  that  as  microglia  represent  a  small   
fraction  of  cells  within  the  brain,  there  are  limitations  in  the  ability  to  understand  
heterogeneity  within  the  cell  type  due  to  low  cell  numbers.   
  
2.1.4  The  impact  on  age  and  sex  on  microglial  transcriptomes  
As  microglia  have  a  distinct  origin  and  are  not  replenished  by  circulating  monocytes  
under  normal  conditions 17 ,  previous  work  has  also  focused  on  how  microglial  
transcriptomes  change  with  age.  Comparison  of  10  aged  (average  age  at  death  =  95)  
bulk  post-mortem  microglia  RNA-sequencing  profiles  to  a  publicly  available  dataset  
of  primary  microglia  from  middle-aged  individuals  (mean  age  =  53)  identified  1060  
upregulated  and  1174  downregulated  genes  in  the  aged  microglia 179 .  Pathway  
enrichment  analysis  showed  that  upregulated  genes  were  enriched  for  amyloid  fiber  
formation  and  those  genes  with  decreased  expression  in  aged  microglia  were  
enriched  for  TGF-β  signaling.  The  loss  of  TGF-β  signaling  in  aged  cells  was  
suggested  to  represent  a  loss  of  the  homeostatic  function  of  microglia  during  aging.   
  
While  comprehensive  aging  studies  in  human  microglia  are  complex,  due  to  the  lack  
of  accessibility  of  the  cell  type,  it  is  possible  to  monitor  changes  in  microglial  
transcriptomes  across  the  lifespan  of  mice 213 .  Using  single  cell  sequencing, 
researchers  were  able  to  identify  populations  of  microglia  enriched  for  cells  from  
aged  mice  and  showed  that  the  gene  expression  profile  of  these  cells  was  shifted  
towards  a  more  active  state,  due  to  increased  expression  of  inflammatory  markers.  
However,  the  authors  noted  that  the  proportion  of  the  cells  in  this  increased  active  
state  was  only  a  small  fraction  of  the  total  cells  in  these  aged  mice.  It  was  suggested  
in  the  study  that  this  may  be  because  the  activated  cells  were  responding  to  local  
disruptions,  such  as  blood  brain  barrier  compromise 214  or  microinfarcts 215 ,  that  can  be   





Previous  work  has  also  focused  on  whether  microglial  transcriptomes  differ  between  
sexes.  Evidence  from  mouse  studies  is  often  conflicting.  One  study 216 ,  noted  large  
numbers  of  differentially  expressed  genes  between  male  and  female  adult  mice  and  
the  authors  highlighted  that  male  microglia  show  an  increased  inflammatory  
phenotype.  The  researchers  also  showed  that  female  microglia  are  protective  during  
ischemia  within  mice  and  suggested  that  it  was  due  to  the  fact  that  the  microglia  were  
able  better  control  excessive  inflammation.  Further  studies  in  mice  have  also  
highlighted  how  microglial  gene  expression  can  be  impacted  in  sex  specific  ways  
during  development 217  and  as  part  of  the  interaction  with  the  microbiome 218 .  However,   
Hammond  et  al. 213 ,  compared  single  cell  microglial  gene  expression  in  male  and  
female  mice  across  three  major  developmental  ages  (E14.5,  P4/P5,  and  P100)  and  
highlighted  only  a  small  difference  between  the  sexes.  While,  as  expected,  genes  on  
the  sex  chromosomes  were  differentially  expressed  between  male  and  female  mice  
there  was  only  a  small  fraction  of  cells  (~0.5%  of  microglia)  that  appeared  to  cluster  
in  a  sex  specific  way.  The  cluster  was  enriched  for  female  cells  of  the  P4/P5  
developmental  age  and  showed  increased  expression  of  genes  such  as  CD74  and  
ARG1 .  In  human  studies,  the  evidence  for  sex-specific  expression  of  genes  in  
microglia  is  limited.  Using  bulk  RNA-sequencing,  Gosselin  et  al. 171  observed  that  a   
small  set  of  genes,  most  located  on  the  sex  chromosomes,  showed  sex-specific  
differences.   
  
One  limitation  of  the  studies  discussed  above  are  their  small  sample  sizes.  This 
means  that  previous  observations  of  correlations  between  microglial  transcriptional  
profiles  and  life-history  or  clinical  pathology  are  based  on  phenotypes  from  small  
numbers  of  individuals.  In  this  chapter,  I  describe  the  analysis  of  bulk  and  single  cell  
RNA-sequencing  data  from  a  cohort  of  141  patients  samples  of  fresh  primary  adult  
human  microglia,  the  largest  cohort  to  date.  I  describe  how  heterogeneous  primary  
microglia  were  across  patients  and  identified  markers  for  individual  subpopulations  of  
the  cell  type.  I  highlight  how  clinical  pathology  was  a  major  driver  of  heterogeneity  
across  microglia  and  how  this  information  can  be  used  in  conjunction  with  
subpopulation  markers  to  infer  biological  relevance  of  clusters.  Using  both  single  cell  
and  bulk  data  I  investigate  how  various  other  clinical  phenotypes,  such  as  age,  sex  
and  brain  region,  can  affect  microglial  transcriptomes.   
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2.2  Methods  
  
2.2.1  Experimental  design  and  sample  collection  
Human  brain  tissue  was  obtained  with  informed  consent  under  protocol  REC  
16/LO/2168  approved  by  the  NHS  Health  Research  Authority.  All  collections  were  
completed  by  Dr  Adam  Young  and  his  colleagues  at  the  Division  of  Clinical  
Neurosciences  based  at  Cambridge  University  Hospital.  Samples  were  collected  
from  neurosurgical  patients  undergoing  scheduled  procedures  where  tissue  would  
normally  be  removed.  Patient  pathologies  were  grouped  into  four  major  categories:  
control,  haemorrhage,  hydrocephalus,  trauma  and  tumour.  Control  samples  include  
tissue  where  the  site  of  sampling  is  a  site  further  away  from  the  site  of  injury  or  
disease  (i.e.  tumour  biopsy  where  the  tissue  sampled  is  considered  pathologically  
normal).  Figure  2.1  summarises  the  metadata  for  all  patient  samples  collected  and  
includes  the  experimental  design  of  the  study.  Tissue  samples  were  used  for  both  
bulk  and  single  cell  RNA-sequencing.  Paired  blood  samples  were  also  taken  from  
each  patient  at  the  induction  of  anaesthesia  for  genotyping.  However,  genotype  
information  was  not  used  in  the  analysis  described  in  this  chapter.  
  
Once  collected  tissue  was  immediately  transferred  to  Hibernate  A  low  fluorescence  
(HALF)  supplemented  with  1x  SOS  (Cell  Guidance  Systems),  2%  Glutamax  (Life  
Technologies),  1%  P/S  (Sigma),  0.1%  BSA  (Sigma),  insulin  (4g/ml,  Sigma),  pyruvate  
(220  g/ml,  Gibco)  and  DNase  1  Type  IV  (40  g/ml,  Sigma)  on  ice  and  transported  to  a  




Figure  2.1   Schematic  of  experimental  design   
Experimental  protocol  for  all  (141)  samples  collected  as  part  of  the  16/LO/2168  linked  
study.  Plot  created  by  Dr  Natsuhiko  Kumasaka.   
  
2.2.2  Tissue  processing  and  cell  sorting  
All  tissue  processing  was  completed  by  Dr  Adam  Young  colleagues  at  the  Division  of  
Clinical  Neurosciences  based  at  Cambridge  University  Hospital  and  the  Wellcome  
Trust  Medical  Research  Council  Cambridge  Stem  Cell  Institute.  
  
Brain  tissue  was  mechanically  digested  in  fresh  ice-cold  HALF  supplemented  with  1x  
SOS  (Cell  Guidance  Systems),  2%  Glutamax  (Life  Technologies),  1%  P/S  (Sigma),  
0.1%  BSA  (Sigma),  insulin  (4g/ml,  Sigma),  pyruvate  (220  g/ml,  Gibco)  and  DNase  1  
Type  IV  (40  g/ml,  Sigma).  The  prepared  mix  was  spun  in  HBSS+  (Life  Technologies)  
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at  300g  for  5  mins  and  supernatant  discarded.  The  digested  tissue  was  rigorously  
triturated  at  4°C  and  filtered  through  a  70  m  nylon  cell  strainer  (Falcon)  to  remove  
large  cell  debris  and  undigested  tissue.  Filtrate  was  spun  in  a  22%  Percoll  (Sigma)  
gradient  with  DMEM  F12  (Sigma)  and  spun  at  800g  for  20  mins.  Supernatant  was  
discarded  and  the  pellet  was  resuspended  in  ice  cold  supplemented  HALF.  
  
For  single  cell  smartseq2  sequencing,  human  microglia  were  sorted  using  
fluorescence-activated  cell  sorting  (FACS).  The  isolated  cell  suspension  was  
incubated  with  conjugated  PE  anti-human  CD11b  antibody  (BioLegend)  for  20  mins  
at  4°C.  Cells  were  washed  twice  in  ice  cold  supplemented  HALF  and  stained  with  
Helix  NP  viability  marker.  Cell  sorting  was  performed  on  BD  AriaIII  cell  sorter  
(Becton,  Dickinson  and  Company,  Franklin  Lakes,  New  Jersey,  US)  at  the  University  
of  Cambridge  Cell  Phenotyping  Hub  at  Cambridge  University  Hospital,  Cambridge,  
UK.  Cells  were  sorted  into  96  well  plates,  prepared  by  the  Wellcome  Sanger  Institute  
for  the  purposes  of  single  cell  sequencing.  
  
To  avoid  sustained  stress  on  microglia  as  a  result  of  prolonged  sorting  times  for  bulk  
sequencing  magnetic-activated  cell  sorting  was  performed  on  these  cells.  Isolated  
cell  suspensions  were  incubated  with  anti-CD11b  conjugated  magnetic  beads  
(Miltenyi)  for  15  mins  at  4°C.  Cells  were  washed  twice  with  supplemented  HALF  and  
passed  through  an  MS  column  (Miltenyi).  Each  sample  was  washed  three  times  in  
the  column  and  then  extracted.  Samples  were  added  to  a  1.5ml  Eppendorf  to  which  
300  l  of  RNAlater  (Qiagen)  was  added,  samples  were  stored  at  -80C  prior  to  library  
preparation  and  sequencing.  
2.2.3  RNA  handling  
For  single  cell  sequencing,  96  well  plates  were  prepared  and  sequenced  by  the  
Wellcome  Sanger  Institute  single  cell  core  facility  using  the  SmartSeq2  protocol  219 .  
Extraction  and  library  preparation  of  bulk  samples  was  completed  by  Dr  Andrew  
Knights  and  myself.  Total  RNA  from  the  bulk  primary  microglia  samples  was  
extracted  with  the  Qiagen  AllPrep  DNA/RNA  micro  kit.  This  was  carried  out  according  
to  the  manufacturer's  instructions.  Following  extraction  samples  were  analysed  using  
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an  A gilent  Technologies  Bioanalyser  RNA  Pico  kit  for  quality  (RIN  number)  and  
quantification.  Extracted  RNA  was  stored  at  -80  °C  until  library  preparation.  
  
The  amount  of  total  RNA  extracted  from  these  samples  was  incredibly  varied,  
ranging  from  >  300  ng  to  0.5  ng  of  approximate  yield,  with  the  majority  of  samples  
producing  less  than  10  ng  of  total  RNA.  This  is  a  much  lower  input  RNA  level  than  is  
required  for  traditional  bulk  sequencing  and,  therefore,  we  used  a  low  RNA  input  
library  preparation  pipeline  developed  in-house  by  Dr  Andrew  Knights  which  is  a  
modified  version  of  the  SmartSeq2  protocol  protocols  developed  for  single  cell  
sequencing.  For  samples  with  large  amounts  of  RNA  yields,  10  ng  was  used  as  a  
maximum  input  for  the  protocol.  Samples  with  lower  than  10  ng  of  RNA  input  were  
processed  in  the  same  way,  although  the  number  of  PCR  amplification  cycles  was  
increased  for  certain  samples  to  compensate  for  the  low  input  amounts  (Figure  2.2).  
In  total  120  of  the  141  collected  samples  were  prepared  for  sequencing,  the  21  
samples  that  were  not  included  in  sequencing  pools  were  discarded  due  to  either  
having  no  quantifiable  RNA  or  large  amounts  of  RNA  degradation,  to  the  point  where  
no  RIN  value  could  be  calculated.   
  
25  µL  of  lysis  binding  buffer  (Table  2.1)  was  added  to  the  extracted  RNA,  that  had  
been  diluted  to  25  µL  with  nuclease  free  water.  20  µL  of  oligo-DT  beads  were  added  
to  wells  of  a  96-well  plated  and  washed  once  with  100  µL  of  lysis  binding  buffer  while  
on  a  magnetic  plate.  The  pelleted  bead  plate  was  removed  from  the  magnet  and  the  
beads  were  resuspended  with  the  50  µL  RNA  samples.  The  wells  were  pipette-mixed  
and  incubated  at  room  temperature  for  15  minutes,  with  shaking  (1100  rpm  Mixmate).  
The  plates  were  then  placed  back  on  the  magnet  for  supernatant  removal  and  two  
washes  with  150  µL  of  wash  buffer  A  (Table  2.1).  Samples  were  then  transferred  to  a  
fresh  plate  before  washing  twice  with  50  µL  of  wash  buffer  B  (Table  2.1).   
  
The  samples  were  washed  again  with  50  µL  of  elution  buffer  before  RNA  is  eluted  
from  the  beads  by  re-suspension  in  9.5  µL  of  elution  buffer  and  incubating  at  75  °C  
for  2  minutes.  Plates  were  then  immediately  transferred  back  to  the  magnetic  plate  
and  7  µL  of  eluted  solution  was  transferred  to  a  fresh  plate  on  ice.  2  µL  10  µM  oligo  
dT 30 VN  and  2.34  µL  10  mM  dNTPs  (Thermo)  were  added  to  each  well  of  the  96-well  
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plates  and  samples  were  heated  at  72  °C  for  3  minutes  before  being  rapidly  chilled  
on  ice.  13.65  µL  of  reverse  transcription  (RT)  master  mix  (Table  2.1)  was  added  to  
each  well  of  the  plate  and  following  mixing  the  samples  were  placed  on  a  PCR  block  
for  RT  (Figure  2.2).  
  
Table  2.1  Reaction  mixes  used  in  low-input  RNA-sequencing  library  preparation  
  
  
Following  RT  of  the  samples,  25  µL  of  nuclease-free  water  (NFW)  was  added  to  each  
well  of  the  96-well  plate  and  a  0.8:1  Ampure  XP  clean-up  (Beckman  Coulter  
A663882)  was  performed  using  a  Zephyr  (PerkinElmer).  The  material  was  then  
eluted  in  10  µL  of  10  mM  Tris-HCl  (pH  7.5)  and  13  µL  PCR  master  mix  was  added  to  
the  solution  (12.5  µL  of  2x  KAPA  HiFi  hotstart  and  0.5  µL  of  10  µM  ISPCR  primer).  A  
further  PCR  reaction  was  carried  out  for  amplification  (Figure  2.2);  due  to  the  
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Lysis  binding  
buffer  (100  mL)  
Wash  buffer  A  
(250  mL)  
Wash  buffer  B  
(100  mL)  
RT  master  mix  (per  reaction) 
20  mL  of  1  M  
Tris-HCl  pH  7.5  
(FC  =  200  mM)  
2.5  mL  1  M  
Tris-HCl  pH  7.5  
(FC  =  10  mM)  
1  mL  1  M  Tris-HCl  
pH  7.5  (FC  =  10  
mM)  
5  µL  5x  SmartScribe  FS  Buffer 
12.50  mL  8  M  LiCl  
(FC  =  1  M)  
4.69  mL  8  M  LiCl  
(FC  =  0.15  M)  
1.88  mL  8  M  LiCl  
(FC  =  0.15  M)  
0.63  µL  SUPERase  Inhibitor  
(Thermo  Fisher  AM2696)  
4  mL  500  mM  
EDTA  pH  8  (FC  =  
20  mM)  
500  µL  500  mM  
EDTA  pH  8.0  (FC  
=  1  mM)  
200  µL  500  mM  
EDTA  pH  8.0  (FC  
=  1  mM)  
1.25  µL  0.1  M  dithiothreitol  
2  g  LiDS  
(L9781-5G)  (FC  =  2 
%  w/v)  
0.25  g  LiDS  (FC  =  
0.1  %  w/v)  
96.92  mL  NFW  
5  µL  5  M  betaine  (Sigma  
PCR-grade  B0300-5VL)  
1  mL  1  M  DTT  
(P2325)  (FC  =  10  
mM)  
242.31  mL  NFW    0.15  µL  1  M  MgCl2  
62.5  mL  NFW      0.38  µL  100  µM  TSO  
      
1.25  µL  SMARTScribe  reverse  
transcriptase  (Takara  Clontech  
639538)  
  
variability  in  input  RNA  quantity  for  this  reaction,  the  number  of  PCR  cycles  used  was  
increased  for  low  input  samples  (see  Figure  2.2  for  range).   
  
  
Figure  2.2  PCR  reactions  in  low-input  RNA-sequencing  library  preparation  
  
  
After  the  PCR  reaction,  a  further  25  µL  of  NFW  was  added  to  samples  and  a  0.8:1  
Ampure  XP  clean-up  was  carried  out  before  elution  in  20  µL  of  10  mM  Tris-HCl  (pH  
8.0).  cDNA  was  then  quantified  with  the  Quant-iT  High  Sensitivity  kit  (Thermo  Fisher  
Q33120),  according  to  the  manufacturer’s  instructions.  Samples  were  read  on  a  BMG  
Pherastar.  4  ng  of  cDNA  was  diluted  with  10  mM  Tris-HCl  (pH  7.5)  to  a  volume  of  9.5  
µL.  5  µL  of  a  3x  tagmentation  buffer  (99  mM  Tris  acetate,  198  mM  potassium  
acetate,  30  mM  magnesium  acetate  and  48  %  v/v  N,N-dimethylformamide)  and  0.5  
µL  of  TDE1  were  then  added  and  mixed  before  samples  were  incubated  at  55  °C  for  
5  minutes.  Tagmentation  was  then  halted  by  the  addition  of  2.5  µL  of  stop  buffer  (220  
mM  EDT  and  1.1%  w/v  sodium  dodecyl  sulphate),  with  samples  then  incubated  at  
room  temperature  for  10  minutes.  Tagmented  cDNA  was  then  diluted  to  a  volume  of  
50  µL  with  10mM  Tris-HCl  (pH  7.5)  and  purified  with  a  2:1  ratio  of  Ampure  XP  beads.  
The  cDNA  samples  were  eluted  in  7  µL  of  10mM  Tris-HCl  (pH  7.5)  and  then  
amplified  and  sample  indexed  using  PCR.  Briefly,  the  eluted  7  µL  of  tagmented  cDNA  
was  added  to  2.5  µL  of  i5  index  adapter  and  2.5  µL  of  i7  index  adapter  from  the  
Nextera  XT  index  kit  v2  set  A  ,  0.25  µL  of  50  µM  PC1  primer,  0.25  µL  of  50  µM  PC2  
primer  and  12.5  µL  of  2x  KAPA  HiFi  polymerase.  Mixed  samples  were  then  incubated  
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at  72  °C  for  3  minutes,  98  °C  for  30  seconds,  followed  by  9  cycles  at  98  °C  for  15  
seconds,  62  °C  for  30  seconds  and  72  °C  for  30  seconds,  followed  by  a  final  
extension  at  72  °C  for  3  minutes.  Libraries  were  purified  using  a  0.8:1  ratio  of  Ampure  
XP  beads  and  the  final  individual  libraries  were  eluted  in  20  µL  of  10mM  Tris-HCl  (pH  
7.5).  Samples  were  then  pooled  together  (three  independent  pools)  at  equal  cDNA  
concentrations  and  submitted  for  75  bp  paired-end  sequencing.   
  
2.2.4  Initial  processing  and  quality  control  of  sequencing  data  
Initial  processing  of  sequencing  was  carried  out  by  Dr  Natsuhiko  Kumasaka.  Prior  to  
alignment  adapter  trimming  of  Tn5  transposon  and  PCR  primer  sequences  was  
carried  out  using  the  skewer  package 220 .  Both  bulk  and  smart-seq2  sequencing  data  
were  aligned  using  the  STAR  package 221 ,  version  2.5.3a,  using  ENSEMBL  human  
gene  assembly  90  as  the  reference  transcriptome.  Samples  were  then  quantified  with  
featureCounts 222 ,  version  1.5.3.  Genotype  information  collected  from  patients  was  
then  used  to  check  for  sample  swaps  or  mixing  of  samples  that  may  have  occurred  
during  processing.  Following  QC  for  sample  swaps  and  mixes,  109  patient  samples  
were  used  in  bulk  analysis.   
  
For  single-cell  analysis  each  individual  cell  was  passed  through  a  further  quality  
control  pipeline  to  remove  poor  quality  cells  from  the  dataset.  The  final  thresholds  
used  were:  number  of  expressed  genes  >  500,  number  of  fragments  >  10000,  <  20  
%  mitochondrial  genes  and  the  percentage  of  fragments  mapped  to  the  top  100  
highly  expressed  genes  is  <  70  %.  Demuxlet  223  was  used  to  remove  doublets  from    
two  different  patients  with  different  genetic  backgrounds  from  within  the  sample.  
Following  QC  analysis  9538  cells  from  129  patients  were  taken  forward  for  further  
analysis.  
  
2.2.5  Comparison  of  bulk  data  to  publicly  available  datasets   
Processed  bulk  microglia  RNA-sequencing  data  was  combined  with  publicly  available  
datasets  from  other  cell  types:  brain  tissue  from  The  Genotype-Tissue  Expression  
(GTEx)  Project  (The  data  used  for  the  analyses  described  in  this  thesis  were  
obtained  from  the  GTEx  Portal),  monocytes  from  the  BLUEPRINT  consortium  (this  
study  makes  use  of  data  generated  by  the  BLUEPRINT  Consortium)  and  a  collection  
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of  publicly  available  in-vitro  model  data  (see  section  3.2.1  for  data  references).  Count  
tables  were  combined  and  converted  into  counts  per  million  (CPM)  and  Uniform  
Manifold  Approximation  and  Projection  (UMAP)  analysis  was  run  using  Seurat’s  
RunUMAP  function  with  the  following  parameters:  5  PCs,  30  nearest  neighbours  and  
a  minimum  distance  set  to  0.3.   
  
2.2.6  Classification  of  microglial  cells  using  publicly  available  datasets   
Full  descriptions  of  the  single  cell  data  analysis  carried  out  by  Dr  Natsuhiko  
Kumasaka  can  be  found  in  the  preprint  of  the  manuscript  describing  this  work  210  but   
the  methodology  will  be  summarised  below.  
  
Gene  count  data  for  single  cell  datasets  of  68k  peripheral  blood  mononuclear  cells  
(PBMCs) 224  and  15K  unsorted  brain  cells 225  were  downloaded  from  publicly  available    
sources  and  all  datasets  (including  the  data  collected  for  this  study)  were  converted  
to  Counts  Per  Million  (CPM).  
  
A  latent  factor  linear  mixed  model  was  used,  with  the  3  studies  treated  as  random  
effects,  to  obtain  12  latent  factors.  These  factors  were  then  used  to  run  Uniform  
Manifold  Approximation  and  Projection  (UMAP)  analysis.  The  publicly  available  
datasets  also  included  pre-determined  cell  type  classification  and  these  
classifications  were  then  used  to  identify  microglia  cells  from  within  our  unclassified  
dataset.  8,662  cells  were  identified  as  microglia  and  taken  forward  for  further  
analysis.  
  
2.2.7  Variance  components  analysis   
Variance  components  analysis  was  used  to  determine  how  clinical  and  technical  
factors  within  the  dataset  impacted  gene  expression.  Count  data  (log(TPM+1))  
across  all  genes  whose  TPM>0  for  at  least  10%  of  cells  was  used  in  a  linear  mixed  
model  to  estimate  variation.  13  known  factors  (patient,  number  of  expressed  genes  
per  cell,  pathology,  plate  ID,  ERCC  percentage,  number  of  fragments,  plate  position,  
age,  mitochondria  RNA  percentage,  brain  region,  brain  hemisphere,  ethnicity  and  





2.2.8  Clustering  of  single  cell  data,  differential  expression  and  clinical  
metadata  links  
A  latent  linear  mixed  model  was  again  used  to  estimate  latent  factors  for  downstream  
dimensionality  reduction  and  clustering  on  only  the  microglia  cells  identified  through  
the  methodology  described  in  section  2.2.6.  The  13  factors  described  in  section  2.2.7  
were  included  in  the  model  to  control  for  potential  confounding  between  the  known  
factors  and  unknown  heterogeneity  within  the  dataset.  The  first  15  latent  factors  were  
then  used  within  Shared  Nearest  Neighbour  Clustering  (as  run  in  Seurat  version  
3.0.2)  with  a  resolution  parameter  of  0.2.  The  first  15  latent  factors  were  also  used  to  
run  UMAP  analysis.  
  
The  same  linear  mixed  model  used  for  variance  component  analysis  was  also  used  
for  differential  expression  analysis,  with  the  addition  of  the  four  subpopulations  fitted  
as  a  random  effect.  The  model  was  fit  on  a  gene-by-gene  basis  and  across  each  
factor.  If  the  factor  of  interest  was  numerical  (i.e.  age)  Bayes  factor  of  effect  size  was  
computed  by  comparing  the  full  model  and  the  model  without  the  factor  of  interest.  If  
the  factor  of  interest  was  categorical  with x  levels  (i.e.  pathology  with  5  levels),  
samples  were  partitioned  into  any  of  two  groups.  There  were  2 x -1  contrasts  which  
were  tested  against  outputs  when  removing  the  factor  of  interest  from  the  model  to  
calculate  Bayes  factors.  Bayes  factors  were  then  used  within  a  finite  mixture  model  to  
calculate  the  posterior  probability  as  well  as  the  local  true  sign  rate  ( lstr ).  Lstr  values  
were  used  to  identify  differentially  expressed  genes  ( lstr  >  0.5  unless  stated  
otherwise)  
  
2.2.9  Pathway  enrichment  analysis  
I  then  used  gProfiler 226 ,  version  e94_eg41_p11_36d5c99  with  significance  
determined  at  a  5%  FDR,  to  estimate  the  significance  of  enrichment  across  defined  
pathways,  through  a  hypergeometric  distribution  model.  Gene  lists  were  established  







2.3  Quality  control  analysis  across  datasets  
  
2.3.1  Bulk  RNA-sequencing  quality  control   
Before  running  downstream  analysis  pipelines,  extended  quality  control  analysis  was  
run  on  all  samples  that  passed  the  technical  quality  control  (109  samples  in  bulk  
dataset).  In  bulk  data  initially  correlation  analysis  was  run  between  all  samples  
(averaged  across  all  genes  for  each  sample).  These  correlations  were  then  
compared  to  those  observed  in  BLUEPRINT  monocytes  and  a  small  primary  
microglia  dataset.  Figure  2.3  is  a  heatmap  of  the  correlation  coefficients  across  all  
samples.  While  correlation  coefficients  between  the  monocyte  and  peadiatric  
microglial  samples  are  high  and  consistent  across  all  samples,  within  the  adult  
primary  microglia  dataset  there  is  a  much  larger  amount  of  variability  amongst  
samples.   
  
After  looking  at  variability  amongst  the  samples  collected  as  part  of  this  study,  I  
wanted  to  compare  global  expression  patterns  in  our  bulk  RNA-seq  dataset  to  other  
large  scale  datasets  in  other  similar  cell  types.  I  used  UMAP  analysis  to  understand  
the  transcriptional  similarities  between  primary  microglia,  brain  tissue  from  GTEx,  
monocyte  data  from  BLUEPRINT  and  a  selection  of  in-vitro  models  (note:  for  detailed  
analysis  of  primary  microglia  versus  in-vitro  models  please  refer  to  Chapter  3,  sect).  
The  UMAP  analysis  plot  (UMAP  1  vs  UMAP  2)  highlights  how  samples  group  
together  based  on  their  transcriptional  similarities  (Figure  2.4).   
  
At  the  top  of  the  plot  the  brain  tissue  samples  split  into  two  distinct  groups,  with  
cerebellum  tissue  on  the  left  and  the  remaining  regions  on  the  right.  The  three  
remaining  distinct  clusters  represented:  monocytes,  primary  microglia  and  in-vitro  
models.  The  separation  of  the  microglia  samples  from  other  large  scale  datasets  
suggested  a  transcriptional  signature  in  microglia  that  is  not  captured  by  other  
available  datasets.  The  primary  microglia  data  collected  as  part  of  this  study,  also  
clustered  with  small  numbers  of  samples  from  other  fresh  human  primary  microglia  
datasets.  This  highlights  that  despite  higher  levels  of  variation  between  samples  
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(Figure  2.3),  the  microglia  collected  as  part  of  this  study  were  transcriptionally  similar  
to  other  publicly  available  datasets.  
  
  
Figure  2.3  Heatmap  of  correlation  of  bulk  RNA-seq  gene  expression  between  
samples  in  primary  microglia  and  BLUEPRINT  monocytes  
Average  Spearman’s  rank  correlations  across  all  genes  of  gene  expression  for  each  
sample  in  the  in-house  primary  microglia  dataset,  fresh  paediatric  microglia  samples  





Figure  2.4  UMAP  analysis  of  bulk  primary  microglia  data  and  publicly  available  
RNA-sequencing  datasets  
UMAP  analysis  from  Seurat’s  RunUMAP  function  on  a  collection  of  publicly  available  
datasets.  Analysis  run  using  the  following  parameters:  PCs=15,  n_neighbours  =  30  
and  min_dist  =  0.3.  Samples  highlighted  as  “Adult  and  paediatric  primary  microglia”  
included  data  from  this  study  and  publicly  available  datasets  (section  3.2.1  for  full  
details).   
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2.3.2  Metadata  comparison  
As  much  of  the  analysis  completed  in  this  chapter  focuses  on  understanding  the  
effect  of  clinical  phenotypes  on  microglial  transcriptomes,  I  initially  wanted  to  ensure  
that  there  were  no  major  confounding  groups  of  clinical  phenotypes.  I,  therefore,  
compared  the  number  of  patients  across  pairs  of  clinical  phenotypes  in  both  the  
single  cell  and  bulk  patient  groups  (Figure  2.5  and  2.6),  all  pairwise  comparisons  for  
the  four  meta  group  (age,  sex,  brain  region  and  clinical  pathology)  are  shown.  Within  
both  the  bulk  and  single  cell,  patient  groups  clinical  pathology  and  brain  region  were  
confounded  because  trauma  patients  were  only  found  in  one  brain  region.   
  
Figure  2.5  Frequency  of  patients  from  metadata  groups  within  the  bulk  (A,  C  
and  E)  and  single  cell  (B,  D  and  F)  RNA-seq  datasets  
Numbers  of  patients  in  different  age  ranges  (A  and  B),  sexes  (C  and  D)  and  brain  





Figure  2.6  Frequency  of  patients  from  metadata  groups  within  the  bulk  (A,  C  
and  E)  and  single  cell  (B,  D  and  F)  RNA-sequencing  datasets  
Numbers  of  patients  with  samples  from  different  brain  regions  (A  and  B)  and  age  






2.4  Single  cell  clustering  and  identification  of  sub-populations  
  
2.4.1  Comparison  to  publicly  available  single  cell  datasets  
Initially  we  compared  our  microglia  single  cell  data  to  two  publicly  available  datasets,  
68K  peripheral  blood  mononuclear  cells 224  (PBMCs)  and  15K  unsorted  brain  cells 225    
(Figure  2.7).  This  allowed  for  the  identification  of  infiltrating  blood  derived  cells  or  
contaminating  neuronal  cells  while  also  providing  a  comparison  of  our  sorted  
microglial  cells  to  an  unsorted  dataset.   
  
Figure  2.7  UMAP  analysis  of  microglia  single  cell  data  and  publicly  available  
PBMC  and  whole  brain  tissue  single  cell  datasets  
Cells  collected  as  part  of  this  study  coloured  in  red.  Cell  type  annotations  were  
obtained  from  original  manuscripts:  glutamatergic  neurons  from  the  PFC  (exPFC);  
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pyramidal  neurons  from  the  hip  CA  region  (exCA);  GABAergic  interneurons  (GABA);  
granule  neurons  from  the  hip  dentate  gyrus  region  (exDG);  astrocytes  (ASC);  
oligodendrocytes  (ODC);  oligodendrocyte  precursor  cells  (OPC);  neuronal  stem  cells  
(NSC);  endothelial  cells  (END);  dendritic  cell  (DC);  B  cell  (B);  hematopoietic  
progenitor  cell  (CD34+);  NK  T  cell  (NK).  Plot  generated  by  Dr  Natsuhiko  Kumasaka.   
  
A  total  8,662  cells  from  our  single  cell  dataset  clustered  with  microglia  identified  
within  the  unsorted  brain  cell  dataset  (see  Table  2.2  for  breakdown  of  identified  cells  
in  the  dataset).  Alongside  the  microglial  cells  identified  a  small  fraction  of  the  single  
cells  collected  as  part  of  this  study  appeared  transcriptionally  similar  to  PBMC  cells,  
specifically  NKT  cells,  monocytes  and  B  cells.  These  cells  could  represent  either  
infiltrating  cells  that  have  entered  the  brain  following  disruption  to  the  BBB  or  
intravascular  contamination  of  the  tissue  that  occurred  during  the  collection.   
  
Table  2.2  Cell  numbers  and  number  of  patients  represented  in  each  immune  
cell  type  collected.   
Cell  type  classification  determined  by  UMAP  analysis  and  comparison  to  publicly  
available  datasets  that  had  been  previously  classified.   
  
The  cells  identified  as  microglia  also  expressed  known  marker  genes  P2RY12 ,  
CX3CR1  and  TMEM119  (Figure  2.8).  These  8,622  cells  were  therefore  taken  forward  
for  further  analysis.  
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Cell  Type Number  of  cells  Number  of  patients  
Microglia 8662  127  
NKT  cells 799  91  
Monocyte 46  18  
B  cell  28  16  
  
  
Figure  2.8  UMAP  analysis  of  microglia  single  cell  data  and  publicly  available  
PBMC  and  whole  brain  tissue  single  cell  datasets   
Cells  coloured  by  expression  (CPM)  of  microglial  marker  genes  P2RY12  (A),  
CX3CR1  (B)  and  TMEM119  (C  ).  Plot  generated  by  Dr  Natsuhiko  Kumasaka.   
  
2.4.2  Clustering  of  microglial  cells  and  cluster  maker  analysis  
Clustering  of  the  microglia  highlighted  a  relative  homogeneity  between  cells  although  
4  transcriptionally  distinct  clusters  were  identified  (Figure  2.9).  A  linear  mixed  model,  
with  the  cluster  membership  fitted  as  a  random  effect,  was  used  to  identify  






Figure  2.9  UMAP  analysis  of  microglia  cells  from  this  study  identified  from  
previous  analysis  (Figure  2.7)  
Cells  coloured  by  cluster  membership  as  determined  by  Louvain  clustering  (see  
section  2.2.8  for  full  clustering  methodology).   
  
Figure  2.10  highlights  some  of  the  cluster  markers  identified  as  part  of  this  analysis  
and  Table  2.3  shows  the  top  5  most  enriched  GO  terms  for  cluster  marker  genes  
(identified  as  any  gene  with  a  LTSR  value  of  >0.5  when  comparing  expression  of  





Figure  2.10  Cluster  maker  genes  for  microglia  single  cell  data  
Averaged,  across  cells  in  each  cluster,  normalised  expression  level  (defined  as  the  
posterior  mean  of  pathology  random  effect  term,  see  section  2.2.8  for  full  details)  of  
differentially  expressed  genes  at  the  local  true  sign  rate  ( ltsr )  greater  than  0.9.   
  
  
As  demonstrated  in  Figure  2.10  cells  in  clusters  A  and  B  had  higher  expression  of  
microglial  marker  genes  P2RY12  and  CX3CR1  than  cells  in  clusters  C  and  D.  Cells  
within  cluster  A  also  had  significantly  reduced  expression  of  immune  activation  
marker  genes,  like  IL1B  and  CCL3 ,  when  compared  to  all  other  cells.  GSEA  of  the  
genes  differentially  expressed  within  this  cluster  identified  an  enrichment  of  metabolic  
and  translational  processes.  Cells  in  cluster  A  were  therefore  identified  as  
homeostatic  microglial  cells  with  those  in  other  clusters  representing  cells  in  differing  




As  well  as  increased  expression  of  marker  genes,  cells  associated  with  cluster  B  had  
increased  expression  of  activation  genes  such  as  JUN  and  EGR3 .  These  often  
represent  early  activation  patterns  of  macrophage  cells  and  therefore  cluster  B  may  
represent  a  population  of  cells  moving  towards  an  activated  state.  Further  
investigation,  using  techniques  such  in-situ  single  cell  transcriptomics,  would  be  
needed  to  confirm  that  these  cells  arise  in  the  brain  and  are  not  artificially  activated  
by  the  tissue  processing  used  in  this  study.   
  
Cells  in  cluster  C  had  significantly  increased  expression  of  genes  such  as  CD14 ,  
ACTB  and  ERC2 .  One  of  the  other  marker  genes  associated  with  cells  in  this  cluster  
is  HAMP  which  encodes  for  hepcidin  protein,  a  key  molecule  in  iron  homeostasis.  
Iron  homeostasis  has  been  linked  to  multiple  brain  disorders  including  ischemia,  
cancer  and  Alzheimer’s  disease 227 .  Enrichment  analysis  of  marker  genes  associated  
with  this  cluster  showed  significant  enrichment  for  terms  such  as  immune  response  
and  immune  system  process,  highlighting  a  clear  activation  pattern  within  these  cells.   
  
Like  in  cells  associated  with  cluster  C,  those  in  cluster  D  were  also  enriched  for  terms  
such  as  immune  system  process.  However,  gene  markers  for  cells  in  cluster  D  were  
also  enriched  for  cell  migratory  and  communication  terms.  Cluster  D  is  also  
characterised  by  expression  of  VEGF  and  a  receptor  for  the  molecule,  FLT1 .  FLT1  
and  VEGF  have  been  shown  to  be  important  in  angiogenesis  in  the  brain  particularly  
following  traumatic  brain  injury 228,229 .  Recent  evidence  has  also  suggested  a  potential  
role  for  VEGF  response  in  microglial  chemotaxis  to  amyloid  beta,  a  key  protein  in  AD  
230 .   
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Cluster  GO  ID  Term  name  Padj  
A  
GO:0016071  mRNA  metabolic  process  6.22e -14 
GO:0006413  translational  initiation  6.22e -14 
GO:0006886  intracellular  protein  transport  4.74e -13 
GO:0006613  cotranslational  protein  targeting  to  membrane  4.74e -13 
GO:0070972  protein  localization  to  endoplasmic  reticulum 5.16e -13 
B  
GO:0006614  
SRP-dependent  cotranslational  protein  targeting  to  
membrane  1.66e -27 
GO:0006613  cotranslational  protein  targeting  to  membrane  3.44e -27 
  
Table  2.3  Top  enriched  biological  process  terms  for  cluster  marker  genes  
Statistical  enrichment  analysis  using  an  ordered  list  through  the  g:GOSt  programme  
of  g:Profiler  with  significance  determined  at  a  5%  FDR.  Five  most  significantly  
enriched  biological  process  terms  for  genes  determined  as  cluster  markers  at  the  
local  true  sign  rate  ( ltsr )  greater  than  0.9  (section  2.2.8  for  full  details).   
  
  
2.5  Clinical  metadata  and  microglial  transcriptome  signatures   
  
2.5.1  Variance  components  analysis   
The  large  sample  size  of  this  study  across  a  variety  of  patients  also  allowed  us  to  
study  how  a  range  of  biological  factors  impact  microglial  gene  expression.  Variance  
components  analysis  highlights  how  much  variability  in  gene  expression  can  be  
explained  by  different  biological  and  technological  factors.  Figure  2.11  shows  that  
individual  patients  were  the  largest  driver  of  variation  within  the  dataset,  this  may  
represent  the  effect  of  genetic  background  on  gene  expression  but  could  also  be  in  




nuclear-transcribed  mRNA  catabolic  process,  
nonsense-mediated  decay  1.06e -26 
GO:0045047  protein  targeting  to  ER  1.83e -26 
GO:0072599  
establishment  of  protein  localization  to  endoplasmic  
reticulum  3.89e -26 
C  
GO:0006955  immune  response  3.34e -14 
GO:0002376  immune  system  process  1.80e -13 
GO:0002252  immune  effector  process  1.50e -08 
GO:0002682  regulation  of  immune  system  process  1.50e -08 
GO:0043299  leukocyte  degranulation  2.74e -08 
D  
GO:0002376  immune  system  process  2.48e -25 
GO:0048583  regulation  of  response  to  stimulus  6.50e -22 
GO:0070887  cellular  response  to  chemical  stimulus  5.78e -21 
GO:0007154  cell  communication  1.31e -20 
GO:0050896  response  to  stimulus  1.79e -20 
  
Of  the  non-technical  factors,  clinical  pathology  was  the  largest  driver  of  variation  
contributing  to  more  variation  in  gene  expression  than  the  other  biological  factors  
combined.  The  variance  components  analysis  also  highlighted  how  technical  factors  
can  impact  gene  expression  and  why  they  need  to  be  accounted  for  in  downstream  
analysis.   
  
Figure  2.11  Variance  components  analysis  
Proportion  of  variance  explained  by  both  biological  and  technical  factors  collected  as  
part  of  this  dataset.  Plot  generated  by  Dr  Natsuhiko  Kumasaka.  
  
2.5.2  Gene  expression  linked  to  clinical  metadata  
Due  to  the  size  of  the  dataset  collected  as  part  of  the  study,  we  were  able  to  
determine  genes  whose  expression  is  affected  by  clinical  factors,  while  controlling  
not  just  for  the  other  interlinked  clinical  factors  but  also  technical  factors  that  can  
influence  gene  expression.   
  
The  variance  component  analysis  highlighted  that  pathology  was  the  largest  known  
clinical  factor  driving  variation  in  this  dataset.  We  therefore  ran  enrichment  analysis  to  
understand  if  cells  part  of  different  clusters  were  enriched  for  patients  with  certain  
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clinical  pathologies.  Figure  2.12  demonstrates  the  log  odds  ratio  for  enrichment  of  
clinical  pathologies  in  each  cluster.  
  
Figure  2.12  Odds  ratios  from  Fisher’s  exact  tests  across  clinical  pathologies  
for  each  cluster.  
The  number  of  cells  contributing  to  each  cluster,  from  each  pathology  group  were  
used  to  run  two-tailed  Fisher’s  exact  tests.  Results  displayed  show  Odds  Ratios  for  
each  test.  Plot  generated  by  Dr  Natsuhiko  Kumasaka.  
  
Enrichment  analysis  showed  that  clusters  C  and  D,  those  with  distinct  activation  
patterns,  were  significantly  enriched  for  trauma  patients,  as  well  as  haemorrhage  
patients,  and  cluster  B  was  enriched  for  tumour  patients  (OR=4.9,  P=7.6x10 -169 ).  
  
While  pathology  was  the  largest  clinical  factor  driving  variation,  other  factors  such  as  
age,  brain  region  and  sex  also  contributed  to  variance  within  the  dataset  and  
therefore  differentially  expressed  genes  were  calculated  across  clinical  groups,  
controlling  for  other  factors.   
  
Table  2.4  summarizes  the  top  5  genes  whose  expression  in  microglia  was  positively  
or  negatively  correlated  with  age  as  well  as  the  top  5  enriched  GO  terms  for  all  
correlated  genes.  Gene  set  enrichment  analysis  of  the  156  genes  whose  expression 
was  positively  correlated,  highlighted  a  significant  enrichment  in  immune  activation  
genes  suggesting  that  microglia  may  take  on  a  more  active  phenotype  as  we  age.  
  
There  were  144  genes  whose  expression  was  negatively  correlated  with  age,  
including  microglia  marker  genes  P2RY12  and  CX3CR1 .  Gene  set  enrichment  
72  
  
analysis  highlighted  an  enrichment  of  genes  involved  in  cell  migration  and  regulation  
of  locomotion  (p  =  1.974×10 -5 ).  
  
Table  2.4  Top  5  genes  and  enriched  biological  process  terms  associated  with  
age  
Statistical  enrichment  analysis  using  an  ordered  list  through  the  g:GOSt  programme  
of  g:Profiler  with  significance  determined  at  a  5%  FDR.  Five  most  significantly  
enriched  biological  process  terms  for  genes  with  local  true  sign  rate  ( ltsr )  greater  than  
0.5.   
  
Differential  expression  focussing  on  brain  region,  highlighted  varying  levels  of  
heterogeneity  across  different  areas  of  the  brain.  There  were  over  400  genes  with  
higher  expression  in  microglia  originating  from  the  occipital  lobe,  whereas  only  two  
genes  were  more  highly  expressed  in  microglia  sourced  from  the  frontal  lobe.  
Pathway  enrichment  analysis  showed  genes  more  highly  expressed  in  occipital  
microglia  were  enriched  for  immune  activation  pathways  but  also  cell  motility  
(GO:0048870)  and  migration  (GO:0016477).  
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Genes  and  GO  terms  positively  correlated  with  age  
Gene  
  
GO  ID  Term  name  Padj  
HLA-DRA  GO:0002376 immune  system  process  6.60e -20   
HLA-DRB1  GO:0006955 immune  response  7.57e -20   
PADI2  GO:0001775 cell  activation  4.65e -18   
MS4A6A  GO:0006952 defense  response  2.62e -17   
HLA-DPA1  GO:0045321 leukocyte  activation  5.20e -17   
  
Genes  and  GO  terms  negatively  correlated  with  age  
Gene  
  
GO  ID  Term  name  Padj  
P2RY12  GO:0030334 regulation  of  cell  migration  1.92e -05   
PDK4  GO:0070887 cellular  response  to  chemical  stimulus  1.92e -05   
CH25H  GO:0010033 response  to  organic  substance  1.92e -05   
C3  GO:0051270 regulation  of  cellular  component  movement  1.92e -05   
CSF1R  GO:1901701  cellular  response  to  oxygen-containing  compound 1.92e -05   
  
Table  2.5  Top  5  genes  and  enriched  biological  process  terms  associated  with  
brain  region  
Statistical  enrichment  analysis  using  an  ordered  list  through  the  g:GOSt  programme  
of  g:Profiler  with  significance  determined  at  a  5%  FDR.  Five  most  significantly  
enriched  biological  process  terms  for  genes  with  local  true  sign  rate  ( ltsr )  greater  than  
0.5.   
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Region  Number  of  DE  genes   GO  ID  Term  name  Padj  
Occipital  441  
  
GO:0006955  immune  response  4.15e -18  
GO:0002376  immune  system  process  1.69e -15  
GO:0002252  immune  effector  process  1.87e -14  
GO:0019221  
cytokine-mediated  signaling  
pathway  3.05e -14  
GO:0034097  response  to  cytokine  6.39e -14  
Cerebellum 51  
GO:2001242  
regulation  of  intrinsic  apoptotic  
signaling  pathway  0.00170 
GO:0090288  
negative  regulation  of  cellular  
response  to  growth  factor  
stimulus  0.00170 
GO:0048583  
regulation  of  response  to  
stimulus  0.00170 
GO:0051091  
positive  regulation  of  
DNA-binding  transcription  
factor  activity  0.00170 
GO:0002376  immune  system  process  0.00260 
Temporal  36  
GO:0006614  
SRP-dependent  cotranslational  
protein  targeting  to  membrane  3.42e -20  
GO:0006613  
cotranslational  protein  targeting 
to  membrane 3.44e -20  
GO:0045047  protein  targeting  to  ER  7.41e -20  
GO:0072599  
establishment  of  protein  
localization  to  endoplasmic  
reticulum  9.05e -20   
GO:0000184  
nuclear-transcribed  mRNA  
catabolic  process,  
nonsense-mediated  decay  1.83e -19   
Parietal  7  
N/A  
Frontal  2  
  
There  were  fewer  genes  whose  expression  differed  significantly  based  on  sex,  55  
with  increased  expression  and  95  with  increased  expression  in  males.  Table  2.6  
shows  the  top  genes  with  higher  expression  in  males  or  females  alongside  the  
enrichment  terms.  
  
Table  2.6  Top  5  genes  and  enriched  biological  process  terms  associated  with  
sex  
Statistical  enrichment  analysis  using  an  ordered  list  through  the  g:GOSt  programme  
of  g:Profiler  with  significance  determined  at  a  5%  FDR.  Five  most  significantly  
enriched  biological  process  terms  for  genes  with  local  true  sign  rate  ( ltsr )  greater  than  





Genes  and  enriched  GO  terms  in  males  
Gene  
  
GO  ID  Term  name  Padj  
HLA-DQB1  GO:0006614  
SRP-dependent  cotranslational  
protein  targeting  to  membrane  4.25e -70   
EEF1A1  GO:0006613  
cotranslational  protein  targeting  to  
membrane  3.05e -69   
HLA-DRA  GO:0045047  protein  targeting  to  ER  1.63e -67   
RPL37  GO:0072599  
establishment  of  protein  localization  
to  endoplasmic  reticulum  7.41e -67   
RPS3A  GO:0000184  
nuclear-transcribed  mRNA  catabolic  
process,  nonsense-mediated  decay  1.74e -65   
  
Genes  and  enriched  GO  terms  in  females  
Gene  
  
GO  ID  Term  name  Padj  
B2M  GO:0098542  defense  response  to  other  organism  1.32e -09   
H2BC8  GO:0006952  defense  response  2.09e -09   
AC011586.2  GO:0051707  response  to  other  organism  5.36e -09   
H4C5  GO:0045814  
negative  regulation  of  gene  
expression,  epigenetic  5.36e -09   
H2BC3  GO:0009607  response  to  biotic  stimulus  5.36e -09   
  
2.6  Microglia  and  disease  
  
2.6.1  Microglial  gene  expression  and  Alzheimer’s  disease  (AD)  
Next,  I  examined  expression  of  known  AD  genes  across  the  microglia  dataset.  I  
included  familial  AD  genes  ( APP,  PSEN1  and  PSEN2 ),  and  a  selection  of  genes  
associated  with  late-onset  AD.  The  late-onset  AD  genes  included  the  large  effect  size  
gene  and  APOE  rare  missense  variant  genes  ( TREM2 ,  PLCG2  and  ABI3 ).  While  
these  genes  have  been  definitively  linked  to  AD,  many  complex  disease  risk  variants  
for  late-onset  AD  identified  by  genome  wide  association  studies  (GWAS)  lie  in  
non-coding  regions  of  the  genome 134,136,137,231 .  This  presents  a  problem  for  expression  
analysis,  because  linking  these  signals  to  candidate  genes  is  challenging.  One 
approach  to  identifying  the  candidate  causal  genes  is  colocalization,  which  compares  
association  signals  between  a  GWAS  and  those  from  an  expression  quantitative  trait  
loci  (eQTL).  I  examined  the  expression  of  a  set  of  genes  identified  as  candidate  
causal  AD  risk  genes  identified  as  part  of  the  same  study  described  in  this  chapter  
(eQTL  analysis  carried  out  by  Dr  Natsuhiko  Kumasaka).  This  gene  set  included:  
BIN1 ,  MEF2A ,  PTK2B ,  CASS4 ,  CD33  and  EPHA1-AS1 .   
  
Table  2.7  summaries  whether  these  genes,  and  genes  that  have  been  identified  as  
the  “nearest  gene”  to  an  AD  risk  variant  in  more  than  one  GWAS  study  (see  Table  
1.1),  had  increased  expression  within  specific  microglia  clusters  or  between  males  
and  females.  I  also  looked  at  whether  the  AD  genes  were  positively  or  negatively  
correlated  with  age  or  whether  expression  was  increased  in  a  particular  brain  region.  
Only  4  of  30  the  AD-linked  genes  studied  here  showed  a  significant  correlation  
between  expression  level  and  age  and  the  majority  of  the  AD  linked  genes  showed  
no  differential  expression  across  clusters.  However  the  6  genes  whose  expression  
was  increased  within  specific  clusters  were  within  the  “activated”  populations  while  








Table  2.7  AD  associated  risk  genes  and  microglia  single  cell  expression.  
AD  associated  genes  cross-referenced  against  differentially  expressed  genes  






Higher  expression  in  
male  or  females?  
Higher  expression  in  
specific  brain  region? 
Correlated  
with  age?  
APP  D        
PSEN1          
PSEN2          
APOE        Positively  
TREM2  B  Male  Occipital    
PLCG2          
ABI3  C        
BIN1        Negatively  
MEF2A      Occipital    
CASS4  B      Negatively  
PTK2B          
CD33          
EPHA1-AS 
1  
        
CR1          
CD2AP          
EPHA1      Occipital    
MS4A6A  D    Occipital  Positively  
PICALM          
ABCA7          
SORL1          
SLC24A4          
DSG2          
INPP5D  D        
ZCWPW1          
FERMT2          
CLU          
ADAM10          
KAT8          
ACE          
ECHDC3          
  
2.7  Discussion  
  
In  this  chapter  I  describe  the  collection  and  sequencing  of  the  largest  human  primary  
microglia  dataset  to  date.  Dr  Adam  Young  collected  brain  samples  from  141  
neurosurgical  patients  and  sorted  CD11b+  cells  for  bulk  and  single  cell  
RNA-sequencing.  From  the  141  samples,  109  were  included  for  bulk  data  analysis  
and  9,538  cells  from  129  patients  were  analysed  from  smartseq  single  cell  
sequencing.  This  provides  the  largest  RNA-sequencing  resource  of  fresh  primary  
human  microglia  to-date  with  patients  in  the  study  coming  from  a  variety  of  clinical  
backgrounds.  Due  to  the  large  scale  of  the  dataset  and  the  range  of  clinical 
backgrounds  we  have  been  able  to  run  comparisons  across  pathologies,  age  ranges,  
sex  and  brain  regions.  The  samples  also  cluster  with  other  smaller  datasets  of  fresh  
primary  cells,  despite  larger  amounts  of  between  sample  variability,  confirming  that  
our  data  matches  well  with  high  quality  published  datasets.   
  
From  single  cell  analysis,we  have  identified  limited  amounts  of  heterogeneity  in  
primary  microglia  and  suggest  that  the  majority  of  the  heterogeneity  is  driven  not  by  
distinct  subpopulations  of  cells  but  of  microglial  populations  that  are  in  differing  
activation  states.  3  of  the  4  clusters  identified  within  this  dataset  had  increased  
expression  of  immune  activation  genes,  although  Cluster  B  may  have  represented  
pre-activated  cells.  The  cells  in  clusters  C  and  D  were  enriched  for  patients  from  
specific  pathological  backgrounds,  most  significantly  trauma  patients.  This  suggests  
that  the  majority  of  microglia  in  the  brain  are  in  a  homeostatic  state  that  is  only  
altered  under  trauma  or  disease.   
  
I  also  demonstrated  that  selected  genes  had  expression  profiles  that  significantly  
correlated  with  age,  with  an  increase  in  expression  of  inflammatory  genes  and  a  
reduced  expression  of  locomotion  and  motility  genes  with  age.  While  there  were  
small  effects  on  gene  expression  linked  with  age  in  the  primary  microglia,  there  were  
almost  no  differentially  expressed  genes  between  male  and  female  samples,  which  is  
similar  to  what  has  been  suggested  in  large  scale  mouse  studies 213 .  It  may  be  that  in  
small  sub-populations  of  cells  there  are  more  subtle  sex  or  age  effects,  but  as  many  
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of  the  populations  described  here  are  made  up  of  small  numbers  of  cells  the  ability  to  
detect  this  subtle  differences  is  reduced.   
  
As  microglia  have  been  suggested  to  be  a  pathogenic  cell  type  in  Alzheimer’s  
disease  (AD)  and  disease  specific  changes  in  microglial  transcriptomes  have  
previously  been  reported  in  AD  patients 166,184 ,  I  also  looked  at  specific  changes  in  AD  
linked  gene  expression  within  our  dataset.  While  many  of  the  AD  linked  genes,  both  
those  identified  in  previous  single  cell  studies  and  GWAS  genes,  were  expressed  
within  this  dataset,  there  was  no  enrichment  for  increased  gene  expression  within  
one  specific  microglia  cluster.  This  further  adds  to  the  theory  microglia  react  in  a  
disease  or  pathology  specific  manner.  Interestly,  reactive  microglia  have  been  
suggested  to  be  a  potential  pathogenic  cell  type  that  links  traumatic  brain  injury  to  an  
increased  long-term  risk  of  dementia.  In  this  dataset  there  was  no  enrichment  for  AD  
linked  genes  within  the  trauma  patients  but  this  may  be  because  samples  were  taken  
within  a  short  time  period  of  the  trauma.  It  may  be  that  as  time  progresses  the  cells  
take  on  a  more  AD  specific  phenotype.   
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Chapter  3:  Comparison  of  in-vitro  models  of  microglia  
  
  
Collaboration  note  
Data  collected  for  this  chapter  comes  mainly  from  publicly  available  RNA-seq  
datasets.  For  details  of  these  data  sources  please  refer  to  the  methods  section  of  the  
chapter.  However,  a  small  number  of  samples  were  generated  as  part  of  other  
projects  in  the  Gaffney  Lab.  The  primary  microglia  are  a  subset  of  samples  from  the  
data  described  in  Chapter  2,  as  part  of  REC  16/LO/2168.  A  number  of  the  
iPSC-derived  macrophage  samples  are  from  the  MacroMap  project,  involving  Dr  
Andrew  Knights,  Dr  Nikos  Panousis  and  the  CGaP  core  facility  at  the  Wellcome  
Sanger  Institute.  Within  the  cancer  cell  line  samples  are  a  selection  of  samples  
generated  by  Carl  Fishwick  (GSK)  as  part  of  an  Open  Targets  project.  
  
  
3.1  Introduction  
  
Although  primary  microglia  are  a  critically  important  cell  there  are  factors  that  limit  the  
use  of  the  primary  cells  in  the  laboratory.  Primary  human  microglia  are  inaccessible,  
particularly  as  fresh  rather  than  post-mortem  samples,  and  recoverable  cell  numbers  
are  relatively  small.  While  it  is  possible  to  culture  primary  cells  following  isolation  from  
the  brain,  previous  data  has  shown  that  culturing  primary  microglia  causes  a  
significant  change  in  gene  expression  and  the  cells  have  limited  proliferation  
potential 171 .  
  
The  limited  ability  for  researchers  to  use  primary  cells  for in-vitro  studies,  particularly  
large-scale  genetics  studies,  means  that  there  is  a  need  to  develop  robust  model 
systems  for  primary  microglia,  and  to  understand  how  well  these  models  capture  the  
biology  of  the  primary  cell.  For  primary  microglia  these  model  systems  can  range  
from  established  macrophage  models  to  more  specialised  microglia  systems.  The  
models  discussed  in  this  chapter  include:  monocyte-derived  macrophages  (MDMs),  
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cancer-cell  lines  (such  as  THP-1  and  U937  lines)  and  induced  pluripotent  stem  cell  
(iPSC)  models  of  both  macrophages  and  microglia.   
  
3.1.1  Monocyte-derived  macrophages   
Both  monocyte-derived  macrophages  (MDMs)  and  primary  microglia  are  part  of  the  
myeloid  cell  family  and  are  both  considered  to  be  macrophages,  with  microglia  
representing  a  tissue-specific  arm  of  the  cell  group.  However,  there  are  fundamental  
differences  in  the  origin  and  developmental  lineages  of  the  two  cell  types.  Primary  
microglia  have  been  shown  to  develop  from  yolk-sac  derived  precursor  cells  that  
arise  in  early  embryonic  development 7,17,232 .  Adult  monocytes,  on  the  other  hand,  are  
constantly  replenished  by  bone-marrow  derived  cells.  How  these  different  lineages  
impact  the  cell  function  remains  a  controversial  topic;  particularly  as  it  is  known  when  
the  blood  brain  barrier  (BBB)  is  disrupted,  circulating  monocytes  can  enter  the  central  
nervous  system  (CNS)  and  differentiate  into  brain  macrophages 232 .  
  
While  human  MDMs  are  somewhat  easier  to  derive  than  primary  microglia,  sampling  
primary  human  cells  is  still  complex  and  comes  with  experimental  limitations  such  as  
an  inability  to  run  repeated  experiments  and  a  lack  system  of  manipulation.  For  
instance  introducing  genetic  modifications  into  MDMs  can  be  inefficient  and  may  
impact  function  and  expression  in  nonspecific  ways 233,234 .   
  
3.1.2  Cancer  cell  lines  
A  large  proportion  of  the  in-vitro  studies  of  macrophage  function  have  been  carried  
out  in  human  myeloid  leukemia  lines,  such  as  THP-1 235  and  U937 236  cells.  The  patient    
derived  cell  lines  are  thought  to  represent  cells  similar  to  that  of  monocytes  that  can  
be  pushed  towards  more  macrophage  like  phenotypes  through  simulations  with  
compounds  such  as  phorbol-12-myristate-13-acetate  (PMA) 237 .  The  differentiated  
cells  appear  morphologically  similar  to  MDMs  and  have  similar  functional  capabilities  
such  as  phagocytosis  as  the  primary  cells 237–239 .  However,  certain  aspects  of  cancer  
cell  line  function  have  already  been  shown  to  differ  from  MDMs.  For  instance,  THP-1  
cell  response  to  lipopolysaccharide  (LPS)  stimulation  significantly  differs  when  
82  
  
compared  to  MDMs 240 ,  showing  a  lack  of  IL-6  and  IL-10  response  and  a  reduction  in  
IL-8  release  compared  to  primary  cells.   
  
As  the  cell  lines  have  been  created  from  single  patients,  they  provide  a  tool  to  
repeatedly  study  cell  effects  on  the  same  genetic  background.  However,  the  cells  are  
derived  from  immortalised  cancer  cell  lines  and,  therefore,  their  genetic  background  
may  not  accurately  represent  that  of  healthy  individuals.  For  instance,  119  genetically  
aberrant  regions  in  the  THP-1  genome  have  been  detected 241 ,  including  deletions  in  
the  PTEN  gene,  a  key  tumour  suppressor  gene,  and  trisomy  of  chromosome  8.   
  
3.1.3  iPSC  derived  macrophages  
As  mentioned  in  section  1.6,  induced  pluripotent  stem  cell  (iPSC)  based  models  
provide  an  attractive  option  for  studying  human  disease 191 .  Like  in  the  primary  cell  
type  (MDMs),  iPSC-derived  macrophage  cells  have  been  shown  to  express  known  
myeloid  cell  marker  genes  such  CD18  and  CD68  as  well  as  being  functionally  similar  
in  their  ability  to  phagocytose  compounds 194,195 .  Gene  expression  studies  and  
cytokine  profiling  have  also  demonstrated  a  conserved  pro-inflammatory  response,  
such  as  that  following  LPS  stimulation,  in  both  iPSC  and  monocyte-derived  
macrophages 194,195 ,  unlike  that  seen  with  cancer-cell  lines.  However,  iPSC  
differentiated  macrophages  do  not  fully  match  the  transcriptional  phenotype  seen  in  
MDMs.  For  instance,  MDMs  have  consistently  shown  an  increased  expression  of  the  
MHC-II  cell  surface  marker 192,193  or  genes  that  encode  for  the  receptor 194,195 .  Using   
differential  expression  analysis,  it  has  also  been  noted  that  iPSC-derived  
macrophages  often  express  selected  genes  at  a  higher  level  than  their  monocyte  
derived  counterparts 194,195 .  These  genes  are  often  enriched  for  extracellular  
matrix 194,195 ,  cell  adhesion 194   or  fibroblast 195   processes.   
  
Interestingly,  through  CRISPR  knock-out  of  a  variety  of  transcription  factors  the  
formation  of  the  myeloid  precursors  cells  generated  by  EB  formation,  as  used  in  
many  of  the  studies  above,  has  been  shown  to  be  MYB  independent 242 .  The  
formation  of  these  precursors  and  downstream  macrophage-like  cell  formation  
appeared  to  be  dependent  on  the  activation  of  RUNX1  and  PU.1  and  this  specific  
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transcription  factor  pattern  is  also  seen  in  yolk-sac  myeloid  progenitor  development.  
It  has,  therefore,  been  suggested  that  the  iPSC-derived  macrophage  differentiation  
protocols  described  above  produce  cells  more  closely  related  to  tissue  resident  cells,  
such  as  microglia,  as  opposed  to  circulating  monocytes 243 ,  especially  as  the  cells  
have  been  shown  to  have  significantly  increased  expression  of  microglia-linked  
genes  such  as  TREM2  and  TMEM119  than  monocytes.  
  
3.1.4  iPSC  derived  microglia  
As  interest  in  microglia  has  increased,  a  number  of  research  groups  have  focussed  
on  pushing  iPSC  derived  myeloid  models  closer  to  a  specialised  microglial  
phenotype  as  opposed  to  more  generic  macrophage-like  cells 197–201 .  The  
iPSC-derived  microglia  cells  have  consistently  shown  expression  of  known  microglial  
genes  such  as  TMEM119 ,  P2RY12 ,  PU.1  and  CX3CR1 197–201  and  often  have  a   
ramified  structure,  with  highly  motile  processes  which  are  a  unique  feature  seen  in  
primary  microglia.   
  
As  with  iPSC-derived  macrophage  studies,  many  of  the  differentiation  papers  
described  here  use  transcriptional  profiling  through  RNA-sequencing  to  determine  
how  closely  the  in-vitro  models  match  the  primary  cell  type.  The  iPSC-derived  
microglia  have  been  shown  to  have  gene  expression  profiles  more  similar  to  
fetal/cultured  adult  primary  microglia  than  dendritic  cells,  monocytes 198,201 ,  other  
neuronal  cell  types 197  and  MDMs 199 .  However  all  of  these  comparisons  come  with   
limitations:  the  number  of  primary  samples  studied  are  often  small  (<  10)  and  the  
comparison  is  also  only  run  against  one  iPSC  differentiation  protocol.  The  largest  
published  model  comparison  dataset  includes  RNA-sequencing  data  from  over  50 
primary  microglia  samples,  from  three  independent  studies,  and  compared  it  two  
iPSC-microglia  differentiation  protocols  along  with  MDMs  from  one  study 200 .  In  this  
dataset,  iPSC-derived  microglia  appeared  transcriptionally  distinct  from  fresh  adult  




3.1.5  Limitations  of  current  transcriptional  comparisons  across  model  systems  
Many  of  the  studies  described  above  use  transcriptional  data  to  compare  in-vitro  
models  to  primary  cell  types  and  in  many  cases  this  requires  comparison  of  
RNA-sequencing  datasets  from  differing  groups.  However,  comparisons  across  
sequencing  studies  comes  with  caveats,  particularly  batch  effects  that  can  arise  in  
these  datasets 207–209 .  These  batch  effects  can  arise  from  a  range  of  biological  and  
technical  factors,  particularly  when  data  is  processed  by  entirely  different  research  
groups.   
  
The  impact  of  batch  effects  can  vary  across  studies.  Unknown  causes  of  variability  
can  increase  noise  in  samples  and,  therefore,  reduce  biological  signals 207 .  In  extreme  
cases,  when  the  unknown  or  technical  batch  effects  are  confounded  with  a  condition  
of  interest,  they  may  even  lead  to  incorrect  biological  conclusions.  This  is  something  
to  consider  in  many  of  the  above  studies,  whereby  often  RNA-sequencing  data  is  
collected  from  different  studies  for  differing  cell  types.  It  is,  therefore,  difficult  to  
determine  if  the  effects  described  are  due  to  the  differing  cell  types  or  differing  
experimental  studies.  However,  it  is  not  just  technical  batch  effects  that  need  to  be  
controlled  for.  Processing  pipelines  post-sequencing  can  also  significantly  impact  the  
quantification  of  gene  expression 209 .  Even  when  the  same  raw  RNA-sequencing  
reads  across  the  same  samples  were  processed  across  independent  analysis  
pipelines,  abundance  estimates  of  protein  coding  genes  varied  by  more  than  
four-fold.  It  is,  therefore,  key  to  not  only  try  to  reduce  experimental  and  technical  
batch  effects  that  arise  during  sample  processing  but  also  to  ensure  all  data  is  
processed  through  identical  analysis  pipelines.  
  
As  well  as  being  aware  of  the  potential  batch  effects  that  may  have  arisen  within  the  
studies  described  in  this  introduction,  it  is  noted  that  none  of  the  currently  published  
work  compares  the  transcriptional  profile  of  all  available  in-vitro  model  systems  for  
primary  microglia.  In  particular,  it  would  be  interesting  to  compare  iPSC-derived  
macrophages  to  the  more  specialised  microglia  differentiation  protocols.  In  an  ideal  
experiment  all  the  samples  would  be  collected  from  the  same  research  group,  
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processed  in  an  identical  manner  and  matched  for  genetic  background  to  try  and  
reduce  any  batch  effects  that  may  arise.  However,  in  a  comparison  of  this  scale,  and  
particularly  when  collecting  difficult  to  access  primary  cells,  often  it  is  not  feasible  to  
run  these  perfectly  controlled  experiments.  In  this  chapter  I  have,  therefore,  collected  
a  mixture  of  publicly  available  and  in-house  generated  data  across  5  cell  types:  
primary  microglia,  MDMs,  cancer  cell  lines  (THP-1/U937)  and  iPSC-derived  
macrophages  and  microglia.  While,  in  the  study  there  must  be  comparisons  across  
samples  collected  from  different  laboratories,  to  try  and  minimise  the  impact  of  study  
batch  effects  I  ensured  that  data  for  each  cell  type  came  from  multiple  studies.  As 
mentioned  previously,  processing  pipelines  can  also  impact  quantification  of  gene  
expression 209  and  so  in  order  to  counteract  some  of  these  potential  issues,  I  collected   
raw  sequencing  data  for  each  sample  and  processed  all  the  data  through  an  identical  
analysis  pipeline.  I  have  used  gene  expression  analysis  to  understand  how  each  of  
the  model  systems  compared  to  primary  microglia  and  gene  network  analysis  to  
determine  which  pathways  may  need  to  be  switched  on  to  move  model  systems  
closer  to  the  primary  cell  type.   
  
  
3.2  Methods  
  
3.2.1  Data  collection  and  initial  processing  
Datasets  for  this  study  were  identified  from  known  large  scale  transcriptional  
comparison  papers,  in  house  datasets  and  through  pubmed  searches  for  data  
accession  of  the  desired  cell  types.  Other  than  in-house  data  (see  collaboration  note  
for  the  sources  of  these  specific  samples),  all  samples  collected  as  part  of  this  study  
were  from  publicly  available  sources  (GEO,  ENA,  EGA  and  dbGAP).  Table  3.1  
summarises  the  12  different  studies  (11  publicly  available  and  in-house  data)  used  
within  this  dataset  including  accession  codes  and  references  for  published  work  
attached  to  the  study.  It  should  be  noted  that  access  to  the  samples  from  the  
Gosselin  et  al.  study 171  are  part  of  a  managed  access  dataset  for  which  use  in  this   




Table  3.1  Sources  of  data  collected  
Accession  codes  and  paper  links  to  datasets  used  within  this  analysis  project.   
  
Table  3.2  shows  a  breakdown  how  samples  from  each  study  are  separated  by  the  
cell  types  studied.  During  collection  of  these  samples,  I  wanted  to  ensure  that  for  
each  cell  type  I  had  samples  from  at  least  three  independent  studies.  As  well  as  
dividing  samples  by  cell  type,  metadata  across  the  studies  was  collected.  The  
available  metadata  varied  across  the  studies  and  particularly  for  studies  with  only  cell  
lines  the  metadata  was  limited.  However,  for  all  samples  data  was  collected  for  a  
mixture  of  technical  (sequencing  type,  sequencing  depth)  and  experimental  (sex,  
stimulation  and  culture  status)  effects.  For  primary  microglia  samples,  the  source  of  
the  samples  was  also  identified.  Samples  collected  as  part  of  this  dataset  originated  
from  5  distinct  sources:  fresh  adult  microglia,  fresh  paediatric  microglia,  fetal  
microglia,  cultured  microglia  and  microglia  purchased  from  repositories.   
  
I  downloaded  raw  sequencing  files  and  converted  all  data  into  FASTQ  file  format.  All 
data  was  then  aligned  to  GRCh38  using  the  STAR  alignment  tool 221 .  Following  
alignment,  reads  were  quantified  using  featureCounts 222 .  I  used  three  different  
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Study  authors  Accession  code  
Abud  et  al.  (2017)  198   GSE89189  
Alasoo  et  al .  (2015)  194   EGAS00001000563  
J.  de  Boer  (GEO  accession  only)  GSE96544  
Douvaras  et  al .  (2017)  199   GSE97744  
Gosselin  et  al.  (2017)  171   dbGAP  :  phs001373.v1.p1  
In-house  N/A  
Gan  et  al .  (2017)  244   GSE97041  
Muffat  et  al .  (2016)  197   GSE85839  
Phanstiel  et  al .  (2017)  245   GSE96800  
Yeung  et  al.  (2017)  246   ERP006216  
Zhang  et  al.  (2015)  195   GSE55536  
Zhang  et  al.  (2016)  247   GSE73721  
  
normalisation  methods  following  calculation  of  raw  counts  for  comparison  in  this  
study:  calculation  of  transcripts  per  million  (TPM),  variance  stabilising  transformation  
(VST)  from  the  DESeq2  package 248  and  quantile  normalisation  as  described   
previously 249 .   
  
Table  3.2  Data  summary  
Table  with  summary  of  number  of  samples  for  each  broad  cell  type  
  
3.2.2  Principal  components  and  variance  components  analysis  
Following  normalisation,  I  used  the  prcomp  function  in  R  to  to  compute  principal  
components  (PCs)  using  either  all  genes  in  the  dataset  or  across  the  top  500  most  
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Abud 198   6  -  -  -  9  
Alasoo 194   -  10  -  8  -  
J.  de  Boer  
(accession  
only)  
-  -  6  -  -  
Douvaras 199  4  8  -  -  10  
Gosselin 171   45  -  -  -  -  
In-house  16  -  24  54    
Gan 244   -  -  4  -  -  
Muffat 197   3  -  -  -  9  
Phanstiel 245  -  -  4  -  -  
Yeung 246   -  -  -  32    
Zhang 195   -  9  -  18    
Zhang 247   3  -  -  -  -  
Total  
(studies)  
77  (6)  27  (3)  38  (4)  112  (4)  28  (3)  
  
variable  genes.  The  most  highly  variable  genes  were  identified  using  the  rowVars  
function,  to  calculate  variance  for  each  gene  row,  as  carried  out  in  the  DESeq2  
plotPCA  function 248 .  Following  principal  components  analysis  (PCA),  using  the  
varimax  function,  I  rotated  calculated  PCs  to  identify  the  most  highly  loaded  genes  for  
each  PC.   
  
As  well  as  identification  of  individual  genes  that  were  driving  PCs,  I  used  variance  
components  analysis  to  identify  which  metadata  may  be  associated  with  variability  in  
gene  expression.  Initially  I  filtered  the  dataset  to  include  only  protein  coding  and 
lincRNA  genes  that  had  at  least  a  Log 2 (TPM+1)  of  five  across  all  samples.  I  used  the  
lmer  function  of  the  lme4  package 250  to  run  a  mixed  effect  linear  model  for  individual   
genes,  with  each  factor  fitted  as  a  random  effect:  
  
lmer  (expression  ~  (1|study)  +  (1|cell)  +  (1|stimulated)  +  (1|sequence_type)  +  
(1|cultured)  +  (1|sex))  
  
As  described  in  Chapter  2,  I  then  used  the  VarCorr  function  of  lmer  to  estimate  the  
amount  of  variance  attributed  to  each  gene.  Following  this  I  calculated  the  proportion  
of  variance  each  factor  explained  by  dividing  individual  factor  variance  by  the  total  
amount  of  variance  for  each  gene.  I  did  this  across  all  genes  analysed  as  well  as  
across  two  subsets  of  genes:  microglia  marker  genes  and  AD  linked  genes  (for  list  of  
genes  see  Table  3.3).  
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Microglia  marker  genes Alzheimer's  disease  genes  
C1QA  ABCA7  CR1L  NME8  
CX3CR1  ACE  DSG2  NYAP1  
GAS6  ADAM10  ECHDC3  PICALM  
GPR34  ALPK2 EED  PILRA  
MERTK  APH1B  EPHA1  PLCG2  
P2RY12  APOC1  FBXO46  PTK2B  
PROS1  APOE  FERMT2  SCIMP  
SALL1  B4GALT3  HESX1  SLC24A4  
  
Table  3.3  Gene  lists  used  in  variance  components  analysis  
Microglia  marker  genes  identified  from  previously  published  studies 177,178,211,212  and   
Alzheimer’s  disease  genes  collated  from  Open  Targets  project  OTAR037  (not  yet  
published).  
  
3.2.3  Differential  expression  and  gene  set  enrichment  analysis   
I  used  the  DESeq2  package 248  to  run  differential  expression  across  the  dataset.   
Before  differential  expression  testing  the  dataset  was  filtered  to  only  include  genes  
with  more  than  5  reads  in  at  least  3  samples  in  the  data.  The  model  was  set  to  
compare  cell  types  while  controlling  for  study  effects  where  possible.  Genes  with  an  
adjusted  p-value  of  <  0.05  (with  Benjamini  &  Hochberg  multiple  testing  correction)  
and  a   log 2   fold  change  (LFC)  of  >  1  were  considered  differentially  expressed.   
  
Gene  lists,  from  differential  expression  or  variance  components  analysis,  were  tested  
for  specific  gene  set  enrichment  using  the  g:OSt  function  of  the  online  gProfiler  tool,  
version  e94_eg41_p11_36d5c99 226 .  The  function  uses  a  hypergeometric  distribution  
model  to  run  over  representation  analysis  on  given  gene  lists,  to  associate  the  gene  
sets  with  known  biological  pathways.  Gene  lists  were  provided  to  the  tool  as  an  
ordered  list  and  significant  terms  were  identified  as  those  with  an  adjusted  p-value  of  





TMEM119  BIN1  HLA-DQA1  SORL1  
  CASS4  HLA-DRB1  TREM2  
  CCDC6  INPP5D  TREML2  
  CD2AP  KAT8  UNC5CL 
  CD33  MEF2C  USP6NL  
  CELF1  MS4A6A  ZCWPW1  
  CLU  MYBPC3  ZNF652  
  
3.3  Technical  comparisons  within  the  dataset  
  
3.3.1  Normalisation  comparison  
It  has  been  demonstrated  that  different  processing  pipelines  can  lead  to  significant  
differences  in  gene  abundance  estimates 209 .  While  a  full  comparison  of  how  differing  
initial  analysis  pipelines  (alignment  and  quantification)  has  not  been  carried  out  as  
part  of  this  study,  I  was  interested  to  look  at  how  differing  normalisation  techniques  
could  impact  downstream  results.  I  compared  transcripts  per  million  (Log 2 (TPM+1)),  
quantile  normalisation  (QN)  and  the  variance  stabilising  transformation  (VST)  
described  as  part  of  the  DESeq2  package 248 .   
  
Following  normalisation  of  the  data  using  each  of  these  methods,  I  ranked  genes  by  
variance  across  all  samples  and  compared  the  top  500  most  variable  genes  for  each  
normalised  dataset.  Figure  3.1  shows  a  venn  diagram  of  the  numbers  of  overlapping  
genes  for  each  normalisation  method.  Only  236  of  the  top  500  genes  for  each  
normalisation  method  were  shared  between  all  three  techniques,  with  QN  
normalisation  having  the  most  unique  genes  (165).  Log 2 (TPM+1)  and  VST  
normalizations  had  the  greatest  overlap  across  highly  variable  genes  with  364  shared  
genes.  This  highlights  that,  even  when  initial  alignment  and  quantification  is  identical  
across  samples,  differing  normalization  methods  can  still  impact  certain  downstream  






Figure  3.1  Venn  diagram  of  overlapping  most  variable  genes  
Top  500  most  variable  genes  were  calculated  following  three  independent  
normalisation  methods:  variance  stabilising  transformation  (VST),  quantile  
normalisation  (QN)  and  transcript  per  million  (Log 2 (TPM+1)).   
  
As  well  as  identifying  specific  differences  in  the  most  variable  genes  across  
normalisation  methods,  I  also  wanted  to  understand  how  these  differences  may  
impact  downstream  PCA  and  the  biological  conclusions  that  could  be  drawn  from  it.  I  
took  the  top  500  genes  calculated  above  for  each  normalisation  and  used  those  
genes  to  run  PCA.  I  plotted  samples  (Figure  3.2)  based  on  their  PC  scores  for  the  
first  two  principal  components  and  coloured  samples  by  cell  type  to  compare  the  
pattern  of  sample  distribution  across  the  normalisation  methods.   
  
Broadly  the  patterns  of  sample  clustering  were  the  same  across  all  three  
normalisation  methods.  PC1  captured  the  variation  in  iPSC  based  models  (both  
macrophages  and  microglia).  Across  all  three  normalisation  methods  PC2  captured  a  
similar  spread  of  cell  types  with  the  cancer  cell  models  at  one  end,  MDM/iPSC  
macrophages/iPSC  microglia  in  the  middle  band  and  a  group  of  primary  microglia  at  
the  opposite  end.  This  suggests  that  even  though  the  specific  genes  driving  the  PCs 
may  differ  slightly  between  normalisation  methods,  the  biological  conclusions  that  




Figure  3.2  PC1  vs  PC2  for  three  normalisation  methods  
Principal  component  analysis  of  RNA-sequencing  samples,  using  the  top  500  most  
variable  genes  following  3  normalisation  methods:  A)  quantile  normalisation  (QN),  B)  
transcripts  per  million  (log 2 (TPM+1))  and  C)  variance  stabilising  normalisation  (VST).  
  
3.3.2  Variance  components  analysis  
In  order  to  futher  understand  which  biological  and  technical  factors  may  be  driving  
variation  within  the  dataset,  I  used  variance  components  analysis  to  calculate  the  
proportion  of  variation  explained  across  individual  genes  for  six  factors:  study,  cell  
type,  cultured/non-cultured  cells,  naive/stimulated  cells,  single/paired  end  sequencing  
and  sex.  I  used  Log 2 (TPM+1)  normalised  data  to  calculate  this  proportion  first  across  
all  genes,  as  well  as  specifically  in  AD  genes  and  microglia  marker  genes.  Figure  3.3  
highlights  the  spread  of  the  proportion  of  variance  for  each  of  the  factors  subdivided  
by  the  gene  groups.  When  looking  at  variation  across  all  genes,  study  explained  the  
largest  proportion  of  variation.  However,  when  looking  at  only  microglia  marker  genes  
cell  type  and  the  culturing  status  of  cells  became  more  important.  Sex  and  
stimulation  status  had  little  effect  on  variation  within  all  three  gene  groups  and,  while  
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on  average  sequence  type  only  explained  a  very  small  proportion  of  variability,  the  
variability  across  all  genes  was  relatively  high  with  over  50%  of  variability  explained  
by  sequence  type  in  a  small  number  of  genes.  
  
Figure  3.3  Variance  components  analysis  
Proportion  of  variance  explained  by  metadata  groups  -  across  all  genes  (green),  
Alzheimer’s  disease  (AD)  linked  genes  (orange)  and  microglia  marker  genes  
(purple).  
  
3.3.3  Effects  of  differing  gene  set  inputs  on  principal  components  analysis  
The  variance  components  analysis  described  above  showed  that  across  all  genes  in  
this  dataset  study  explains  on  average  the  largest  proportion  of  variation  in  gene  
expression,  however  this  changed  as  the  genes  were  subsetted.  I  wanted  to  
understand  if  changing  the  number  of  genes  included  in  PCA  would  impact  the  
outcome  and  interpretation  of  the  analysis.  I  used  all  genes  and  the  500  top  most  
variable  genes,  as  suggested  in  the  standard  DESeq2  pipeline,  to  run  PCA  and  
compared  sample  distribution  across  PC1  and  PC2  (Figure  3.4).  When  looking  at  
grouping  of  different  cell  types  across  the  first  two  PCs,  both  gene  inputs  appeared  to  
capture  some  similar  biological  patterns,  with  PC2  appearing  to  separate  the  cancer  
cell  models  from  the  other  cell  types  included  here.  However,  when  all  genes  were  
used  as  an  input  (Figure  3.4  A),  PC1  appears  to  capture  variability  in  primary  
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microglia.  The  same  PC  when  using  the  top  500  most  variable  genes  (Figure  3.4  B),  
appears  to  capture  variability  in  the  iPSC  based  systems.  Colouring  samples  by  
study  shows  that  there  may  be  less  integration  of  different  studies  when  all  genes  are  
used  (Figure  3.4  C)  compared  to  the  top  500  (Figure  3.4  D).  Although  this  is  only  true  
outside  of  the  cancer  cell  line  samples,  where  in  both  gene  inputs,  the  cell  type  
differences  appear  to  be  a  larger  driver  of  variation  than  study  to  study  effects.  Based  
on  these  results,  in  all  downstream  analysis  of  computed  principal  components  
using  top  500  most  variable  genes  (Figure  3.4  B)  in  order  to  minimise  any  study  
based  effects.  
  
Figure  3.4  PC1  vs  PC2  for  all  genes  and  top  500  genes  
Samples  plotted  following  calculation  of  principal  components  with:  all  genes  (A  and  
C)  and  the  500  most  variable  genes  (B  and  D).  All  samples  are  coloured  by  cell  type  
(A  and  B)  or  study  (C  and  D).  
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3.4  Utilising  principal  component  analysis  to  identify  sources  of  variation  
  
3.4.1  Defining  principal  components  
Following  the  assessment  of  how  technical  factors  could  influence  PCA  described  
above,  I  then  wanted  to  understand  whether  PCA  could  be  used  to  understand  
drivers  of  variation  within  this  dataset.  First  I  focused  on  the  spread  of  samples  
across  PC1  and  PC2  as  shown  in  Figure  3.5.  The  largest  amount  of  variation  in  the  
top  500  most  variable  genes  (33%)  appeared  to  capture  variation  within  the  iPSC  
derived  macrophages  and  microglia,  while  PC2  (14%  of  variation)  appeared  to  
separate  samples  by  cell  type  (Figure  3.5  A).  The  cancer  cell  models  had  the  lowest  
PC2  scores,  with  a  band  of  MDMs  and  iPSC-derived  cells  falling  in  the  middle  range  
of  scores  and  the  primary  microglia  with  the  highest  PC2  scores.  The  primary  
microglia  separated  into  two  almost  distinct  groups,  with  some  samples  sitting  much  
closer  to  the  iPSC  model/MDM  band  in  the  central  part  of  the  PC.  In  order  to  
understand  what  might  have  been  driving  this  variation  along  PC2,  particularly  
amongst  the  primary  microglia  samples,  I  looked  at  the  culture  status  of  each  sample  
(Figure  3.5  B).  This  showed  that  samples  that  had  been  cultured  had  lower  PC2  
score  than  the  fresh  primary  microglia  and  suggested  that  cultured  primary  microglia  
cells  looked  more  like  iPSC-derived  samples.  It  is  also  worth  noting  that  fetal  
microglia  (Figure  3.5  C),  even  when  sequenced  without  culturing,  also  had  PC2  
scores  more  similar  to  that  of  iPSC-derived  cells.   
  
Next  I  tried  to  characterise  the  variation  in  expression  captured  by  additional  PCs.  
Figure  3.6  shows  samples  projected  on  PC3  vs  PC4  coloured  by  available  metadata  
groups.  PC3  was  associated  with  stimulation  status  (p  =  5.11e -14  following  Welch  Two   
Sample  t-test  between  PC3  score  and  stimulation  status),  while  the  factors  driving  




Figure  3.5  PC1  vs  PC2  calculated  using  the  top  500  genes  
Samples  plotted  following  calculation  of  principal  components  with  top  500  most  







Figure  3.6  PC3  vs  PC4  calculated  using  the  top  500  genes  
Samples  plotted  following  calculation  of  principal  components  with  top  500  most  
variable  genes.  Coloured  by:  A)  cell  type,  B)  study,  C)  stimulation,  D)  sequencing  




3.4.2  Varimax  analysis  of  principal  components  
While  PCA  provides  a  tool  for  understanding  drivers  of  variation  with  a  gene  
expression  dataset,  as  shown  above  this  often  relies  on  associating  principal  
components  with  known  metadata  which  is  not  always  possible.  Therefore,  
techniques  have  been  developed  to  increase  the  interpretability  of  PCA.  Varimax  is  
an  orthogonal  rotation  technique  that  allows  the  identification  of  specific  variables  
that  heavily  load  principle  components.  In  the  case  of  gene  expression  data,  it  links  
the  expression  of  specific  genes  with  each  PC.  I,  therefore,  used  the  varimax  function  
in  R  to  rotate  the  first  5  PCs  in  order  to  further  understand  what  may  have  been  
driving  the  major  sources  of  variation  within  the  dataset.  Table  3.4  highlights  the  most  
heavily  loaded  genes  for  each  component.  The  genes  most  negatively  loaded  on  
PC1  included  collagen  genes  as  well  as  genes  linked  to  the  extracellular  matrix  and  
cell  adhesion.  Previous  work  comparing  iPSC-derived  macrophages  to  MDMs,  
showed  that  similar  gene  sets  were  more  highly  expressed  in  the  iPSC-derived  
cells 194 .  It  may  be  that  the  variability  in  expression  of  these  genes  across  the  iPSC  
based  model  systems,  represents  variation  in  the  completeness  of  differentiation  as  
many  of  the  genes  are  also  highly  expressed  in  undifferentiated  cells.   
Table  3.4  Top  5  loaded  genes  for  each  principal  component   
Varimax  analysis  of  the  first  5  principal  components  from  the  top  500  most  variable  
genes.  Top  5  most  negatively  and  positively  loaded  genes  for  each  component.  
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  PC1  PC2  PC3  PC4  PC5  
Top  5  loaded  genes  
(-ve)  
COL3A1  CCL13  GPR34  RNASE1  RN7SL2  
COL1A1  MMP9  ADORA3  C1QC  CHIT1  
IGFBP5  ANXA2  PALD1  STAB1  RN7SL3  
POSTN  S100A4  DDIT4L  C1QB  HIST1H1E  
CTGF  CD36  PDK4  C1QA  SCARNA7  
Top  5  loaded  genes  
(+ve)  
CAT  FOSB  CXCL10  ELANE  RNASE2  
MMP9  CH25H  IDO1  CTSG  CD93  
SPN  P2RY12  ACOD1  AZU1  MT-TN  
CHI3L1  CX3CR1  TNFAIP6  PRTN3  MT-ATP8  
CSTA  EGR3  CCL8  CES1  MT-TL1  
  
  
When  looking  at  the  genes  that  were  driving  PC2,  those  most  positively  loaded  
included  many  known  microglia  marker  genes  such  as  P2RY12  and  CX3CR1  as  well  
as  transcription  factors  such  as  SALL1 .  Figure  3.9  highlights  expression  
(log 2 (TPM+1))  of  P2RY12  and  SALL1  across  the  first  two  PCs.   
  
Figure  3.7  PC1  vs  PC2  coloured  by  expression  of  genes  heavily  loading  PC2  
Samples  plotted  following  calculation  of  principal  components  using  the  top  500  most  
variable  genes.  Samples  coloured  by:  A)  cell  type  and  B)  &  C)  expression  
(Log 2 (TPM+1))  of  microglia  marker  genes  SALL1  and  P2RY12  respectively.   
  
Genes  most  negatively  loading  on  the  third  PC  were  linked  to  inflammatory  pathways  
in  immune  cells  (such  as  CXCL10  and  CCL8).  This  further  supports  the  hypothesis  
that  PC3  may  capture  stimulation  effects.  The  genes  most  negatively  loading  on  PC4  
included  many  of  the  C1Q  complex  and  gene  set  enrichment  analysis  highlighted  
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terms  such  as  defense  response  (GO:0006952).  The  genes  most  positively  loaded  
on  PC4  included  immune  activation  linked  genes.  Genes  that  were  found  to  drive  
PC5  included  mitochondrial  genes  and  apoptosis-linked  genes  such  as  CD93 .  This  
suggested  that  PC5  may  have  been  capturing  sample  quality.  As  much  of  the  data  
collected  for  this  analysis  was  from  publicly  available  sources  it  is  difficult  to  obtain  
information  regarding  the  quality  of  the  cells  that  are  used  in  the  analysis  prior  to  
sequencing  (i.e.  ratio  of  live/dead  cells  prior  to  sequencing,  RIN  value  of  RNA)  and  
therefore  accurately  determining  what  may  have  been  driving  PC5  was  difficult.   
  
  
3.5  Differential  expression  between  cell  types  
  
3.5.1  Primary  microglia  vs  all  models   
Initially  I  used  differential  expression  (DE)  analysis,  using  the  DESeq2  package,  to  
compare  primary  microglia  to  all  the  in-vitro  model  systems  in  order  to  understand 
which  regulatory  mechanisms  and  programmes  were  not  well  captured  by  all  existing  
models.  Figure  3.8  shows  the  MA  plot  following  DE  analysis  comparing  primary  
microglia  to  all  other  model  systems.  I  used  this  analysis  to  curate  a  list  of  7297  
genes  which  had  a  significantly  (p adj  <  0.05  and  a  LFC  >  1)  higher  expression  in   
primary  microglia  than  any  of  the  in-vitro  model  systems.  I  shall  refer  to  this  gene  set  
as  the  primary  microglia  marker  (PMM)  gene  set  throughout  the  remainder  of  this  
thesis.  The  PMM  gene  set  included  many  known  microglia  marker  genes  including:  
P2RY12  (p adj  =  5.73e -41  and  LFC  =  7.4),  CX3CR1  (p adj  =  4.23e- 27  and  LFC  =  6.4)  and      
TMEM119  (p adj  =  9.05e -80  and  LFC  =  7.0).  As  well  as  including  microglial  cell  surface    
markers,  the  list  of  genes  also  included  transcription  factors  such  as  SALL1  that  may  
need  to  be  switched  on  in  order  for  model  systems  to  move  closer  to  the  primary  
phenotype.   
  
As  well  as  identifying  individual  genes  of  interest  in  the  PMM  gene  set,  I  also  ran  
gene  set  enrichment  analysis  (GSEA)  on  the  PPM  genes  to  identify  molecular  
pathways  that  were  not  switched  on  in  the  model  systems.  Table  3.5  highlights  the  
top  10  enriched  terms  within  the  PMM  gene  set.  Many  of  the  enriched  terms  were  
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linked  to  neuronal  signalling,  including  nervous  system  development  and  synaptic  
signalling.  This  suggests  that  many  of  the  signalling  processes  missing  from  the  
in-vitro  model  systems  studied  here  are  related  to  the  CNS  microenvironment  that  
microglia  are  normally  found  in.   
  
There  were  also  2686  genes  with  a  significantly  (p adj  <  0.05  and  a  LFC  >  1)  higher   
expression  in  the  in-vitro  model  systems  compared  to  primary  microglia  (Figure  3.8),  
including  genes  such  as  POSTN  and  TTR .  GSEA  of  the  genes  highlighted  an  
enrichment  for  extracellular  matrix  terms  like  extracellular  matrix  organization  
(GO:0030198,  p adj  =  3.5e -27 )  and  extracellular  structure  organization  (GO:0043062,   
p adj   =  2.52e -25 ).  
  
  
Figure  3.8  MA  plot  following  differential  expression  analysis  comparing  
primary  microglia  to  all  other  cell  types  
Average  normalised  counts  of  individual  genes  plotted  against  Log 2 (fold  change)  in  
expression  when  comparing  primary  microglia  to  all  other  cell  types.  Points  coloured  
in  red  represent  genes  reaching  a  p adj  threshold  of  <  0.05  and  triangular  points  are  






Table  3.5  Top  enriched  biological  process  terms  in  the  PMM  gene  set  
Statistical  enrichment  analysis  using  an  ordered  list  through  the  g:GOSt  programme  
of  g:Profiler  with  significance  determined  at  a  5%  FDR.  Ten  most  significantly  
enriched  biological  process  terms  for  genes  with  higher  expression  in  primary  
microglia  compared  to  all  model  systems.  
  
3.5.2  Primary  microglia  vs  individual  model  systems   
PCA  analysis  of  the  dataset  (section  3.4.1)  identified  cell  type  as  a  potential  factor  
driving  PC2  with  iPSC  derived  cells  sitting  as  an  intermediate  along  the  PC  between  
primary  microglia  and  cancer  models.  This  suggested  that  iPSC-derived  cells  may  
represent  a  closer  cell  type  to  primary  microglia  than  cancer  cell  models.  To  confirm  
this  theory,  I  ran  DE  comparing  primary  microglia  to  cancer  cell  models  and  
iPSC-derived  cells  individually  (Figure  3.9).  There  were  more  genes  with  significantly  
higher  expression  (p adj  <  0.05  and  a  LFC  >  1)  when  primary  microglia  were  compared   
to  cancer  cell  models  than  when  compared  to  iPSC-derived  cells  (13996  and  6963  
respectively).  As  well  as  having  more  DE  genes  in  total,  the  average  Log 2 (fold  
change)  across  the  primary/cancer  cell  model  comparison  was  also  higher  than  the  
primary/iPSC-derived  comparison  (3.9  and  2.7  respectively).   
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Term  name  Term  ID  P adj   
nervous  system  development  GO:0007399 8.18e -29   
ion  transport  GO:0006811 8.80e -28   
trans-synaptic  signaling  GO:0099537 2.89e -26   
cell  adhesion  GO:0007155 7.66e -26   
anterograde  trans-synaptic  signaling  GO:0098916 7.66e -26   
chemical  synaptic  transmission  GO:0007268 7.66e -26   
biological  adhesion  GO:0022610 8.76e -26   
synaptic  signaling  GO:0099536 4.02e -25   
cell  development  GO:0048468 1.57e -24   
cation  transport  GO:0006812 2.04e -23   
  
  
Figure  3.9  MA  plots  comparing  primary  microglia  to  cancer  cell  lines  and 
iPSC-derived  cells 
Average  normalised  counts  of  individual  genes  plotted  against  Log 2 (fold  change)  in  
expression  when  comparing  primary  microglia  to  cancer  cell  models  (A)  or  
iPSC-derived  cells  (B).  Points  coloured  in  red  represent  genes  reaching  a  p adj  
threshold  of  <  0.05  (FDR).  
  
I  also  ran  GSEA  on  both  gene  lists  and  table  3.6  highlights  the  top  enriched  terms  on  
genes  more  highly  expressed  in  primary  microglia  when  compared  to  cancer  cell  
models  and  iPSC-derived  cells  individually.  While  each  gene  list  identified  unique  
terms,  such  as  cell  adhesion  and  ion  transport,  neuronally  linked  terms  were  also  
present  in  both  GSEA.   
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Top  GO:BP  terms  for  primary  microglia  vs  
cancer  cell  models  
Top  GO:BP  terms  for  primary  microglia  
vs  iPSC-derived  cells  
Term  name  Term  ID  P adj   Term  name  Term  ID  P adj   
cell  adhesion  GO:0007155 1.17e -41   
nervous  system  
development  
GO:0007399 6.03e -36   
biological  adhesion  GO:0022610 1.17e -41   
trans-synaptic  
signaling  
GO:0099537 2.74e -28   
cell  communication  GO:0007154 1.50e -29   neurogenesis  GO:0022008 2.74e -28   
signaling  GO:0023052 2.92e -29   ion  transport  GO:0006811 5.21e -28   
regulation  of  
multicellular  organismal  
process  
GO:0051239 3.34e -29   
chemical  synaptic  
transmission  
GO:0007268 5.21e -28   
  
Table  3.6  Significantly  enriched  biological  process  terms  for  genes  with  
significantly  higher  expression  in  primary  microglia  compared  to  individual  
model  systems.  
Statistical  enrichment  analysis  using  an  ordered  list  through  the  g:GOSt  programme  
of  g:Profiler  with  significance  determined  at  a  5%  FDR.  Ten  most  significantly  
enriched  biological  process  terms  for  genes  with  higher  expression  in  primary  
microglia  compared  to  cancer  cell  models  and  iPSC-derived  cells  individually.   
  
The  output  of  these  individual  DE  analyses  suggested  that,  when  looking  at  gene  
expression,  iPSC-derived  cells  were  transcriptionally  more  similar  to  primary  
microglia  than  cancer  cell  models  but  both  systems  still  lacked  the  CNS  
microenvironment  stimulus  identified  by  GSEA  on  the  PMM  gene  set.  
  
3.5.3  iPSC  macrophages  vs  iPSC  microglia  
Within  the  iPSC-derived  data  collected  for  this  study,  some  of  the  protocols  were  
developed  to  push  myeloid  progenitor  cells  towards  macrophages  whereas  others  
were  more  specifically  developed  to  move  the  progenitor  cells  closer  towards  primary  
microglia.  Next  I  compared  iPSC-derived  macrophages  and  iPSC-derived  microglia  
to  understand  whether  more  complex  microglia  differentiation  protocols  produce  
markedly  different  cells  to  standard  macrophage  differentiation  protocols.  It  should  be  
noted  that  for  this  differential  expression  analysis,  study  could  not  be  fitted  in  the  
differential  expression  model  (unlike  all  previous  analysis),  because,  for  this  
comparison,  study  was  confounded  with  cell  type.   
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GO:0098916 5.21e -28   
nervous  system  
development  
GO:0007399 4.76e -28   synaptic  signaling  GO:0099536 5.89e -28   
anatomical  structure  
development  
GO:0048856 3.40e -26   
generation  of  
neurons  
GO:0048699 3.21e -26   
regulation  of  signaling  GO:0023051 2.53e -25   cell  development  GO:0048468 7.51e -26   
multicellular  organismal  
process  




GO:0032501 2.62e -25   
  
I  found  4975  genes  with  significantly  higher  expression  in  iPSC-derived  microglia  
and  5461  genes  that  had  higher  expression  in  iPSC-derived  macrophages  (p adj  <0.05   
and  LFC  >  1).  Genes  with  significantly  increased  expression  in  iPSC-derived  
microglia  were  enriched  for  ion  transport  terms  whereas  those  with  significantly  
increased  expression  in  iPSC-derived  macrophages  were  enriched  for  
developmental  terms  (Table  3.7).  As  I  wanted  to  understand  whether  specific  
microglia  differentiation  protocols  pushed  the  cell  model  systems  closer  to  the  
primary  cell  type,  I  compared  the  list  of  genes  more  highly  expressed  in  iPSC  
microglia  to  the  PMM  gene  set  described  in  section  3.5.1.  There  were  2,164  genes  
that  overlapped  between  the  two  lists,  approximately  30%  of  the  total  genes  in  the 
PMM  gene  set.  This  suggested  that  there  were  some  PMM  genes  that  were  also  
enriched  in  iPSC-derived  microglia  compared  to  their  macrophage  counterparts,  
potentially  highlighting  a  shift  closer  to  the  primary  phenotype.  These  genes  included  
some  known  microglia  marker  genes  such  as  P2RY12  and  CX3CR1 .  
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Top  GO:BP  terms  for  genes  with  
increased  expression  in  iPSC-derived  
macrophages  
Top  GO:BP  terms  for  genes  with  
increased  expression  in  iPSC-derived  
microglia  
Term  name  Term  ID  P adj   Term  name  Term  ID  P adj   




GO:0007275 1.43 e-52   cation  transport  GO:0006812 1.50e -16  
anatomical  structure  
development  
GO:0048856 3.86e -52   
transmembrane  
transport  
GO:0055085 4.51e -15  
anatomical  structure  
morphogenesis  
GO:0009653 2.00e -50   
regulation  of  ion  
transport  
GO:0043269 2.87e -14  
developmental  
process  
GO:0032502 1.63e -48   
ion  transmembrane  
transport  
GO:0034220 3.80e -14  
multicellular  
organismal  process  
GO:0032501 6.86e -43   
cation  transmembrane 
transport  
GO:0098655 6.01e -14  
cell  adhesion  GO:0007155 1.59e -39   metal  ion  transport  GO:0030001 3.56e -13  
biological  adhesion  GO:0022610 1.65e -39   
inorganic  ion  
transmembrane  
transport  
GO:0098660 1.33e -11  
animal  organ  
development  
GO:0048513 7.37e -38   
regulation  of  biological 
quality  
GO:0065008 1.71e -11  
  
Table  3.7  Significantly  enriched  biological  process  terms  for  genes  with  
significantly  higher  expression  in  iPSC-derived  macrophages  or  microglia  
when  compared  to  each  other  
Statistical  enrichment  analysis  using  an  ordered  list  through  the  g:GOSt  programme  
of  g:Profiler  with  significance  determined  at  a  5%  FDR.  Ten  most  significantly  
enriched  biological  process  terms  for  genes  with  higher  expression  in  primary  
microglia  compared  to  cancer  cell  models  and  iPSC-derived  cells  individually.   
  
  
3.6  Expression  of  Alzheimer’s  disease  genes  across  model  systems  
  
One  common  use  of  the  scalable  in-vitro  cell  model  systems  is  to  study  the  
mechanism  of  action  of  individual  genes  and  how  perturbation  of  gene  expression  
may  impact  cell  function.  This  is  particularly  useful  when  trying  to  understand  how  
disease  risk  linked  genes  identified  by  genome  wide  association  studies  (GWAS)  
may  impact  cell  function  in  disease.  As  microglia  have  been  suggested  to  be  a  
pathological  cell  type  in  Alzheimer’s  disease  (AD) 1,31 ,  I  examined  the  level  of  
conservation  of  expression  of  known  or  suspected  AD  risk  genes  between  primary  
microglia  and  the  different  cellular  model  systems.  
  
3.6.1  Expression  of  known  Alzheimer’s  disease  genes  
I  first  looked  at  the  expression  of  three  genes  associated  with  familial  AD:  APP ,  
PSEN1  and  PSEN2 .  Figure  3.10  shows  expression  (DESeq2  normalised)  of  each  of  
the  three  genes  for  each  sample.  Expression  of  each  of  the  three  genes  was  not  
significantly  increased  in  primary  microglia  compared  to  in-vitro  cell  models.  
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regulation  of  
multicellular  
organismal  process  
GO:0051239 1.97e -35   chemical  homeostasis GO:0048878 5.13e -11  
  
  
Figure  3.10  Expression  of  familial  AD  genes  by  cell  type  
DESeq2  normalised  expression  data  of  familial  AD  disease  genes,  samples  
separated  by  broad  cell  type.   
  
Next  I  examined  the  expression  of  genes  associated  with  late-onset  AD.  The  
strongest  signal  of  gene  association  with  AD  risk  is  the  APOE  region,  with  APOEε4  
associated  with  the  largest  risk  increase 123 .  APOE  was  significantly  more  highly  
expressed  in  primary  microglia  when  compared  to  all  other  model  systems  (p adj  =   
1.41e -10 ,  LFC  =  2.24)  Figure  3.11  A,  and  particularly  comparing  primary  microglia  to  
cancer  cell  lines  (p adj  =  1.96e -15 ,  LFC  =  4.42).  APOE  was  also  significantly  (p adj  =    
3.03e -10 ,  LFC  =  2.1)  more  highly  expressed  in  iPSC-derived  microglia  than  in  
iPSC-derived  macrophages,  suggesting  that,  for  studying  APOE  function,  microglia  
rather  than  macrophage  differentiation  protocols  may  be  preferable.   
  
Rare  missense  variants  in  TREM2 251,252 ,  ABI3  and  PLCG2 130  have  all  been   
associated  with  increased  AD  risk,  and  have  suggested  immune  functions  .  There  
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was  no  significant  difference  in  expression  of  PLCG2  (Figure  3.14  B)  across  any  of  
the  cell  types.  Expression  of  TREM2  and  ABI3  (Figure  3.14  C  and  D  respectively)  
were  significantly  reduced  in  cancer  cell  lines  compared  to  primary  microglia  (p adj  =   
2.7e -8 ,  LFC  =  3.1  and  p adj  =  2.87e -128 ,  LFC  =  7  respectively).  However,  expression  in   
iPSC-derived  cells  was  not  significantly  different  to  that  seen  in  primary  microglia  
and,  therefore,  iPSC  based  systems  could  be  used  as  in-vitro  models  for  studying  the  
effect  of  these  genes.   
  
Figure  3.11  Expression  of  late  onset  AD  rare  and  high  effect  size  genes  by  cell  
type  
DESeq2  normalised  expression  data  of  late  onset  AD  disease  genes,  samples  
separated  by  broad  cell  type.   
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3.6.2  Expression  of  late  onset  Alzheimer’s  disease  linked  genes  
As  described  in  section  2.6.2  the  study  described  in  Chapter  2  of  this  thesis  was  part  
of  a  large  collaborative  project  that  also  included  an  expression  quantitative  trait  loci  
(eQTL)  map  of  adult  primary  human  microglia(Young  et  al.  -  paper  in  preparation).  
The  identified  eQTLs  were  then  co-localised  with  variants  identified  from  AD  genome  
wide  association  studies  (GWAS)  to  identify  candidate  causal  AD  risk  genes  and  
variants.  
  
One  of  the  strongest  signals  of  colocalisation  we  identified  was  found  at  the  BIN1  
locus  that  appeared  to  be  driven  by  the  rs6733839  SNP  which  in  turn  perturbed  a  
binding  site  for  the  transcription  factor  MEF2A.  BIN1  had  significantly  increased  
expression  in  primary  microglia  when  compared  to  all  model  systems  (p adj  =  8.03e -33    
and  LFC  =  3.18),  (Figure  3.12  A).  While  the  expression  of  MEF2A  (Figure  3.12  B)  
was  not  significantly  different  when  primary  microglia  were  compared  to  the  model  
systems  collectively,  expression  of  the  gene  was  significantly  reduced  when  primary  
microglia  were  compared  to  cancer  cell  models  individually  (p adj  =  2.09e -13  and  LFC  =    
2.14).   
  
As  well  as  developing  our  understanding  of  the  BIN1  risk  loci,  the  eQTL/GWAS  
co-localisation  also  identified  other  potential  SNP-gene  links  at  AD  risk  loci  including:  
PTK2B ,  CASS4 ,  CD33  and  EPHA1-AS1  (Figure  3.12  C-F).  There  was  no  significant 
difference  in  expression  of  CD33 ,  PTK2B  or  EPHA1-AS1  when  comparing  primary  
microglia  and  the  model  systems  but  expression  of  CASS4  was  significantly  
increased  in  primary  cells  compared  to  all  other  model  systems(p adj  =  3.57e -14  and    
LFC  =  2.61).   
  
Table  3.8  summarises  the  DE  between  primary  microglia  and  cancer  cell  models  or  
iPSC-derived  cells  for  all  of  the  genes  described  in  this  section  (3.6)  as  well  as  other  
genes  that  have  been  identified  as  the  “nearest  gene”  to  an  AD  risk  variant  in  more  
than  one  GWAS  study  (see  Table  1.1  for  full  list  and  matching  subset  in  Table  2.11).  
Of  the  30  AD  genes  identified,  70  %  had  a  statistically  similar  expression  in  at  least  
one  model  system  compared  to  primary  microglia.  However,  for  9  individual  AD  
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genes  neither  cancer  cell  models  or  iPSC-derived  cells  accurately  captured  the  
expression  profile  of  primary  microglia  (p adj   <  0.05  and  LFC  >  1).  
  
  
Figure  3.12  Expression  of  late  onset  AD  risk  genes  
DESeq2  normalised  expression  data  of  late  onset  AD  disease  genes,  samples  




Table  3.8  Comparison  of  AD  gene  expression  in  primary  microglia  and  model  
systems  
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Gene  name 
Is  expression  statistically  similar  in  primary  microglia  and  
cancer  cell  models?  iPSC-derived  cells?  
APP  Yes  Yes  
PSEN1  Yes  Yes  
PSEN2  Yes  Yes  
APOE*  No  No  
TREM2  No  Yes  
PLCG2  Yes  Yes  
ABI3  No  Yes  
BIN1*  No  No  
MEF2A  No  Yes  
CASS4*  No  No  
PTK2B  Yes  Yes  
CD33  Yes  Yes  
EPHA1-AS1 Yes  Yes  
CR1*  No  No  
CD2AP  Yes  Yes  
EPHA1  Yes  Yes  
MS4A6A  No  Yes  
PICALM  No  Yes  
ABCA7  Yes  Yes  
SORL1*  No  No  
SLC24A4*  No  No  
DSG2  Yes  Yes  
INPP5D*  No  No  
ZCWPW1  No  Yes  
FERMT2  Yes  Yes  
CLU*  No  No  
ADAM10  Yes  Yes  
KAT8  Yes  Yes  
ACE  Yes  Yes  
ECHDC3  No  No  
  
Summary  of  differential  expression  of  AD  genes  in  primary  microglia  when  compared  
to  cancer  cell  models  and  iPSC-derived  cells.  Statistical  differences  determined  by  
DESeq2  analysis  and  genes  with  an  p adj  <  0.05  and  LFC  >  1.  *  next  to  a  gene  name   
highlights  genes  not  captured  by  either  of  the  model  systems  studied  here.  
  
  
3.7  Discussion  
  
In  this  chapter  I  used  publicly  available  RNA-sequencing  datasets  to  compare  the  
transcriptome  of  primary  human  microglia  to  a  variety  of  in-vitro  cell  models.  I  
obtained  raw  read  level  data  from  multiple  independent  studies  and  processed  them  
using  a  uniform  analysis  pipeline.  I  showed  that  even  with  the  uniform  alignment  and  
quantification  pipeline,  downstream  analysis  can  still  be  impacted  by  normalisation  
techniques.  The  normalisation  methods  studied  here,  Log 2 (TPM+1),  QN  and  VST,  
had  relatively  low  levels  of  overlap  when  identifying  the  top  500  most  variable  genes  
within  the  dataset,  with  less  than  250  genes  matching  across  all  three  methods.  
However,  PCA  using  the  top  500  most  variable  genes  resulted  in  broadly  similar  
sample  distribution  when  PC1  vs  PC2  scores  for  each  sample  were  plotted.  Variance 
components  analysis  revealed  that,  when  expression  at  all  genes  was  considered,  
study  was  the  major  driver  of  gene  expression  variation  illustrating  the  importance  of  
collecting  data  from  the  same  cell  type  across  multiple  experiments.   
  
Using  PCA  I  was  able  to  capture  interpretable  biological  signals  including  the  
completeness  of  iPSC  differentiation  across  PC1  and  the  differing  cell  types  along  
PC2.  Interestingly,  PC2  also  captured  a  separation  in  primary  microglia  samples  with  
cultured  primary  microglia  and  fetal  samples  having  lower  PC2  scores  than  fresh  
adult/pediatric  primary  cells.  It  appeared  that  along  this  PC,  these  cells  became  more  
transcriptionally  similar  to  iPSC-derived  cells.  Linking  PCs  with  biological  factors  
often  requires  prior  knowledge  of  sample  metadata  to  identify  drivers  of  variation  or  
technical  batch  effects.  However,  as  the  data  collected  for  this  study  was  mainly  
sourced  from  publicly  available  sources,  I  could  only  collect  metadata  provided  
alongside  the  samples.  The  amount  of  information  about  samples  varied  from  source  
to  source  meaning  there  may  have  been  technical  batch  effects  within  the  dataset  
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that  could  not  be  identified  and  so  the  driver  behind  each  PC  could  not  be  
established.  
When  comparing  primary  microglia  to  all  the  model  systems  studied  here  many  of  the  
enriched  gene  sets  were  linked  to  neuronal  processes.  Previous  work  in  primary  
human  microglia,  has  shown  that  even  culturing  primary  cells  for  6  hours  following  
dissociation  of  brain  tissue  can  reduce  the  expression  of  specific  gene  patterns  in  
primary  cells 171 .  Many  of  the  genes  that  were  identified  as  part  of  the  environmentally  
linked  signature  described  in  primary  cells  including  TMEM119 ,  CX3CR1  and  
P2RY12 ,  were  also  identified  as  having  significantly  lower  expression  in  the  model  
systems  when  compared  to  primary  microglia.  This  environmental  signalling  may  
also  explain  the  separation  of  primary  microglia  samples  along  PC2,  with  cultured  
and  fetal  samples  lacking  the  cues  and  stimuli  from  the  developed  CNS  fully  capture  
the  microglia  specific  transcriptional  signature.   
  
Comparison  of  iPSC-derived  macrophages  to  iPSC-microglia  suggested  that  more  
specific  differentiation  protocols  pushed  differentiated  cells  closer  towards  the  
primary  phenotype  with  significantly  increased  expression  of  genes  such  as  P2RY12  
and  CX3CR1 .  However,  the  iPSC-microglia  still  did  not  fully  reflect  the  transcriptional  
signature  of  primary  cells,  and  expression  of  microglial-linked  TFs  such  as  SALL1  
was  lower  in  iPSC-derived  cells.  All  of  the  iPSC-derived  microglia  samples  used  here  
represent  monoculture  systems,  with  only  the  chemical  components  of  the  
differentiation  media  being  used  to  push  the  cells  towards  the  microglial  phenotype.  
However,  more  complex  differentiation  protocols  that  involve  culturing  microglia  
alongside  neurons  have  also  been  developed 198,200,202–206 .  These  culturing  systems  
should  more  closely  represent  the  brain  environment,  as  they  provide  both  the  
chemical  stimuli  and  contact  with  neurons  microglia  may  require  for  complete  
differentiation.  This  concept  is  explored  further  in  Chapter  4  of  this  thesis,  where  I  
have  used  bulk  and  single  cell  RNA-sequencing  of  co-culture  and  organoid  derived  
microglia,  from  a  previously  published  protocols 200 ,  to  look  at  how  neurons  influence  
microglial  gene  expression.   
  
As  microglia  are  thought  to  be  pathogenic  cells  in  Alzheimer’s  disease 31 ,  I  also  used  
this  dataset  to  compare  expression  of  disease  risk  genes  across  the  model  systems.  
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This  builds  on  extended  analysis  carried  out  on  the  primary  microglia  dataset  
described  in  Chapter  2,  in  which  it  has  been  shown  that  iPSC-derived  macrophages  
share  a  similar  genetic  architecture  to  primary  microglia(Young  et  al.  -  paper  in  
preparation).  In  the  analysis  carried  out  by  Dr  Natsuhiko  Kumasaka,  eQTL/GWAS  
co-localisations  identified  in  primary  microglia  were  replicated  in  iPSC-derived  
macrophages.  However,  as  demonstrated  this  does  not  always  translate  to  similar  
expression  levels  across  cell  types,  genes  such  as  BIN1 ,  APOE  and  CASS4  all  had  
significantly  higher  expression  in  primary  microglia  compared  to  the  iPSC  model  
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Chapter  4:  Complex  in-vitro  model  systems  
  
Collaboration  note  
The  samples  collected  as  part  of  this  chapter  were  processed  as  part  of  a  
collaboration  with  the  Livsey  Lab,  based  at  the  time  at  the  Gurdon  Institute  and  now  
at  UCL.  Stem  cell  differentiations  were  carried  out  by  Dr  Phil  Brownjohn  and  Dr  
Moritz  Haneklaus  as  well  as  10X  sample  processing,  along  with  Dr  Julie  Jerber.  Bulk  
sample  processing  was  completed  by  Dr  Andrew  Knights.  All  sequencing  was  
completed  at  the  Wellcome  Sanger  Institute,  and  initial  analysis  (alignment  and  
quantification)  of  sequencing  data  was  done  by  core  informatics  facilities  at  the  
institute.   
  
4.1  Introduction  
  
Work  carried  out  in  Chapter  3  of  this  thesis  compared  primary  microglia  to  a  variety  
of  in-vitro  model  systems  and  highlighted  that,  while  induced  pluripotent  stem  cell  
(iPSC)  based  model  systems  provide  a  closer  model  system  than  cancer-cell  lines, 
they  still  lack  expression  of  many  genes  associated  with  primary  microglia.  Many  of  
the  genes  with  higher  expression  in  primary  microglia  can  be  linked  to  neuronal  and  
central  nervous  system  (CNS)  pathways.  This  suggests  that  the  unique  microglial  
transcriptomic  signatures  are  driven  by  environmental  stimuli  in  the  brain  that  are  not  
well  captured  by  monoculture  based  in-vitro  models.  Consistent  with  this,  freshly  
sequenced  primary  microglial  samples  have  an  environment  dependent  gene  
expression  signature  that  is  not  observed  in  cultured  primary  cells 171 .   
  
While  culturing  primary  human  microglia  has  been  shown  to  cause  a  reduction  in  
expression  of  specific  CNS-linked  genes,  it  has  also  been  demonstrated  that  
culturing  cells  with  factors  that  mimic  the  neuronal  environment  can  rescue  some  of  
that  expression 171 .  Therefore,  some  of  the  monoculture  iPSC  microglia  models  use  
small  compounds,  such  as  C3CL1  and  CD200,  within  the  media  of  their  cultures  in  
order  to  better  mimic  the  environment  of  the  central  nervous  system  (CNS) 198,201 .  
However,  microglia  are  in  constant  contact  with  neurons 4  and  it  may  be  that  it  is  a   
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mixture  of  both  soluble  factors  in  the  CNS  and  physical  contact  with  neurons  that  
provides  the  signals  needed  for  specific  microglia  gene  expression.   
  
4.1.1  Co-culture  and  organoid  model  systems   
In  order  to  better  mimic  the  CNS  environment  of  primary  microglia  in  a  dish,  there  
have  been  methods  developed  to  culture  in-vitro  microglia  in  the  presence  of  neurons  
in  order  to  push  them  closer  towards  the  primary  cell  type.  The  most  straightforward  
method  is  to  co-culture  single  layers  of  both  cell  types  together.  Co-culturing  
iPSC-derived  microglia  with  rat  hippocampal  neurons  has  been  shown  to  cause  a  
significant  upregulation  of  156  genes  (adjusted  p  <  0.01),  including  SIGLEC11 ,  MITF  
and  SLC2A5 ,  when  compared  to  their  monoculture  iPSC-derived  cells 198 .  However  as  
iPSC-derived  neuronal  differentiation  protocols  exist,  it  is  also  possible  to  culture  
iPSC-derived  microglia  alongside  iPSC-derived  neurons 202 .  The  media  used  in  these  
co-culture  systems  often  requires  supplementation  with  compounds  such  as  IL-34  
and  GM-CSF  in  order  to  maintain  microglial  survival  and  the  distinctive  ramified  
morphology  of  the  cells.  When  compared  to  monocultured  iPSC-derived  
macrophages,  co-cultured  microglial  cells  have  been  shown  to  have  higher  levels  of  
expression  of  genes  linked  to  chemotaxis/migration  and  regulation  of  cell  
adhesion 202 .   
  
While  co-culture  systems  provide  the  most  simple  way  to  closer  mimic  the  CNS  
environment,  3D  organoid  systems  can  provide  an  even  more  realistic  method  of  
modeling  the  brain  environment  in  a  dish.  These  culture  systems  use  microfluidic  
culture  platforms  with  different  chambers  for  unique  cell  types 205  or  spinning   
bioreactors 200,203,204,206  in  order  to  maintain  the  3D  architecture  of  the  organoids.  It  has   
been  suggested  that  microglia  will  spontaneously  form  within  certain  neuronal  
organoids  that  are  developed  through  embryoid  body  formation 204 .  However,  while  
the  cells  detected  in  these  organoids  are  IBA1  positive  and  express  RUNX1  at  
comparable  levels  to  primary  microglia,  expression  of  microglia  marker  genes  such 
as  TMEM119 ,  P2RY12  and  CX3CR1  were  significantly  lower.  Expression  of  these  
genes  increased  as  culture  time  increased,  suggesting  there  was  some  maturation  of  




Although  it  may  be  possible  to  allow  microglia  to  spontaneously  develop  within  
neuronal  organoids,  iPSC  microglia-like  cells  can  also  be  differentiated  externally  and  
then  added  to  already  formed  organoids.  Brownjohn  et  al. 200  generated  myeloid   
precursors  through  established  iPSC  differentiation  protocols 192,193  and  matured  the   
precursors  with  IL-34  and  GM-CSF  to  create  a  monoculture  of  microglia-like  cells.  
The  cells  were  then  added  to  neuronal  3D  organoids  to  understand  how  the  microglia  
would  interact  with  neuronal  cultures.  The  iPSC-derived  microglia  were  shown  to  
rapidly  migrate  from  the  surface  to  deep  within  the  organoid  structure  and  assume  a  
highly  ramified  morphology.  The  authors  also  noted  that  the  microglia  cells  survived  
in  the  organoid  culture  using  only  the  standard  organoid  culture  media,  they  required  
no  supplementation,  suggesting  of  all  the  required  signals  for  microglial  survival  were  
supplied  by  the  neuronal  culture  system,  unlike  when  using  co-cultured  models.  
  
While  some  efforts  have  been  made  to  compare  these  complex  models  to  primary  
microglia  and  monoculture  systems,  no  comprehensive  analysis  comparing  all  three  
has  been  carried  out.  This  means  it  is  not  entirely  clear  whether  culturing  
iPSC-microglia  alongside  iPSC-derived  neurons  moves  them  along  a  trajectory  
towards  primary  microglia.  
  
4.1.2  Single  cell  sequencing  and  developmental  trajectory  inference   
Bulk-RNA  sequencing  of  iPSC-derived  differentiated  cultures  can  provide  a  method  
to  look  at  how  well  the  transcriptional  profile  of  model  systems  captures  the  profile  of  
the  primary  cell  type  being  studied.  However,  as  single  cell  RNA-sequencing  
technology  has  developed  our  ability  to  understand  two  key  points  of  
iPSC-differentiation  has  significantly  increased.  First,  it  provides  researchers  with  the  
power  to  better  understand  the  heterogeneity  of  cells  within  a  differentiated  
population 253–255 ,  which  means  rare  populations  can  be  identified  that  may  be  missed  
with  bulk  RNA-sequencing.  Secondly,  single  cell  sequencing  allows  researchers  to  
track  individual  cells  along  a  developmental  or  differentiation  trajectory 256,257 .   
  
Computationally  these  dynamic  processes  within  individual  cells  can  be  studied  using  
trajectory  inference  methods,  sometimes  referred  to  as  pseudotime  analysis,  in  which  
cells  are  ordered  along  a  process  based  on  gene  expression.  There  are  a  large  
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number  of  analysis  tools  available  to  run  pseudotime  analysis.  Each  of  the  tools  has  
a  unique  algorithm  for  determining  cell  trajectories  but  they  can  broadly  be  split  into  
two  groups  depending  on  whether  they  are  built  around  free  or  fixed  trajectory 258 .  
Monocle3  is  one  example  of  a  free,  unbiased  algorithm  that  builds  a  tree  based  
trajectory  of  cells  along  a  differentiation  pathway 259 .  The  package  works  by  projecting 
cells  onto  a  Uniform  Manifold  Approximation  and  Projection  (UMAP)  plot 260 ,  
clustering  cells  through  a  Louvain  algorithm.  The  algorithm  not  only  divides  cells  into  
clusters  but  also  larger  “partitions”  of  cells.  When  determining  the  trajectory  pathways  
in  a  dataset,  Monocle  3  can  recognise  the  movement  of  cells  within  different  
partitions  as  distinct  trajectories.  The  authors  argue  this  removes  the  assumption  
from  their  model  that  every  cell  derives  from  a  common  ancestor  cell.   
  
The  first  part  of  this  chapter  focuses  on  this  question  by  combining  bulk  
RNA-sequencing  data,  generated  in  collaboration  with  the  Livesey  lab,  from  
monoculture,  co-cultured  and  organoid  derived  microglia  with  the  large  comparative  
dataset  analysed  in  Chapter  3.  I  have  then  used  single  cell  analysis  and  trajectory  
inference  analysis  to  further  understand  how  differing  stem  cell  derived  models  of  
microglia  may  fit  along  a  developmental  trajectory.  Using  the  tools  available  in  the  
Monocle3  package,  I  have  identified  genes  differentially  expressed  across  the  
developmental  trajectories  in  order  to  understand  which  cellular  pathways  are  key  to  
pushing  in-vitro  models  of  microglia  towards  the  primary  cell  type.   
  
  
4.2  Methods   
  
4.2.1  Cell  culture,  dissociation  and  sorting  
Monoculture  stem  cell  derived  microglia  were  derived  using  a  previously  developed  
protocol  from  within  the  Livesey  lab 200 .  Cultures  were  created  using  the  H9  embryonic  
stem  cell  line  and  the  KOLF_2  iPSC  line,  from  the  HiPSC  database.  For  bulk  
sequencing  samples,  the  two  lines  were  cultured  individually  whereas  the  lines  were  
combined  for  single  cell  sequencing.  Stem  cell  derived  neurons  were  cultured  using  
an  established  protocol 261  and  combined  with  fully  differentiated  stem  cell-derived   
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microglia  cells.  Organoid  cultures  were  also  differentiated  as  previously  described 200 ,  
although  the  number  of  days  organoids  were  kept  in  cultured  varied  (between  12  and  
15  days).   
  
Sample  dissociation  was  carried  out  using  the  Papain  Dissociation  System  
purchased  from  Worthington  Biochemical  Corporation.  Cells  were  initially  washed  
with  PBS  before  being  transferred  into  a  1.5  mL  tube  containing  200  µl  of  dissociation  
mix  (Table  4.1)  and  incubated  for  20-40  minutes.  During  the  incubation  cell  solutions  
were  agitated  regularly  or  incubated  directly  on  a  heated  shaking  block.  Following  
incubation,  samples  were  then  titrated  to  further  break  down  clumps  of  cells  before  
using  centrifugation  to  pellet  the  cells.  The  cell  pellet  was  resuspended  in  175  µl  of  
the  inhibitor  mix  (Table  4.1)  and  then  a  further  90  µl  of  Ovomucoid  and  90  µl  of  EBSS  
were  added  to  the  resuspended  cell  pellet.  The  cells  were  then  centrifuged  again  and  
the  resulting  liquid  was  removed  leaving  the  dissociated  cell  pellet.  Dissociated  cells  
were  then  used  in  the  next  stage  of  the  processing  pipeline,  detailed  in  section  4.2.2  
and  4.2.3.  For  samples  that  required  cell  sorting,  pellets  were  resuspended  in  FACS  
buffer  and  sorted  using  CD45  FACS  staining.   
Table  4.1  Buffer  compositions  for  cell  dissociation  and  sorting  
  
4.2.2  Bulk  sequencing  preparation   
As  the  numbers  of  isolated  microglia  cells  from  the  complex  model  systems  were  
relatively  low  the  samples  were  processed  by  a  slightly  modified  version  of  the  
low-input  pipeline  developed  in-house  by  Dr  Andrew  Knights  and  described  in  section  
2.2.3  of  this  thesis.  Isolated  cells  were  lysed  directly  in  50  µL  of  the  lysis  binding  
buffer  described  in  Table  2.1,  for  monoculture  cells  this  was  following  dissociation  
and  for  the  complex  models,  this  was  after  CD45  FACS  sorting  to  isolate  myeloid  
cells.  The  lysed  samples  were  then  directly  added  to  oligo-DT  beads  without  the  
need  for  a  kit-based  RNA  extraction.  The  RNA-sequencing  libraries  were  then  
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Dissociation  mix  Inhibitor  mix  FACS  buffer  
145  µl  Papain  148.25  µl  EBSS  18.6  ml  PBS  
10  µl  Dnase  I  8.75  µl  Dnase  I  1.33  ml  BSA  (7.5  %)  
45  µl  EBSS  17.5  µl  Ovomucoid  80  µl  EDTA  (0.5  M)  
  
prepared  exactly  as  described  for  the  primary  microglia  samples  in  section  2.2.3.  All  
samples  used  in  this  study  went  through  a  14  cycle  amplification  PCR  (Figure  2.2).  
Samples  varied  in  cell  number  across  the  culture  systems,  with  those  isolated  from  
the  organoid  systems  falling  in  the  lower  range  (Table  4.2).  
Table  4.2  Sample  summary  for  bulk  RNA-sequencing  
  
4.2.3  Single  cell  sequencing  preparation  
Samples  generated  for  10X  single  cell  sequencing  were  a  mixture  of  sorted  and  
unsorted  samples,  summarised  in  Table  4.3.  Single  cell  suspensions  were  processed  
by  the  Chromium  Controller  (10x  Genomics)  using  single  Cell  3’  Reagent  Kit  v2  
(PN-120237).  All  the  steps  were  performed  according  to  the  manufacturer’s  
specifications.  Barcoded  libraries  were  sequenced  using  HiSeq4000  (Illumina,  one  
lane  per  10x  chip  position)  with  75bp  paired  end  reads.  Information  regarding  the  
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Cell  line  Culture  system  Cell  numbers  
H9GFP  Co-culture  50k  
KOLF2  Co-culture  50k  
H9GFP  Co-culture  35k  
KOLF2  Co-culture  32k  
H9GFP  Co-culture  27k  
KOLF2  Co-culture  50k  
H9GFP  Organoid  12k  
H9GFP  Organoid  7k  
KOLF2  Organoid  7k  
H9GFP  Organoid  6.5k  
KOLF2  Organoid  13k  
KOLF2  Organoid  23k  
H9GFP  Monoculture  30k  
KOLF2  Monoculture  30k  
H9GFP  Monoculture  50k  
KOLF2  Monoculture  50k  
H9GFP  Monoculture  50k  
KOLF2  Monoculture  50k  
KOLF2  Monoculture  25k  
  
number  of  cells  loaded  into  each  inlet  as  well  as  the  number  of  returned  cells  and  
resulting  reads/cell  can  also  be  found  in  Table  4.3.  
  
Table  4.3  Sample  summary  for  10X  single  cell  sequencing   
  
4.2.4  Bulk  RNA-sequencing  data  processing  and  analysis   
In  order  to  ensure  continuity  with  the  data  analysed  in  Chapter  3  of  this  thesis,  raw  
bulk  RNA-sequencing  data  generated  as  part  of  this  data  was  processed  through  the  
same  pipeline:  STAR  followed  by  featureCounts  quantification.  Following  
Log 2 (TPM+1)  normalisation,  I  again  used  the  prcomp  function  in  R  to  carry  out  
principal  components  analysis  (PCA),  principal  components  (PCs)  were  calculated  
using  the  top  500  most  variable  genes  or  genes  identified  as  having  significantly  
higher  expression  in  primary  microglia  when  compared  to  all  monocultured  models  
(see  section  3.5.1).  I  also  used  the  varimax  function  to  rotate  calculated  PCs  to  
identify  the  highly  loaded  genes  for  each  PC.  I  extended  my  dimensionality  reduction  
analysis  to  also  compute  PCs  from  the  residuals  following  linear  regression  study  
effects,  to  control  for  the  known  batch  effects  that  can  arise  when  comparing  across  
sequencing  studies.  Residuals  were  calculated  for  each  sample  across  each  gene  
using  either  of  the  following  linear  model:  
lm  (expression  ~  study)  
  
Differential  expression  analysis  was  carried  out  using  the  DESeq2  package 248  with   
sequence  preparation,  (normal  or  low-input  library  preparation)  used  as  a  variable  in  
the  analysis.  Gene  lists  were  run  through  gene  set  enrichment  analysis  using  g:OSt  
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Culture  
system  FACS  
Days  in  
culture  
Number  of  cells  
loaded  
Number  of  cells  
sequenced  
Mean  reads  per 
cell  
monoculture unsorted NA  16670  8675  40800  
co-culture  unsorted NA  21537  8353  41685  
organoid  unsorted 12  25826  9045  36152  
organoid  sorted  12  9835  4215  73349  
organoid  sorted  15  8450  3223  98736  
organoid  unsorted 15  17765  8862  35045  
  
function  of  the  online  gProfiler  tool 226 .  For  full  description  of  the  analysis  pipelines  see  
section  3.2.3.  
  
4.2.5  Single  cell  RNA-sequencing  data  processing  and  quality  control   
10X  single  cell  samples  were  aligned  and  quantified  using  cellranger  version  3.0.2  
and  GRCh38,  the  final  combined  dataset  contained  42317  cells.  Following  Seurat’s  
standard  preprocessing  pipeline,  I  calculated  the  percentage  of  mitochondrial  genes  
across  samples  and  filtered  out  cells  with  >  10%  mitochondrial  genes  to  remove  
dying  cells.  I  also  removed  cells  with  less  than  100  or  greater  than  3000  features  to 
remove  poor  quality  cells  and  potential  doublets.  Following  these  quality  control  
steps,  31259  cells  remained  for  further  analysis.  Data  was  then  normalised  and  
scaled,  before  PCA  was  run  on  the  3000  most  variable  genes.  I  then  ran  clustering  
and  UMAP  analysis  using  15  PCs  and  a  0.5  resolution.  I  used  known  myeloid  marker  
gene  (CD45  and  AIF1)  expression  to  identify  and  subset  the  microglia-like  cells  from  
the  dataset,  identifying   8928  myeloid  cells  for  downstream  analysis.   
  
4.2.6  Cluster  identification,  differential  expression  analysis  and  trajectory  
analysis   
Filtered  and  subsetted  raw  count  data  for  the  identified  myeloid  cells  was  then  
processed  using  the  Monocle3  package 259 .  Raw  count  data  was  normalised  and  
preprocessed  using  the  first  100  PCs.  Normalisation  was  carried  out  by  the 
estimation  of  size  factors  for  each  cell  and  dispersions  across  genes  before  log 10   
normalisation.  UMAP  analysis  was  used  to  visualise  the  cells  and  the  cluster_cells  
function  within  Monocle3  was  used,  with  a  resolution  of  1x10 -4 ,  to  group  cells.  The  
initial  clustering  of  cells  by  Monocle3  used  “community  detection”  as  a  method  of  
classifying  cells 262  which  was  first  used  as  part  of  the  phenoGraph  package 263 .  As   
well  as  grouping  cells  into  “clusters”  the  cluster_cells  function  also  split  cells  into  
“partitions”  using  the  PAGA  algorithm 264 ,  which  are  considered  more  “well  separated”  
cells  than  those  seen  in  clusters.  Partition  markers  were  identified  using  the  
“top_markers”  function,  across  all  genes,  and  significant  markers  were  identified  as  




The  initial  trajectory  graph  was  identified  using  the  “learn_graph”  function  of  
Monocle3  before  cells  were  ordered  along  a  pseudotime  using  the  “order_cells”  
function.  The  function  requires  the  selection  of  a  “start  node”,  i.e.  the  group  of  cells  
thought  to  represent  the  earliest  point  in  the  developmental  pathway.  For  this  
analysis  the  start  node  was  selected  by  identifying  the  earliest  branch  node  from  the  
trajectory  analysis.  Genes  whose  expression  was  significantly  linked  to  a  position  
within  the  pseudotime  were  identified  using  the  “graph_test”  function.  This  runs  a  
spatial  autocorrelation  analysis,  known  as  Moran’s  I,  which  identifies  correlations  of  
gene  expression  in  cells  considered  in  nearby  space  to  each  other 259 ,  which  in  this  
case  means  cells  in  close  space  within  the  pseudotime  trajectory.  Again  significant  
genes  were  identified  as  those  with  a  q  value  of  <  0.05.  
  
  
4.3  Bulk  RNA-sequencing  comparison  of  complex  and  simple  model  
systems   
  
4.3.1  Dimensionality  reduction  
Following  initial  processing  of  data  I  combined  the  newly  generated  samples  with  the  
gene  counts  matrix  used  in  Chapter  3  and  then  calculated  Log 2 (TPM+1)  normalised  
counts  for  all  samples.  I  ran  PCA  across  the  dataset,  using  the  top  500  most  variable  
genes  and  plotted  the  samples  based  on  their  PC  scores.  Figure  4.1  shows  samples,  
plotted  based  on  PC1  vs  PC2  and  coloured  by  cell  type  with  the  new  samples  
included.  While  the  distribution  of  samples  with  new  samples  was  broadly  similar  to  
the  original  dataset  (Figure  3.5  A)  there  are  two  important  points  to  note.  Firstly  the  
iPSC-derived  and  ES-derived  (red  data  points  in  Figure  4.1)  monoculture  samples  
clustered  close  to  the  other  monoculture  samples,  despite  being  from  different  
studies.  Secondly,  the  co-cultured  and  organoid  derived  microglia  moved  slightly  
further  up  PC2  closer  to  the  primary  microglia  than  the  monoculture  models.  This  
suggested  that  for  genes  heavily  loading  PC2,  the  complex  model  microglia  had  an 
expression  profile  more  similar  to  that  of  primary  microglia  than  their  monoculture  




To  get  a  clearer  picture  of  the  drivers  of  variation  within  the  updated  dataset  I  also  
continued  to  plot  the  samples  further  down  the  PCs.  Figure  4.2  shows  samples  
plotted  on  the  PC3  vs  PC4  axis  coloured  by  cell  type  (A)  and  stimulation  (B).  Figure  
4.2  shows  samples  plotted  on  the  PC4  vs  PC5  axis  coloured  by  study  (C)  and  
sequencing  preparation  method  (D).  Although  simply  looking  at  the  PC  plots  does  not  
provide  comprehensive  proof  of  what  may  have  been  driving  variation  in  the  dataset,  
PC3  appeared  to  capture  a  stimulation  effect  while  PC5  may  have  represented  a  
mixture  of  study  and  sequence  preparation  effects.   
  
  
Figure  4.1  PC1  vs  PC2  of  model  comparison  dataset   
Principal  components  analysis  (PCA)  across  the  top  500  most  variable  genes,  plotted  
as  PC1  vs  PC2  scores  and  coloured  by  cell  type.  The  original  dataset  (A),  described  
in  Chapter  4,  is  included  for  comparison  to  the  complete  dataset  described  in  this  







Figure  4.2  PC3  vs  PC4  and  PC4  vs  PC5  of  model  comparison  dataset  
Principal  components  analysis  (PCA)  across  the  top  500  most  variable  genes,  plotted  
as  PC3  vs  PC4  scores  and  coloured  by  cell  type  (A)  and  stimulation  (B)  and  PC4  vs  
PC5  scores  and  coloured  by  study  (C)  and  sequencing  preparation  method  (D).   
  
As  well  as  looking  at  the  visual  representation  of  the  PCA,  I  used  varimax  analysis  to  
determine  which  of  the  most  variable  genes  used  in  the  PCA  was  driving  each  
component.  Table  4.4  shows  the  top  5  most  heavily  loaded  genes  for  each  PC,  which  
were  compared  to  the  genes  identified  using  the  same  analysis  for  the  original  
dataset,  see  table  3.5  in  section  3.3.4.  The  majority  of  genes  identified  in  the  varimax  
analysis  matched  those  seen  in  the  original  dataset  and  the  PCs  had  a  similar  
sample  spread.   
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PC1  PC2  PC3  
+ve  -ve  +ve  -ve  +ve  -ve  
CAT  COL3A1  FOSB  CCL13  CXCL10  GPR34  
MMP9  COL1A1  CH25H  S100A4  IDO1  ADORA3  
CCL22  IGFBP5  P2RY12  ANXA2  ACOD1  SLC40A1  
CHI3L1  POSTN  CX3CR1  CD36  TNFAIP6 PALD1 
CSTA  CCN2  EGR3  MMP9  CCL8  PDK4  
  
Table  4.4  Varimax  analysis  of  the  first  5  PCs  
Varimax  analysis  of  the  first  5  principal  components  from  the  top  500  most  variable  
genes.  Top  5  most  negatively  and  positively  loaded  genes  for  each  component.  
  
While  the  principal  components  analysis  described  above,  suggested  that  the  
complex  models  may  move  closer  to  the  primary  phenotype,  it  did  not  control  for  
known  study  based  batch  effects.  Variance  components  analysis  on  the  original  
dataset  (Figure  3.3)  identified  study  as  the  largest  driver  of  variation  across  all  genes  
in  the  dataset  and  it  is  therefore  important  to  take  this  potential  batch  effect  into  
account  when  comparing  samples.  I  used  linear  regression  to  calculate  the  residuals  
for  each  gene  across  all  samples  when  fitting  study  as  a  random  effect.  I  then  used  
the  residuals  as  input  for  PCA,  using  both  all  genes  (Figure  4.3)  and  the  top  500  
most  variable  genes  (Figure  4.4).  While  the  regression  of  study  based  effects  allows  
for  the  control  of  potential  study  based  effects,  as  this  analysis  compares  cell  types  
across  different  studies,  the  effects  may  have  been  confounded.  This  is  highlighted  in  
Figures  4.3  B  and  4.4  B  whereby  samples  from  cancer  cell  lines  are  clustered  with  
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MARCO  CCN1  EGR1  IGFBP4  CXCL11  MAF  
CD48  COL1A2  SALL1  ANPEP  RSAD2  DDIT4L  
CD52  LUM  SIGLEC8  DDIT4L  CCL5  P2RY12  
S100A4  LOX  DUSP1  MT-TN  SLAMF7  HPGDS  
AC245128.3  SERPINE1  LINC01736  CYP1B1  CXCL9  GPR82  
  
PC4  PC5  
  
+ve  -ve  +ve  -ve  
RNASE1  ELANE  RN7SL2  RNASE2  
C1QC  CTSG  RN7SL3  MT-TA  
STAB1  AZU1  CHIT1  F13A1  
C1QA  PRTN3  SCARNA7  MT-TL1  
C1QB  CES1  HIST1H1E  IL1B  
CCL13  CITED4  CYP27A1  RNA5SP151 
VSIG4  SLPI  RN7SL471P  MT-TN  
GPR34  CD70  FBP1  MT-ATP8  
MRC1  ASS1  C015660.2  RPL41P1  
SPP1  COL9A2  SCARNA21  AC090498.1 
  
primary  microglia,  despite  differential  expression  analysis  (section  3.5.2)  highlighting  
large  transcriptional  differences  between  the  cell  types.  This  suggested  that  using  a  
linear  model  to  regress  out  study  based  effects,  may  have  also  removed  some  of  the  
biology  that  is  confounded  by  the  study.   
  
  
Figure  4.3  PC1  vs  PC2  of  residual  values  across  all  genes  following  removal  of  
study  based  effects   
Principal  components  analysis  (PCA)  calculated,  using  residuals  from  a  linear  
regression  of  study  effects,  across  all  genes.  Samples  are  plotted  by  PC1  vs  PC2  




Figure  4.4  PC1  vs  PC2  of  residual  values  from  the  top  500  most  variable  genes  
following  removal  of  study  based  effects   
Principal  components  analysis  (PCA)  calculated,  using  residuals  from  a  linear  
regression  of  study  effects,  across  the  top  500  most  variable  genes.  Samples  are  
plotted  by  PC1  vs  PC2  scores  and  are  coloured  by  study  (A)  and  cell  type  (B).   
  
As  well  as  using  linear  models  to  regress  out  study  based  effects  for  input  into  PCA,  I  
also  ran  the  analysis  using  Log 2 (TPM+1)  normalised  values  for  the  7297  genes  
identified  as  part  of  the  PMM  dataset  (section  3.5.1)  as  shown  in  Figure  4.5.  The  
PMM  gene  set  was  identified  as  genes  with  a  significantly  higher  expression  in  
primary  microglia  than  all  the  monocultured  based  models  studied  in  Chapter  3  of  
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this  thesis.  Importantly  the  analysis  used  to  identify  this  gene  set  controlled  for  study  
based  batch  effects.  
  
Figure  4.5  shows  that  when  using  these  genes  as  input  for  PCA,  PC1  captured  
variability  in  cell  type  with  primary  microglia  most  positively  loading  the  PC.  The  
primary  microglia  were  again  separated  along  the  first  PC,  with  cultured  and  fetal  
microglia  sitting  closer  to  the  monocultured  in-vitro  models  (Figure  4.5B).  Using  the 
PMM  gene  set  as  input  for  PCA  also  showed  the  complex  in-vitro  models  were  closer  
on  PC1  to  fresh  primary  microglia.   
  
Figure  4.5  PC1  vs  PC2  of  all  samples  using  the  PMM  input  gene  list   
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Principal  components  analysis  (PCA)  calculated  using  the  7297  genes  identified  in  
the  PMM  gene  set  (section  3.5.1).  Samples  are  plotted  by  PC1  vs  PC2  scores  and  
are  coloured  by  cell  type  (A)  and  primary  microglia  source  (B).   
  
4.3.2  Differential  expression  analysis   
The  dimensionality  reduction  techniques  described  in  the  section  above  provide  
useful  tools  for  understanding  global  patterns  of  gene  expression  across  the  model  
systems.  However,  I  was  also  interested  in  specific  differences  in  gene  expression  
when  comparing  the  complex  model  systems  to  both  their  monoculture  counterparts  
and  primary  microglia.  As  the  number  of  samples  collected  for  the  model  systems  in  
this  bulk  analysis  was  relatively  small,  differential  expression  (DE)  was  run  with  these  
samples  as  one  “complex  models”  group  of  samples.   
  
Initially  I  compared  monocultured  iPSC-derived  microglia  to  the  stem  cell  derived  
complex  models  and  found  that  there  were  only  760  genes  expressed  at  a  
significantly  higher  level  in  the  monoculture  model  systems  whereas  4783  genes  
were  more  highly  expressed  in  the  complex  models  (p adjust  <  0.05  and  +/-  1  log 2    
fold-change  (LFC)).  The  majority  of  gene  expression  changes  between  monoculture  
and  complex  models  involved  higher  gene  expression  in  the  complex  models  (as  
highlighted  by  the  MA  plot  in  Figure  4.6)  at  the  lower  end  of  expression  which  





Figure  4.6  MA  plot  of  differentially  expressed  genes  comparing  monoculture  vs  
complex  stem  cell  derived  microglia  
Log 2  fold  change  (LFC)  plotted  against  the  mean  of  normalised  counts  for  each  gene   
tested  when  comparing  monoculture  iPSC-derived  microglia  to  iPSC-derived  
microglia  from  complex  model  systems.  Points  coloured  in  red  are  those  reaching  
significance  (following  5%  FDR  correction)  and  triangular  points  represent  genes  that  
have  a  LFC  outside  the  limits  of  the  graph.   
  
Using  the  online  gProfiler  tool  I  ran  gene-set  enrichment  analysis  (GSEA)  within  the  
differential  expressed  genes.  The  small  number  of  genes  with  higher  expression  in  
the  monoculture  systems  were  linked  to  extracellular  matrix  pathways  and  pattern  
specification  process,  which  have  been  linked  to  cell  differentiation,  suggesting  that  
monocultured  stem  cell  derived  microglia  may  represent  a  less  mature  cell  or  less  
complete  differentiation.  GSEA  of  the  genes  more  highly  expressed  in  complex  
models  showed  an  enrichment  for  nervous  system  development  and  neuronal  
differentiation  (Table  4.5).  This  suggested  that  culturing  stem  cell  derived  microglia  
alongside  neurons  may  help  to  capture  some  of  the  CNS-linked  transcriptional  





Table  4.5  GSEA  on  genes  with  higher  expression  in  CD45+  from  complex  
models  when  compared  to  monoculture  cells.    
Statistical  enrichment  analysis  through  the  g:GOSt  programme  of  g:Profiler  with  
significance  determined  at  a  5%  FDR.  Top  ten  GO:  biological  process  terms   
  
I  also  ran  DE  to  compare  the  complex  model  samples  to  the  primary  microglia  and  
found  4622  genes  with  significantly  higher  expression  in  primary  cells,  including  
known  microglia  marker  genes  such  as  P2RY12,  CX3CR1  and  TMEM119.  GSEA  
(Table  4.6,  left  hand  column)  for  these  genes  showed  an  enrichment  for  cell  
activation  terms.  There  were  also  5536  genes  with  a  significantly  higher  expression  
in  the  complex  model  systems,  including  the  CSF2RA  gene,  which  is  involved  in  
macrophage  differentiation.  Within  the  genes  more  highly  expressed  in  the  model  
systems  there  was  a  significant  enrichment  for  genes  linked  to  the  axoneme  and  
cilium  assembly  (Table  4.6)  which  could  be  linked  to  the  formation  of  the  ramified  
morphology  seen  in  microglial  cells.  Interestingly,  both  gene  lists  showed  enrichment  
for  CNS  linked  terms.  Genes  with  higher  expression  in  primary  microglia  were  
enriched  for  terms  such  as  oligodendrocyte  differentiation  (GO:0048709,  p adj  =   
1.51e -7 )  and  central  nervous  system  myelination  (GO:0022010,  p adj  =  4.7e -7 )  while   
genes  with  higher  expression  in  the  complex  models  were  enriched  for  terms  like  
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Term  name  Term  ID  P adj  
nervous  system  development  GO:0007399 8.99e -67  
neuron  differentiation  GO:0030182 2.17e -48  
neurogenesis  GO:0022008 6.15e -48  
generation  of  neurons  GO:0048699 8.22e -48  
chemical  synaptic  transmission  GO:0007268 1.87e -45  
anterograde  trans-synaptic  signaling  GO:0098916 1.87e -45  
trans-synaptic  signaling  GO:0099537 1.98e -45  
cell  projection  organization  GO:0030030 3.93e -45  
synaptic  signaling  GO:0099536 1.06e -44  
plasma  membrane  bounded  cell  projection  organization  GO:0120036 8.95e -43  
  
forebrain  development  (GO:0030900,  p adj  =  0.003)  and  brain  morphogenesis   
(GO:0048854,  p adj   =  0.005).   
  
Table  4.6  GSEA  on  DE  genes  comparing  primary  microglia  to  complex  models   
Statistical  enrichment  analysis  using  an  ordered  list  through  the  g:GOSt  programme  
of  g:Profiler  with  significance  determined  at  a  5%  FDR.  Five  most  significantly  
enriched  biological  process  terms  for  both  genes  with  higher  expression  in  primary  
cells  and  complex  models  when  compared  to  each  other.  
  
  
4.4  Identification  and  clustering  of  myeloid  cells  within  the  single  cell  
dataset  
  
To  extend  the  analysis  carried  out  with  the  bulk  sequencing  data,  I  wanted  to  
understand  how  the  three  in-vitro  model  systems  varied  at  the  single  cell  level  and  
whether  culturing  stem  cell  derived  microglia  with  neurons  moved  the  cells  further  
along  a  developmental  trajectory.   
  
4.4.1  Clustering  analysis  to  identify  myeloid  cells  within  the  full  population  
The  single  cell  dataset  generated  for  this  study  was  from  a  mixture  of  sorted  and  
unsorted  samples  from  the  complex  model  systems  and  therefore  contained  a  
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Primary  microglia  Complex  models  
Term  name  Term  ID  Padj  Term  name  Term  ID  Padj  
leukocyte  
activation  
GO:0045321  4.67e -16 
cilium  
assembly  
GO:0060271  4.92e -13 
cell  activation  GO:0001775  4.67e -16 
cilium  
organization 
GO:0044782  6.23e -13 




GO:0007018  2.96e -12 
immune  system  
process  
GO:0002376  3.01e -14 
cilium  
movement  
GO:0003341  1.29e -11 
interferon-gamma- 
mediated  signaling  
pathway  




GO:0007017  4.51e -11 
  
mixture  of  myeloid  and  non-myeloid  cells.  Following  removal  of  poor  quality  cells,  
(high  mitochondrial  gene  percentage  and  too  many  or  too  few  captured  genes),  I  
normalised  and  scaled  the  31259  cell  dataset.  Following  PCA,  I  used  the  top  15  PCs  
to  run  UMAP  analysis  (Figure  4.7).   
  
  
Figure  4.7  UMAP  of  full  dataset  
UMAP  analysis  following  Seurat  filtering,  normalisation  and  scaling.  UMAP  run  using  
the  RunUMAP  function  of  Seurat,  using  the  first  15  principal  components.  Cells  
coloured  by  model  system  
  
Following  initial  UMAP  analysis,  I  ran  clustering  analysis  using  Seurat’s  graph  based  
clustering  algorithm  with  the  first  15  principal  components  and  a  resolution  of  0.5  
(Figure  4.8  A)  and  also  looked  at  expression  of  known  myeloid  cell  marker  genes,  
CD45  and  AIF1  (Figure  4.8  B  and  C).  Expression  of  myeloid  marker  genes  was  only  
seen  in  clusters  1,  4,  11  and  12  and  therefore  these  cells  were  subsetted  from  the  





Figure  4.8  Identification  of  myeloid  cells   
UMAP  analysis  following  Seurat  filtering,  normalisation  and  scaling.  UMAP  run  using  
the  RunUMAP  function  of  Seurat,  using  the  first  15  principal  components.  Clustering  
carried  out  using  Seurat’s  clustering  algorithm  using  15  principal  components  and  a  
0.5  resolution.  Cells  coloured  by:  cluster  (A)  and  expression  of  myeloid  marker  genes  
CD45  (B)  and  AIF1  (C).   
  
4.4.2  Partition  and  cluster  analysis  using  Monocle3  
Following  quality  control  filtering  and  identification/separation  of  the  myeloid  cells  
from  within  the  single  cell  dataset,  I  used  the  raw  data  and  processed  the  new  
myeloid  only  dataset,  through  the  standard  Monocle3  processing  pipeline.  Initially,  I  
used  UMAP  analysis  to  visualise  the  cells  and  Figure  4.9  shows  each  cell  coloured  
by  the  sample  it  originated  from.  The  UMAP  plot  was  split  into  three  major  groups  of  
cells,  one  made  up  of  entirely  cells  from  the  monoculture  system  and  a  second  made  
up  of  cells  originating  from  all  the  model  systems  studied.  The  final  large  group  of  
cells,  was  dominated  by  CD45  sorted  myeloid  cells  from  organoid  culture  systems.  
However,  there  were  also  cells  present  in  this  cluster  that  were  from  the  unsorted  
organoid  and  unsorted  co-culture  model  systems.  The  fraction  of  these  cells  within  
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the  larger  cluster  was  small  but  this  may  be  due  to  a  smaller  number  of  cells  arising  
from  these  samples  in  total  (2817  cells  from  sorted  organoid  sample  versus  206  and  
299  from  the  unsorted  co-culture  and  organoids  respectively).   
  
Figure  4.9  UMAP  of  myeloid  cells  in  Monocle3  
UMAP  analysis  following  Monocle3  preprocessing.  UMAP  run  using  the  
reduce_dimension  function  of  Monocle3.  Cells  coloured  by  model  system.  
  
After  running  UMAP  analysis  to  visualise  the  cells,  I  used  the  “cluster_cells”  function  
to  formally  group  cells.  Figure  4.10  shows  the  UMAP  plot  of  cells  coloured  by  both  
partitions  (A)  and  clusters  (B)  and  Figure  4.11  summarises  the  number  of  cells  within  
each  partition  attributed  to  the  different  culture  systems  (A)  and  the  partition  assigned  





Figure  4.10  UMAP  of  myeloid  cells  in  Monocle3  
UMAP  analysis  following  Monocle3  preprocessing.  UMAP  run  using  the  
“reduce_dimension”  function  of  Monocle3.  Cells  coloured  by  partition  (A)  and  cluster  
(B)  determined  by  the  “cluster_cells”  function.   
  
Interestingly,  three  partitions  (2,  4  and  5)  only  contained  cells  from  within  the  
monoculture  system  whereas  partitions  1  and  3  were  made  up  of  cells  from  each  
model  system  studied  here,  although  the  contribution  of  monoculture  based  cells  to  
partition  1  was  minimal  (2  cells).  This  suggests  that  monoculture  differentiations  
generate  a  more  heterogeneous  population  of  cells  than  complex  models.  As  
suggested  above,  partition  1  was  dominated  by  cells  from  the  sorted  organoid  
sample,  2639  cells  out  of  2800  total,  but  35%  of  cells  from  the  unsorted  organoid  and  
26%  of  cells  from  the  co-culture  system  were  also  present  in  this  partition  just  at  





Figure  4.11  Number  of  cells  in  each  partition  
Number  of  cells  in  each  partition,  using  monocle3  “cluster_cells”  function,  coloured  
by  the  culture  system  the  cells  originated  from  (A).  Number  of  cells  in  the  culture  
system  coloured  by  the  partition,  using  monocle3  “cluster_cells”  function,  the  cells  
were  assigned  to  (B).   
  
4.4.3  Partition  marker  genes  
First,  I  wanted  to  identify  differentially  expressed  genes  within  each  partition,  using  
the  “top_marker”  function,  to  understand  what  transcriptional  changes  may  have  
been  impacting  the  partitioning  of  the  cells.  Figure  4.12  highlights  specific  marker  





Figure  4.12  UMAP  of  myeloid  cells  in  Monocle3  coloured  by  marker  gene  
expression  
UMAP  analysis  following  Monocle3  preprocessing.  UMAP  run  using  the  
“reduce_dimension”  function  of  Monocle3.  Cells  coloured  by  expression  of  marker  
genes  for  each  partition  (1-5)  determined  by  “top_marker”  function  of  Monocle3.   
  
Table  4.7  highlights  the  top  gene  markers  for  each  partition  (based  on  the  marker  
score)  and  the  top  enriched  biological  process  terms  for  the  50  marker  genes  
identified  for  each  partition.  The  partitions  only  associated  with  only  monoculture  
cells  (2,  4  and  5)  were  all  enriched  for  distinct  gene  sets,  which  suggested  they  
represented  different  subpopulations  of  cells  within  the  same  culture  system.  
Partition  2  for  instance,  appeared  to  represent  a  more  activated  population  of  cells  
while  partition  5  cells  were  linked  to  cytoskeleton  terms.  Partition  3  cells  were  




Of  the  top  50  partition  1  marker  genes,  28  were  also  identified  within  the  PMM  gene  
set,  described  in  section  3.5.1  in  this  thesis,  which  included  genes  with  higher  
expression  in  primary  microglia  compared  to  the  simple  in-vitro  model  systems.  This  
was  compared  to  between  1  and  4  overlapping  genes  in  the  other  partitions.  This  
suggested  that  partition  1  cells  may  represent  a  population  closer  to  that  of  primary  
microglia,  with  increased  expression  of  genes  such  as  APOC1 ,  CCL3L1  and  PDK4 .  
GSEA  of  partition  1  markers  highlighted  an  enrichment  in  cell  migration  genes  as  well  
as  genes  associated  with  organic  substance  response  which  would  support  this  
theory.  As  the  cells  in  partition  1  were  mainly  associated  with  organoid  samples,  they  
would  be  expected  to  be  more  active  than  those  in  a  monoculture  system  as  they  
would  be  constantly  responding  to  and  interacting  with  neurons.  
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    GSEA  
Partition Marker  genes Term  name  Term  ID  padj  
1  
CCL4L2  response  to  organic  substance  GO:0010033 3.38e -07  
APOC1  ERK1  and  ERK2  cascade  GO:0070371 3.38e -07  
RNASET2 response  to  stress  GO:0006950 3.38 e-07  
CCL3L1  response  to  external  stimulus  GO:0009605 6.37e -07  
ABCA1  mononuclear  cell  migration  GO:0071674 7.34e -07  
2  
IL7R  leukocyte  activation  GO:0045321 1.22e -14  
FTH1 neutrophil  degranulation  GO:0043312 1.77e -14  
CCL13  cell  activation  involved  in  immune  response  GO:0002263 1.77e -14  
BRI3  
leukocyte  activation  involved  in  immune  
response  
GO:0002366 1.77e -14  
S100B  
neutrophil  activation  involved  in  immune  
response  
GO:0002283 1.77e -14  
3  
ACTB  
SRP-dependent  cotranslational  protein  
targeting  to  membrane  
GO:0006614 3.29e -39  
GAPDH  cotranslational  protein  targeting  to  membrane GO:0006613 6.54e -39  
EEF1A1  protein  targeting  to  ER  GO:0045047 3.40e -38  
ARHGDIB 
establishment  of  protein  localization  to  
endoplasmic  reticulum  
GO:0072599 6.69e -38  
AIF1  
nuclear-transcribed  mRNA  catabolic  process,  
nonsense-mediated  decay  
GO:0000184 4.10e -37  
4  
PCLAF  electron  transport  chain  GO:0022900 3.24e -05  
  
Table  4.7  Partition  marker  genes  and  GSEA  on  top  50  partition  markers  
Partition  markers  determined  using  the  “top_marker”  function  of  monocle3.  Top  5  
markers  (determined  by  marker  score)  displayed  for  each  partition.  Top  50  markers  
for  each  partition  then  used  for  statistical  enrichment  analysis  using  an  ordered  list  
through  the  g:GOSt  programme  of  g:Profiler  with  significance  determined  at  a  5%  
FDR.  Five  most  significantly  enriched  biological  process  terms  displayed.  
  
As  marker  gene  expression  had  suggested  cells  in  partition  1  represented  cells  
potentially  closer  to  primary  microglia  I  also  wanted  to  see  if  expression  of  
Alzheimer’s  disease  (AD)  linked  genes  increased  within  that  specific  cluster.  I  took  
the  list  of  9  AD  genes,  identified  in  Table  3.7,  whose  expression  was  not  well  
captured  by  any  of  the  monoculture  based  systems  studied  in  Chapter  3  and  
compared  expression  across  partitions  (Figure  4.13).  Many  of  the  genes  were  not  
well  expressed  across  any  of  the  cell  partitions  and  may  represent  AD  genes  with  
functions  linked  to  very  specific  microglial  pathways  that  are  still  not  captured  by  
these  model  systems.  APOE  was  identified  as  a  marker  gene  for  cells  within  partition  
1  and,  while  not  significant,  CLU  also  appeared  to  have  increased  expression  within  
the  same  population  of  cells.  Both  of  these  genes  are  involved  in  lipid  processing  
pathways  and  suggests  this  may  be  an  AD  linked  pathway  that  is  only  possible  to  
study  in  more  complex  model  systems.   
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TOP2A  oxidation-reduction  process  GO:0055114 3.24e -05  
DEK  oxidative  phosphorylation  GO:0006119 6.76e -05  
HIST1H4C leukocyte  activation  GO:0045321 7.24e -05  
MYBL2  
mitochondrial  ATP  synthesis  coupled  electron  
transport  
GO:0042775 8.17e -05  
5  
TAGLN  actin  filament-based  process  GO:0030029 2.39e -09  
TPM2  actin  cytoskeleton  organization  GO:0030036 2.89e -08  
TPM1  symbiotic  process  GO:0044403 5.93e -08  
KRT18  cytoskeleton  organization  GO:0007010 5.93e -08  
KRT8  
SRP-dependent  cotranslational  protein  
targeting  to  membrane  
GO:0006614 9.06e -08  
  
  
Figure  4.13  UMAP  of  myeloid  cells  in  Monocle3  coloured  by  AD  gene  
expression  
UMAP  analysis  following  Monocle3  preprocessing.  UMAP  run  using  the  
“reduce_dimension”  function  of  Monocle3.  Cells  coloured  by  expression  of  AD  genes  
not  well  captured  by  monoculture  model  systems,  identified  in  Table  3.7.  
  
  
4.5  Cell  trajectory  analysis  across  model  systems  
  
4.5.1  Creation  of  the  trajectory  graph  
Following  identification  of  partitions  and  marker  genes,  I  then  used  the  trajectory  tool  
within  Monocle3  to  determine  a  cell  trajectory  graph  and  order  cells  along  the  
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pseudotime  established  from  that  trajectory  (Figure  4.14).  Broadly  the  pseudotime  
analysis  showed  cells  moving  from  the  monoculture  system,  through  an  intermediate  
step  in  partition  3  (which  includes  cells  from  all  culture  systems)  along  to  the  cells  in  
partition  1  which  are  predominantly  from  organoid  systems.  This  further  supports  the  
theory  that  cells  from  the  complex  model  systems  may  move  along  a  developmental  
pathway.   
  
Figure  4.14  UMAP  of  myeloid  cells  in  Monocle3  coloured  by  order  in  
pseudotime  
UMAP  analysis  following  Monocle3  preprocessing.  UMAP  run  using  the  
“reduce_dimension”  function  of  Monocle3.  Cells  coloured  by  order  within  pseudotime,  
identified  using  the  “learn_graph”  followed  by  “order_cells”  functions  in  Monocle3.  
Light  grey  circles  within  the  pseudotime  represent  different  cell  fates  while  black  cells  
are  branch  nodes.   
  
Monocle3  also  identifies  key  points  of  cell  differentiations  along  the  trajectory  it  
determines,  determining  both  cell  fates  (grey  circles  in  Figure  4.14)  and  branch  
nodes  (black  circles).  Branch  nodes  represent  points  within  the  developmental  
trajectory  where  cells  can  travel  down  differing  paths.  Three  major  branch  nodes  are  
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highlighted  in  Figure  4.14,  each  representing  a  node  within  the  trajectory  where  cells  
either  move  further  along  the  differentiation  trajectory  or  transition  towards  a  cell  fate  
end  point  (grey  circles).   
  
4.5.2  Gene  expression  changes  along  pseudotime  
As  well  as  generating  the  standard  trajectory  graph,  I  also  used  the  Monocle3  
package  to  identify  genes  whose  expression  dynamically  changes  along  the  
pseudotime.  I  was  able  to  identify  genes,  such  as  MMP9  and  IL7R,  which  had  a  
significant  reduction  in  expression  along  the  pseudotime  of  differentiation  (Figure  
4.15).  IL7R  has  recently  been  linked  to  the  early  stages  of  the  differentiation  of  tissue  
resident  macrophages  from  fetal  precursors  in  mice 265 .  This  supports  the  theory  that  
the  monoculture  systems  represented  at  the  beginning  of  this  pseudotime  are  more  
similar  to  fetal  macrophages  (as  suggested  by  bulk-RNA  sequencing  data  analysis  
shown  in  Figure  3.5  C)  and  that  as  the  cells  move  closer  towards  adult  microglia  the  
early  differentiation  regulators  such  as  IL7R  are  switched  off.   
  
I  was  also  able  to  identify  genes  with  dynamic  expression  along  the  trajectory,  such  
as  PRDX2  and  STMN1  which  both  increased  expression  in  the  intermediate  portion  
of  the  pseudotime  but  decreased  in  the  later  stages  of  the  trajectory  (Figure  4.15).  
These  two  genes  are  potentially  interesting  as  they  have  both  been  individually  linked  
to  microglia  in  a  more  activated  state.  For  instance,  single  cell  sequencing  of  the  
adult  mouse  brain  identified  a  population  of  cells  with  increased  expression  of  genes,  
including  PRDX2 ,  linked  to  energy  production  that  could  suggest  the  cells  were  in  a  
more  “immune-alert  state” 266 .  STMN1  has  also  been  shown  to  have  increased  
expression  in  amoeboid  microglial  cells,  which  are  associated  with  increased  immune  
activity,  when  compared  to  ramified  cells  which  are  linked  to  more  homeostatic  






Figure  4.15  Expression  of  genes  along  pseudotime  
Genes  whose  expression  was  significantly  linked  to  a  cell’s  position  within  the  
pseudotime  trajectory,  identified  using  the  “graph_test”  function  of  Monocle3.  
  
The  trajectory  analysis  also  highlighted  genes  whose  expression  increased  along  the  
pseudotime  trajectory  (Figure  4.16).  For  instance  APOC1  and  FOS  represented  
genes  that  appeared  to  have  a  gradual  increase  along  the  pseudotime,  with  APOC1  
continuing  to  increase  at  the  end  stages,  while  FOS  expression  reached  a  plateau.  
C1QB  was  a  gene  not  identified  as  a  partition  marker,  potentially  because  the  
increase  in  gene  expression  appeared  earlier  in  the  pseudotime  analysis  and  
appeared  to  reach  a  plateau  after  the  intermediate  stage.  NR4A1 ,  appeared  to  have  
a  very  specific  increase  in  gene  expression  along  the  pseudotime  with  a  sharp  
increase  in  the  first  phase  of  partition  1  towards  the  end  of  the  trajectory.  NR4A1 ,  has  
been  suggested  to  play  an  important  role  in  the  regulation  of  the  activation  of  
microglia  in  mice  and  is  thought  to  help  maintain  the  resting  state  profile  of  the  




Figure  4.16  Genes  with  increasing  expression  along  pseudotime  
UMAP  analysis  following  Monocle3  preprocessing.  UMAP  run  using  the  
“reduce_dimension”  function  of  Monocle3.  Cells  coloured  by  order  within  pseudotime,  
identified  using  the  “learn_graph”  followed  by  “order_cells”  functions  in  Monocle3.  
Light  grey  circles  within  the  pseudotime  represent  different  cell  fates  while  black  cells  
are  branch  nodes.   
  
  
4.6  Discussion   
  
The  results  in  this  chapter  have  suggested  that  culturing  stem  cell  derived  microglia  
with  neuronal  cells  may  move  them  closer  to  the  primary  cell  type,  with  PCA  analysis  
of  bulk  RNA-sequencing  data,  using  the  PMM  gene  set  identified  in  Chapter  3,  
showing  complex  model  system  samples  closer  to  the  primary  cells  than  their  
monocultured  counterparts.  Differential  expression  between  monocultured  
iPSC-derived  microglia  and  those  deriving  from  complex  models  highlighted  an  
increased  gene  expression  of  CNS  linked  gene  sets  following  culturing  with  neurons.  
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This  suggested  that  in  an  in-vitro  setting  microglia-like  cells  modified  their  
transcriptome  in  response  to  the  environment  they  were  in.  Although,  comparison  to  
primary  microglia  highlighted  specialised  neuronal  functions,  such  as  oligodendrocyte  
differentiation  and  myelination,  that  were  still  not  captured  by  the  more  complex  
models.   
  
Single  cell  analysis  also  allowed  for  the  identification  of  specific  subpopulations  of  
cells  that  expressed  PMM  genes.  These  populations  of  cells  showed  increased  
expression  genes  enriched  for  cell  migratory  functions,  suggesting  they  represent  a  
cell  type  that  are  more  motile  within  a  dish.  Interestly,  monocultured  microglial  cells  
that  showed  the  most  heterogeneity  across  the  single  cell  populations.  Cells  from  
complex  model  systems  were  found  in  two  identified  partitions  where  monoculture  
populations  were  seen  in  four  partitions.  Of  the  four  partitions  monoculture  cells  were  
found  in  3  contained  cells  only  from  this  culture  system,  suggesting  they  represent  
distinct  populations  only  present  in  monoculture  iPSC-derived  microglia.  This  may 
mean  that  as  the  cells  move  to  a  more  differentiated  state  they  also  converge  
towards  a  specific  transcriptional  phenotype,  whereas  the  monocultured  cells  are  in  a  
more  dynamic  transcriptional  state.  The  trajectory  analysis  allowed  for  individual  cells 
to  be  ordered  along  a  developmental  pseudotime  and  for  the  identification  of  genes  
whose  expression  changed  dynamically  across  the  trajectory.  Evidence  from  the  
trajectory  analysis  also  suggested  a  shift  from  microglia  in  a  more  active  state  at  the  
intermediate  stage,  to  a  more  homeostatic  cell  type  towards  the  end  of  the  trajectory.   
  
However,  the  single  cell  dataset  only  included  cells  from  the  cultured  systems  and  
the  conclusion  that  the  complex  models  moved  cells  along  a  trajectory  towards  the  
primary  cell  type  was  based  on  comparisons  of  differentially  expressed  genes.  
Ideally,  this  experiment  would  also  have  included  single  cell  data  collected  from  
primary  microglia.  The  data  generated  from  primary  microglia  in  Chapter  2  of  this  
thesis  used  smartseq2  rather  than  the  10X  technology  used  here.  Batch  correction  
methods  have  been  developed  to  integrate  datasets  across  differing  sequencing  
technologies,  such  as  within  Seurat’s  updated  analysis  pipeline 269 .  However,  this  
relies  on  the  batch  effect  not  being  correlated  with  biological  factors  of  interest.  
Combining  the  primary  microglia  from  Chapter  2  with  the  model  system  data  
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described  in  this  chapter  would  leave  sequencing  technology  confounded  with  cell  
type.  As  part  of  the  project  described  in  Chapter  2,  primary  microglia  samples  were  
collected  and  processed  through  the  10X  pipeline.  However,  the  samples  were  of  
poor  quality  and  when  compared  to  the  smartseq  dataset  the  cells  had  an  activated  
phenotype  that  suggested  an  activation  response  to  the  processing  pipeline.  The  
samples  were  therefore  not  used  in  analysis  as  they  were  determined  to  not  
accurately  represent  cells  within  the  brain. 
  
While  partition  markers  and  differential  expression  analysis  highlighted  a  potential  
shift  towards  primary  microglia,  expression  of  many  AD  genes  did  not  increase  in  the  
complex  model  systems.  Of  the  9  AD  linked  genes  identified  in  Chapter  3,  whose  
expression  was  shown  to  be  higher  in  primary  microglia  than  any  of  the  monoculture  
model  systems,  only  APOE  was  shown  to  have  a  statistically  significant  increase  in  
expression  with  organoid  derived  microglia.  This  suggests  that  the  other  AD  linked  
genes  may  be  involved  in  highly  specialised  microglial  functions  that  are  not  well  
captured  by  any  model  system.   
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Chapter  5:  Discussion   
  
In  this  thesis  I  have  used  multiple  RNA-sequencing  technologies  to  generate  a  
transcriptional  map  of  human  adult  primary  microglia  and  to  compare  these  cells  to  
available  in-vitro  model  systems.  I  have  demonstrated  that  microglia  are  constantly  
responding  to  the  CNS  environment.  In  the  brain  they  react  to  trauma  or  disease  to  
respond  in  a  disorder-specific  manner  and  it  is  the  complex  CNS  environment  that  
appears  to  give  rise  to  the  unique  transcriptional  signature  of  the  primary  cells.   
  
5.1  Sequencing  primary  human  microglia  
  
In  the  second  chapter  of  this  thesis,  I  described  the  analysis  of  the  largest  
RNA-sequencing  dataset  of  fresh,  adult  primary  microglial  cells  to  date  and  
demonstrated  that  microglia  display  pathology  specific  activation  patterns,  particularly  
following  traumatic  brain  injury.  The  scale  of  this  study  also  allowed  for  comparisons  
across  a  variety  of  clinical  factors  and  demonstrated  only  a  small  impact  of  age  or  
sex  on  microglial  transcriptomes.   
  
Data  described  in  Chapter  2  of  this  thesis  identified  potential  pathology  driven  
activation  patterns  in  microglial  cells  through  single  cell  RNA-sequencing.  
Identification  of  marker  genes  for  these  subpopulations  of  cells  will  allow  researchers  
to  understand  how  different  microglial  phenotypes  impact  disease  outcome  or  how  
the  activated  microglia  may  play  differing  roles  in  microglial  responses  to  trauma  or  
disease.  One  limitation  of  this  work  is  that  we  have  not  conducted  functional  
validation  to  verify  potential  marker  genes  or  to  map  the  functional  consequences  for  
each  of  the  populations.  Spatial  transcriptomics  provides  a  method  to  combine  
transcriptional  data  with  in-situ  hybridization  and  allows  for  the  identification  of  cells  
expressing  specific  gene  markers  within  a  tissue 270,271 .  If  brain  tissue  slices  could  be  
collected  from  patients  with  particular  pathologies,  such  as  traumatic  brain  injury,  
spatial  transcriptomics  could  be  used  to  not  only  verify  the  marker  gene  sets  
identified  but  also  see  how  particular  cell  populations  are  distributed  within  a  brain  




Transcriptomic  studies  of  any  cell  come  with  multiple  experimental  caveats  and  
challenges.  The  largest  challenge  is  balancing  sample  access  and  control  of  
experimental  or  technical  factors  that  may  unknowingly  impact  microglial  
transcriptomes.  For  instance,  certain  microglial  transcriptomes  can  never  be  captured  
using  fresh  samples.  In  Chapter  2,  we  collected  “control”  patients  but  it's  important  to  
note  that  these  were  unlikely  to  be  truly  healthy  samples.  Additionally,  tissue  samples  
from  certain  disease  pathologies,  such  as  Alzheimer’s  disease,  cannot  be  collected  
fresh.  In  order  to  sequence  microglia  from  these  specific  cohorts,  they  must  be  
collected  from  post-mortem  brain  tissue.  It  is  not  clear  how  post-mortem  delay  may  
impact  microglial  transcriptomes,  especially  as  data  in  this  thesis  has  demonstrated  
that  an  active  CNS  environment  is  vital  for  the  maintenance  of  the  microglial  
transcriptional  signature.  While  collecting  fresh  surgery  samples  removes  the  
potential  impact  of  post-mortem  delay  on  the  transcriptome,  there  are  still  stages  of  
the  single  cell  sequencing  process,  such  as  tissue  dissociation,  that  might  introduce  
transcriptional  changes  or  cell  biases.  Single-nucleus  sequencing  may  provide  a  
method  to  overcome  some  of  the  technical  biases  introduced  in  single  cell  
sequencing,  but  these  technologies  are  even  more  costly.   
  
As  mentioned  above,  single  cell  and  single  nucleus  sequencing  technologies  are  
expensive  in  comparison  to  bulk  RNA-sequencing.  Deconvolution  techniques  allow  
for  the  identification  of  cell  types  from  within  bulk  data 272 .  This  means  that  single  cell  
maps  such  as  the  one  generated  in  Chapter  2,  could  in  future  be  used  to  deconvolute  
even  larger  collections  of  whole  brain  tissue  samples  to  identify  microglial  
populations.  Increasing  sample  size  within  RNA-sequencing  studies  would  allow  for  
more  complex  genetic  association  studies,  such  as  subtype  specific  eQTL  studies  
that  could  identify  specific  cell  populations  that  may  be  involved  in  disease.  
Importantly,  deconvolution  of  bulk  whole  tissue  samples  also  allows  the  removal  of  
two  major  steps  required  for  processing  of  single  cell  microglial  samples,  tissue  
dissociation  and  cell  sorting,  which  could  potentially  have  an  unknown  impact  on  
microglial  transcriptomes.  However,  deconvolution  does  not  come  without  limitations,  
particularly  when  identifying  rare  populations  of  cells  within  tissues  such  as  microglia  
in  the  brain.  
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5.2  Modelling  primary  microglia  in-vitro  
  
Studies  such  as  the  ones  described  in  Chapter  3  and  4  highlight  the  need  for  
transcriptional  comparisons  of  in-vitro  model  systems  to  their  primary  counterpart  in  
order  to  identify  potential  limitations  of  the  culture  systems.  For  instance,  
monoculture  iPSC-derived  microglia  were  shown  to  lack  the  specialised  CNS-linked  
transcriptional  signature  seen  in  primary  microglia  and,  therefore,  some  of  the  CNS  
connected  cell  functions  may  also  be  lacking  in  these  systems.  Organoid  cultures  
can  provide  certain  CNS  stimuli  and  single  cell  trajectory  analysis  suggested  that  a  
population  of  organoid  derived  microglia  cells  moved  further  along  a  differentiation  
pathway.  However,  gene  set  enrichment  analysis  still  suggested  that  certain  
specialised  CNS  linked  functions  were  missing  in  the  model  systems,  such  as  
oligodendrocyte  differentiation  and  myelination.  Even  more  complex  brain  organoid  
models  are  being  developed,  such  as  systems  with  a  developing  vasculature  
network 273  or  in-vitro  systems  that  mimic  the  BBB 274 .  These  extensive  models  may   
begin  to  capture  more  brain  functions  and  lead  to  further  development  of  specialised  
cellular  phenotypes  such  as  those  seen  in  primary  microglia.   
  
However,  these  complex  systems  also  come  with  caveats  that  have  to  be  considered  
when  deciding  which  model  should  be  used  experimentally.  They  are  time  consuming  
to  generate,  require  expensive  equipment  and  reagents  and  can  be  more  
complicated  to  assay  than  monoculture  systems.  Many  of  these  factors  mean  that  
brain  organoids  cannot  be  used  at  scale.  Large  scale  genetics  studies,  such  as  
quantitative  trait  loci  (QTL)  experiments,  require  experimental  data  from  hundreds  of  
samples  across  varying  genetic  backgrounds  and,  therefore,  standard  organoid  
differentiation  pipelines  would  not  be  a  feasible  experimental  tool  for  these  studies.  
Single  cell  sequencing  has  provided  a  potential  way  to  overcome  this  issue;  it  allows  
for  the  deconvolution  of  pools  of  iPSC  lines  from  within  one  sample 275  and  can   
attribute  single  cells  back  to  their  original  donors.  Pooling  of  iPSC  lines  allows  for  the  
differentiation  of  multiple  donors  within  one  experimental  study.  This  not  only  reduces  
the  number  of  required  differentiations  but  also  removes  some  of  the  batch  effects  
that  can  arise  from  comparing  different  differentiation  experiments  across  different  




While  iPSC  pooling  can  increase  the  scalability  of  organoid  differentiations,  the  
protocols  remain  expensive  and  complex  and  so  it  is  important  to  understand  where  
using  these  more  extensive  model  systems  is  necessary.  For  instance,  monoculture  
iPSC  differentiated  cells  appear  to  capture  some  of  the  transcriptional  profile  of  
primary  microglia  and  studies  have  shown  they  have  comparable  behavioural  and  
morphological  features  of  the  primary  cell  type 197–201 .  In  many  cases  it  may,  therefore,  
be  suitable  to  study  certain  aspects  of  microglia  function  with  the  more  simple  
monoculture  model  systems.  However,  the  monoculture  models  cannot  accurately  
capture  how  the  cells  interact  with  neurons  or  how  they  may  respond  to  
environmental  changes.  In  these  situations  more  complex  models  may  be  required  
for  studying  changes  in  microglial  function.   
  
Large  scale  transcriptional  comparisons  such  as  the  ones  carried  out  in  this  thesis  
could  also  be  used  to  inform  these  choices,  particularly  when  studies  focus  on  one  
specific  gene  or  pathway.  Before  a  model  system  is  chosen,  caution  should  be  taken  
to  ensure  the  gene  or  pathway  of  interest  is  expressed  at  comparable  levels  in  the  
model  being  used  to  the  primary  cell  type.  While  this  doesn’t  guarantee  comparable  
responses,  it  at  least  provides  some  evidence  that  the  model  system  being  used  has  
a  similar  profile  to  that  of  primary  microglia.   
  
It  is  also  worth  noting  that  all  of  the  studies  described  in  this  thesis  utilise  
RNA-sequencing,  and  therefore,  gene  expression  as  a  measure  of  classifying  and  
characterising  cell  function.  However,  this  does  not  account  for  the  complicated  
relationship  between  gene  and  protein  expression  or  whether  gene/protein  
expression  directly  translates  to  a  specific  cell  function.  There  are  multiple  processes  
following  gene  transcription  that  can  impact  protein  expression 276,277  including  the   
translation  rate,  a  protein’s  half-life  and  the  rate  or  method  by  which  a  protein  is  
transported  to  its  functional  location.  Variation  in  any  of  these  stages  can  lead  to  a  
divergence  between  mRNA  levels  and  protein  expression.  This  is  particularly  true  
when  cells  are  transitioning  between  states  and  responding  to  environmental  
stimuli 277 .  This  means  that  the  gene  expression  changes  seen  in  some  of  the  studies  
described  within  this  thesis  may  not  represent  correlated  changes  in  protein  levels  
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and,  therefore,  functional  outputs  of  the  cells.  This  may  be  particularly  true  within  the  
primary  microglial  single  cell  dataset  where  the  cells  appeared  to  be  dynamically  
responding  to  environmental  changes.   
  
  
5.3  Studying  microglia  in  Alzheimer’s  disease   
  
Microglia  are  thought  to  be  pathogenic  cells  in  the  development  and  progression  of  
Alzheimer’s  disease  (AD)  and  therefore  each  chapter  within  this  thesis  has  looked  at  
expression  of  AD  linked  genes  in  a  variety  of  contexts.  Evidence  from  the  single  cell  
analysis  of  fresh  adult  primary  microglia  in  Chapter  1  suggested  that  microglia  
respond  in  a  pathology  specific  manner  and  studies  in  both  mice  and  human  brain  
tissue  have  also  demonstrated  AD  specific  activation  patterns  within  
microglia 164,166,184 .  While  some  of  the  genes  identified  by  these  studies  were  
expressed  across  the  primary  microglia  studied  in  Chapter  1,  there  was  no  clear  
enrichment  within  a  particular  cluster  which  suggested  our  study  did  not  capture  AD  
specific  microglial  activation.   
  
It  should  also  be  noted  that  the  AD  risk  gene  lists  used  throughout  this  thesis  were  in  
the  most  part  curated  from  genes  identified  in  genome  wide  association  studies  
(GWAS)  and  these  gene  lists  come  with  caveats.  As  described  in  section  1.5.2  
GWAS  often  identifies  a  “lead  SNP”  and  associates  the  SNP  to  the  “nearest  gene”  
despite  many  of  the  SNPs  falling  within  the  non-coding  region  of  the  genome.  This  
may  mean  that  the  genes  used  in  this  analysis  do  not  represent  the  true  causal  risk  
genes.   
  
Identification  of  specific  gene  expression  changes  that  occur  in  microglia  during  AD  
can  also  highlight  genesets  and  pathways  that  would  need  to  be  mimicked  in  model  
systems  to  accurately  capture  AD  pathology  in  a  dish.  Organoid  iPSC-based  systems  
have  already  been  used  to  study  AD  pathology  in  a  dish,  often  beginning  with  iPSC  
lines  containing  familial  AD  mutations  to  push  the  cultures  towards  a  disease  
phenotype 278,279 .  With  identification  of  AD  specific  transcriptional  profiles,  it  may  be  
possible  to  understand  how  close  in-vitro  microglia  capture  the  changes  seen  in  
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microglia  throughout  disease  progression.  One  of  the  major  problems  with  using  
iPSC  differentiated  cells  to  model  AD  is  the  maturity  of  the  cultures,  age  is  a  major  
risk  factor  for  neurodegenerative  disorders  such  as  AD  and  capturing  that  affect  in  a  
culture  system  is  challenging  as  neuronal  cultures  in  particular  often  more  closely  
represent  an  immature  cell  population.  
  
As  well  as  using  familial  AD  mutations  within  iPSC-derived  cultures,  it  is  also  possible  
to  engineer  late  onset  AD  mutations  in  iPSC,  however  there  are  also  caveats  with  
these  experiments  that  should  be  considered.  First,  the  analysis  in  this  thesis  has  
shown  that  certain  AD  risk  genes  were  not  expressed  at  comparable  levels  in  any  of  
the  model  systems  to  primary  microglia.  This  means  for  certain  disease  genes  the  
effects  of  risk  alleles  may  not  be  captured.  Even  if  the  expression  of  the  gene  of  
interest  is  comparable  across  model  systems,  the  model  system  chosen  is  highly  
dependent  on  the  question  and  function  of  interest.  For  instance,  basic  microglial  
functions  such  as  phagocytosis  may  be  well  captured  by  monoculture  systems  but  if  
the  variants  are  impacting  interactions  between  cell  types  then  more  complex  models  
may  be  required.  Unfortunately,  for  many  of  the  risk  alleles  associated  with  AD  a  
clear  function  has  not  been  identified  and  so  it  is  difficult  to  know  which  model  system  
to  choose.   
  
The  variants  associated  with  late  onset  AD  risk  also  tend  to  have  relatively  small  
effect  sizes  that  gradually  build  throughout  life,  meaning  their  effects  on  individual  cell  
types  may  be  relatively  small  and  not  easily  seen  in  cell  culture  systems.  For  
instance,  mutations  in  the  TREM2  gene  in  iPSC-derived  microglia  have  been  shown  
to  have  no  impact  on  cell  differentiation,  response  to  stimuli  or  the  ability  of  microglia  
to  phagocytose  compounds 200 .  Therefore,  it  may  require  the  combination  of  AD  risk  
genes  to  model  AD  cell  changes  in  a  dish.  Polygenic  risk  scores  are  statistically  
based  scores  that  combine  genotypes  across  all  risk  variants  of  a  disease  to  predict  
the  likelihood  of  a  person  developing  a  specific  trait 280 .  Patient-derived  cell  lines,  such  
as  iPSC,  could  be  classified  by  their  polygenic  risk  scores  and  differentiated  before  
running  functional  comparisons  across  a  spectrum  of  scores.  While  this  would  not  
allow  researchers  to  unpick  disease  causal  mechanisms  behind  individual  genes,  it  
may  mean  that  the  subtle  impacts  of  each  SNP  would  combine  to  generate  a  more  
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realistic  disease  phenotype  within  cells.  Using  a  spectrum  of  scores  may  allow  for  a  
greater  understanding  of  how  differing  levels  of  disease  risk  could  impact  disease  
progression  or  development.   
  
5.4  Concluding  remarks   
  
In  summary,  in  this  thesis  I  have  shown  that  the  microglial  transcriptome  is  constantly  
reacting  to  the  CNS  environment.  Initially  to  develop  a  unique  transcriptional  
signature  and  subsequently  to  respond  to  disease  or  trauma.  It  appears  to  be  signals  
from  the  CNS  environment  that  are  not  well  captured  by  monoculture  in-vitro  model  
systems.  However,  more  complex  systems  that  culture  microglia  alongside  other  
neuronal  cells  and  features,  such  as  the  BBB,  may  move  the  cells  closer  towards  the  
primary  phenotype  and  the  combination  of  iPSC  pooling  and  single  cell  sequencing  
techniques  may  make  large  scale  studies  of  these  systems  more  feasible  in  the  
future.  The  potential  use  of  these  more  complicated  and  extensive  model  systems  
does  not  always  mean  they  are  required.  Studies  have  shown  that  monoculture  
in-vitro  models  have  certain  comparable  traits  to  the  primary  cell  type,  such  as  
phagocytosis,  whereas  other  functions  of  microglia  that  involve  interaction  with  
neuronal  signals,  like  in  learning  and  memory,  may  only  be  captured  by  complex  
models.  It  is,  therefore,  vital  to  consider  the  function  of  interest  when  identifying  an  
appropriate  model  system  to  use  for  study.  This  is  of  particular  importance  when  
looking  to  understand  how  disease  risk  genes  may  modulate  cell  function.  If  the  
model  system  selected  does  not  accurately  capture  the  linked  cellular  phenotype  
then  the  biological  function  of  a  risk  gene  may  be  missed.  
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